

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

SUPERIOR COURT OF THE STATE OF CALIFORNIA
FOR THE COUNTY OF LOS ANGELES

THOMAS WAYNE REESE,	)	
	)	
Plaintiff,	)	
	)	
vs.	)	No. BC332936
	)	
GANS INK & SUPPLY CO., a California	)	
corporation, and DOES 1 through 200,	)	
inclusive,	)	
	)	
Defendants.	)	
_____	)	

DEPOSITION OF
KENNETH A. MUNDT, Ph.D.
LONG BEACH, CALIFORNIA
OCTOBER 13, 2009

Atkinson-Baker, Inc.
Court Reporters
(800) 288-3376
www.depo.com

Reported by: SHERI A. PLY, CSR No. 6507, RPR

FILE No.: A3074BC

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

	SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF LOS ANGELES) THOMAS WAYNE REESE,) Plaintiff,) vs.) No. BC332936) GANS INK & SUPPLY CO., a California corporation, and DOES 1 through 200, inclusive,) Defendants.) DEPOSITION of KENNETH A. MUNDT, Ph.D., taken on behalf of the PLAINTIFF, at 401 East Ocean Boulevard, Suite 800, Long Beach, California, commencing at 9:05 a.m., on Tuesday, October 13, 2009, before Sheri A. Ply, CSR No. 6507, RPR.																														
Page 2		Page 2																													
	A P P E A R A N C E S FOR THE PLAINTIFF: METZGER LAW GROUP BY: RAPHAEL METZGER, ESQ. 401 East Ocean Boulevard Suite 800 Long Beach, California 90802 (562)437-4499 FOR THE DEFENDANT 3M: STEPTOE & JOHNSON BY: JENNIFER B. BONNEVILLE, ESQ. 633 West Fifth Street Suite 700 Los Angeles, California 90071-3500 (213)43909421 FOR THE DEFENDANT SAFETY-KLEEN: (OF RECORD, NOT PRESENT) LEWIS BRISBOIS BISGAARD & SMITH LLP 221 North Figueroa Street Suite 1200 Los Angeles, California 90012 (213)250-1800 -AND- (VIA TELEPHONE) JONES CARR McGOLDRICK, LLP BY: HEATHER FORGEY, ESQ. 5307 E. Mockingbird Lane Suite 600 Dallas, Texas 75206 (214)828-9200	A P P E A R A N C E S FOR THE DEFENDANT VAN SON HOLLAND INK AND WEIMAN PRODUCTS: (VIA TELEPHONE) WOOD SMITH HENNING & BERMAN LLP BY: JOSHUA A. QUINONES, ESQ. 10960 Wilshire Boulevard 18th Floor Los Angeles, California 90024-3804 (310)481-7600 FOR THE DEFENDANT CNA HOLDINGS, INC.: (OF RECORD, NOT PRESENT) MORRIS POLICH & PURDY LLP BY: RICHARD E. STULTZ, ESQ. 1055 West Seventh Street 24th Floor Los Angeles, California 90017-2503 (213)417-5189 FOR THE DEFENDANTS SUPERIOR PRINTING INK COMPANY, BRADEN SUTPHIN INK COMPANY, REYNOLDS GRAPHIC ARTS CORPORATION AND RECKITT-BENCKISER: POOLE & SHAFFERY, LLP BY: JOHN GRANNIS, ESQ. 445 South Figueroa Street Suite 2520 Los Angeles, California 90071 (213) 439-5390 FOR THE DEFENDANT KOHL & MADDEN: (VIA TELEPHONE) ROPER MAJESKI KOHN BENTLEY BY: LEE HAMMER, ESQ. 515 South Flower Street Suite 1100 Los Angeles, California 90071 (213)312-2000																													
Page 3		Page 5																													
	I N D E X WITNESS: KENNETH A. MUNDT, PH.D. <table border="0"> <tr> <td>EXAMINATION BY:</td> <td>PAGE</td> </tr> <tr> <td>MR. METZGER</td> <td>7</td> </tr> </table> INFORMATION REQUESTED: (NONE) QUESTIONS WITNESS INSTRUCTED NOT TO ANSWER: (NONE) E X H I B I T S: <table border="0"> <thead> <tr> <th>DEPOSITION NUMBER</th> <th>DESCRIPTION</th> <th>PAGE</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Multipage Curriculum Vitae</td> <td>10</td> </tr> <tr> <td>2</td> <td>Three-page Testimony and Fees</td> <td>32</td> </tr> <tr> <td>3</td> <td>One-page Prior Testimony</td> <td>64</td> </tr> <tr> <td>4</td> <td>Two-page list of materials received</td> <td>65</td> </tr> <tr> <td>5</td> <td>Three-page NHL Epidemiology Articles</td> <td>67</td> </tr> <tr> <td>6</td> <td>One-page Misc. Articles</td> <td>68</td> </tr> <tr> <td>7</td> <td>One-page Summary of Opinions in Reese</td> <td>71</td> </tr> </tbody> </table>	EXAMINATION BY:	PAGE	MR. METZGER	7	DEPOSITION NUMBER	DESCRIPTION	PAGE	1	Multipage Curriculum Vitae	10	2	Three-page Testimony and Fees	32	3	One-page Prior Testimony	64	4	Two-page list of materials received	65	5	Three-page NHL Epidemiology Articles	67	6	One-page Misc. Articles	68	7	One-page Summary of Opinions in Reese	71		
EXAMINATION BY:	PAGE																														
MR. METZGER	7																														
DEPOSITION NUMBER	DESCRIPTION	PAGE																													
1	Multipage Curriculum Vitae	10																													
2	Three-page Testimony and Fees	32																													
3	One-page Prior Testimony	64																													
4	Two-page list of materials received	65																													
5	Three-page NHL Epidemiology Articles	67																													
6	One-page Misc. Articles	68																													
7	One-page Summary of Opinions in Reese	71																													

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 EXHIBITS: 2 3 DEPOSITION <table><tr><th>NUMBER</th><th>DESCRIPTION</th><th>PAGE</th></tr><tr><td>8</td><td>Multipage E-mail correspondence</td><td>71</td></tr><tr><td>9</td><td>Multipage Invoices</td><td>71</td></tr></table> 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Page 6	NUMBER	DESCRIPTION	PAGE	8	Multipage E-mail correspondence	71	9	Multipage Invoices	71	1 entire file. 2 MR. METZGER: That is not going to work, John. 3 Come on. We can recess and have all this stuff printed 4 out, but I mean -- 5 MR. GRANNIS: Can you have your CV E-mailed to 6 us or faxed to us here? 7 MR. METZGER: That is not the point. I mean 8 that is going to require him to make a call. I want to 9 get this deposition going. At least that is usually 10 produced; not just given on a CD. 11 So if we need to recess or -- 12 MR. GRANNIS: In the time we have been talking, 13 Dr. Mundt could have called his office and asked to have 14 it faxed here. We would be glad to do that. It is on 15 the disk. 16 Q BY MR. METZGER: Dr. Mundt, is your curriculum 17 vitae on this disk? 18 A Yes, sir. 19 Q Is there a publications list with that 20 curriculum vitae? 21 A Yes, there is. 22 Q Is that a separate document or is it 23 incorporated within the CV? 24 A Part of the same. 25 Q Is there a list of the cases that you have Page 8
NUMBER	DESCRIPTION	PAGE								
8	Multipage E-mail correspondence	71								
9	Multipage Invoices	71								
1 LONG BEACH, CALIFORNIA, TUESDAY, OCTOBER 13, 2009 2 9:05 A.M. 3 * * * 4 KENNETH A. MUNDT, PH.D., 5 having been first duly sworn, was examined 6 and testified as follows: 7 8 EXAMINATION 9 BY MR. METZGER: 10 Q Would you introduce yourself, please. 11 A Kenneth Mundt. I am an epidemiologist by 12 training and practice. 13 Q And you are a Ph.D.; correct? 14 A That is correct. 15 Q Do you prefer to be called doctor, therefore? 16 A It is appropriate. I don't have a preference. 17 Q Okay. Since it is appropriate, I will call you 18 Dr. Mundt. 19 Dr. Mundt, I don't believe we have met before, 20 have we? 21 A We have not. 22 Q Okay. So I never had the pleasure of deposing 23 you before, okay. 24 So do you have a curriculum vitae with you? 25 A Yes, it is on the DVD that I provided with my Page 7	1 testified on this CD? 2 A There is a list of trial testimony. 3 Q And deposition testimony? 4 A Not deposition testimony. 5 Q Where is that? 6 A I have -- I have a list of all testimony in the 7 past four years. 8 Q Where is that? 9 A That is in my office. I don't have it -- trial 10 testimony on this file. 11 Q We are going to need that so I will ask you to 12 call for that. 13 What else is on the CD that you have provided 14 me? 15 A A listing of all of the case materials that I 16 was provided by counsel, files containing all of the 17 articles in which I rely to form my opinions. 18 Q Is there a list of those? 19 A No. They are actual copies of the articles. 20 Q Is there an index or bibliography? 21 A No. 22 Q Okay. What else is on the CD? 23 A Copies of all correspondence and billings in 24 this matter. 25 Q What else? Page 9									

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 A This statement, summary of opinions. 2 Q What else? 3 A I believe that is it. 4 Q Okay. We are going to go off the record and we 5 will print out this stuff so we can do your deposition. 6 (Brief recess.) 7 MR. METZGER: Back on the record. 8 (Deposition Exhibit 1 was marked for 9 identification.) 10 Q BY MR. METZGER: Dr. Mundt, is Exhibit 1 your 11 curriculum vitae? 12 A Yes, sir. 13 Q Is it current? 14 A Yes, it is. 15 Q Is it complete? 16 A I believe so. 17 Q Is it accurate? 18 A Yes, I believe so. 19 Q When was it prepared, the last updated? 20 A Within a month. 21 Q Are there any articles or presentations or 22 abstracts that are not listed on here? 23 A I believe it is up to date. 24 Q So is the answer to my question no? 25 A It is current. I don't recall the wording of Page 10	1 non-Hodgkin's lymphoma in patients for deaths? 2 A No, I have not. 3 Q Have you ever conducted any epidemiologic study 4 that was specifically designed to investigate risks 5 specifically for non-Hodgkin's lymphoma? 6 A Specifically and excluding other causes of 7 death or disease? 8 Q Yes. 9 A That is correct, I have not. 10 Q Okay. Have you conducted any epidemiologic 11 studies which investigated disease outcomes amongst 12 benzene-exposed workers? 13 A Yes, I have. 14 Q What studies are those? 15 A There is a series of publications based on a 16 large complex study of river workers in Germany and 17 portions of the cohort workers were presumed to have 18 been exposed to benzene among many other solvents and 19 chemicals. 20 Q Would you show me on your publications list 21 where those publications are. 22 Is it more than one? 23 A Yes. And I can't recall specifically which of 24 the publications address non-Hodgkin's lymphoma 25 specifically. Page 12
1 your question. 2 Q I asked you if there are any publications, 3 articles, abstracts or presentations that you have given 4 or prepared that are not listed on this? 5 A I am sorry. It is complete. It is up to date. 6 Therefore, there are no other presentations or abstracts 7 that have taken place that are not identified on this. 8 Q Okay. Have you conducted any epidemiologic 9 studies regarding non-Hodgkin's lymphoma? 10 A I have conducted several epidemiological 11 studies in which non-Hodgkin's lymphoma was among the 12 diseases of interest. 13 Q Were these all cancer mortality studies, that 14 type of thing? 15 A Mostly, yes. 16 Q Okay. 17 A I also conducted a review of the literature on 18 perchloroethylene and -- perchloroethylene that looked 19 at various categories of cancers. 20 Q There is a difference between an epidemiologic 21 study and a review, isn't there? 22 A Absolutely. 23 Q I am asking about epidemiologic studies so 24 let's stick with that for the moment, please. 25 Have you ever conducted a case control study of Page 11	1 Q Do you recall that any of them do? 2 A I believe, yes. 3 On page 14, the penultimate entry is authored 4 by Straif. This Part 2 of a two-part article covers 5 mortality from non-respiratory cancers. 6 Q All right. Any others? 7 A On page 15, the third entry by Weiland is from 8 the same study, as is the sixth, I believe, also by 9 Weiland. 10 I think those are the three that provide -- I 11 am sorry. There is one more. 12 On page 14 again, middle of the list, I'm the 13 first author of the study of women in the German rubber 14 industry. 15 Q You are the first named author on that? 16 A Correct. 17 Q Okay. So it is those four studies? 18 A Those are the most likely to contain results on 19 NHL. 20 Q Did you review the actual data regarding 21 non-Hodgkin's lymphoma in those publications of yours 22 with respect to your opinions in this case as to whether 23 benzene can cause non-Hodgkin's lymphoma? 24 A That is a complicated question. If you could 25 clarify what you mean by did I examine the data on Page 13

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 non-Hodgkin's lymphoma. 2 Q I am asking if you actually looked at the data 3 in your own publications regarding benzene and 4 non-Hodgkin's lymphoma in preparation for your opinions 5 in this case on the causal relationship between benzene 6 and non-Hodgkin's lymphoma. 7 Did you do that or not? 8 MR. GRANNIS: It is argumentative. Lacks 9 foundation. 10 THE WITNESS: I am sorry. The way I view data 11 are the raw materials of a study we gather, so I didn't 12 know if you were asking if I looked at the death 13 certificates that reported NHL. 14 I think that would have been -- that is how I 15 interpreted your use of the word "data." 16 Did I review the published results in these 17 publications in preparation for this deposition, no, I 18 did not. 19 Q BY MR. METZGER: Are you able to tell me what 20 your own studies that you just identified indicate 21 regarding whether there is an increased risk of 22 non-Hodgkin's lymphoma among benzene-exposed rubber 23 workers in any of these studies? 24 MR. GRANNIS: Argumentative. 25 THE WITNESS: Not from memory, no. Page 14	1 identification number; is that correct? 2 A I provided Mr. Grannis with that information 3 this morning. 4 Q So this is your handwriting? 5 A No, it is not. 6 Q Okay. 7 A I read it from an E-mail that I received. 8 Q And he wrote it down? 9 A And he wrote it down. 10 MR. GRANNIS: Poorly, I might add. 11 MR. METZGER: Off the record. 12 (Interruption in the proceedings.) 13 MR. METZGER: Back on the record. 14 Q Are you employed full time by Environ? 15 A Yes, sir. 16 Q And how many hours a week do you work in your 17 work for Environ? 18 A Between 50 and 60. 19 Q Do you have any other professional work outside 20 of Environ? 21 A No, sir. 22 Q Your curriculum vitae indicates that you have 23 an appointment as an adjunct professor in the department 24 of epidemiology at the University of North Carolina at 25 Chapel Hill; is that correct? Page 16
1 Q BY MR. METZGER: Okay. Are you more familiar 2 with the epidemiologic studies regarding benzene and 3 non-Hodgkin's lymphoma that have been published by other 4 authors than yourself? 5 MR. GRANNIS: Argumentative. Lacks foundation. 6 THE WITNESS: I am very familiar with my study. 7 I don't recall one of hundreds of specific results. 8 Q BY MR. METZGER: Okay. 9 A I am also familiar with other's studies of 10 benzene-exposed populations and the range of causes of 11 disease and death they examined. 12 Q Okay. You are currently a principal of 13 Environ; correct? 14 A Yes, sir. 15 Q And that is an environmental consulting firm? 16 A That is correct. 17 Q And Environ has as clients major oil companies 18 and chemical companies; is that correct? 19 MR. GRANNIS: Argumentative. 20 THE WITNESS: Not exclusively but including oil 21 companies as clients, correct. 22 Q BY MR. METZGER: Before the deposition began 23 you provided me or counsel provided me an indication 24 that your check for today's testimony should be made 25 payable to Environ International Corp. with its tax Page 15	1 A Yes, sir. 2 Q Where do you live? 3 A Amherst, Massachusetts. 4 Q How frequently do you go to the University of 5 North Carolina to serve as an adjunct professor? 6 A Rarely. 7 Q How rarely? 8 A Once per year. 9 Q When is the last time you went there? 10 A Couple years ago, a year ago. 11 Q And what did you do on that occasion? 12 A Colleagues in the department of epidemiology 13 and I prepared a large research proposal that was not 14 ultimately funded. 15 Q What was that proposal for? 16 A It was for a large study of health of workers 17 in the semiconductor industry. 18 Q And from whom were you seeking funding for that 19 study? 20 A I don't recall specifically, but it was from 21 the trade association of semiconductor interests. 22 Q So when you went there on that one occasion a 23 year or two ago, did you actually do any teaching on 24 that occasion? 25 A On that occasion, no. Page 17

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 Q When is the last time that you actually taught 2 a course -- strike that. 3 Have you taught a course as an adjunct 4 professor at UNC? 5 A I have not, no. 6 Q Okay. Are you in fact still an adjunct 7 professor at UNC? 8 A Yes, sir. I think the CV accurately represents 9 that my appointment is from 2007 to 2012. 10 Q I see. 11 Are you presently scheduled to teach any 12 courses in the future at UNC? 13 A No, sir. 14 Q When you were appointed an adjunct professor 15 for the period 2007 to 2012, did you have any 16 understanding whether you would be expected to teach 17 courses at UNC? 18 A Yes, sir. 19 Q What was your understanding? 20 A That it was not expected because of my 21 location. 22 Q Do you have an understanding as to why you were 23 appointed an adjunct professor at UNC if you would not 24 be teaching any courses there? 25 A Yes, sir. Page 18	1 helped introduce or arrange. This occurred early part 2 of this year. 3 Q What is the project? 4 A It is the further development of some 5 sophisticated models that pertain to, I think, exposure, 6 dispersion of exposure generated from various sources. 7 Q Is there any particular chemicals that are the 8 subject of that project? 9 A I don't know the details of that. I was much 10 more participating as a matchmaker than as a 11 practitioner on that project. 12 Q You mean you were hooking up Environ with the 13 university for this project? 14 A That is correct. 15 Q Okay. Any other consultation that you have 16 provided for the university? 17 MR. GRANNIS: Vague. 18 THE WITNESS: Not that I can think of right 19 now. 20 Q BY MR. METZGER: Okay. Are you currently 21 preparing any exams for the university? 22 A I am not now, no. 23 Q When is the last time that you did that? 24 A I believe you asked me that already. It was a 25 year or two ago. Page 20
1 Q What is that? 2 A Adjunct faculty provide a wide range of service 3 and some include teaching. My appointment at UNC does 4 not include teaching responsibilities. 5 Q What does it include? 6 A It includes advising, consulting, preparing 7 exams for doctoral candidates in advanced areas in which 8 I am an expert or at least have something to contribute 9 as a knowledgeable practitioner. 10 I provide networking of resources and contacts 11 for my clients and my colleagues to a mutual benefit of 12 the university and other professional activities of the 13 department and school. 14 Q Are you currently advising any doctoral 15 candidates? 16 A No, I am not. 17 Q When is the last time that you did? 18 A Probably in the same time frame of a year or 19 two ago. 20 Q Are you presently providing any consultation 21 for the university? 22 A Yes, I am. 23 Q What is that? 24 A There is a joint project that Environ is 25 pursuing with the school of public health at UNC that I Page 19	1 Q And what exam or exams did you prepare? 2 A My specialty is in occupational epidemiology 3 and the exams that I would prepare are limited to 4 questions on occupational epidemiology for written 5 doctoral exams. 6 Q I am not asking what you would prepare; I am 7 asking what you did prepare. 8 Did you actually prepare any exams regarding 9 occupational epidemiology for UNC within the last two 10 years? 11 A I'm not sure if it was within the last two 12 years, but I certainly have prepared exam questions for 13 that purpose. 14 Q These were for doctoral candidates? 15 A Yes. 16 Q How many? 17 A I don't recall. Not a large number. 18 Q Less than five? 19 A Two or three I would say. 20 Q And the rest of your activities for the 21 university are networking of resources and contacts and 22 some promotional work; is that correct? 23 A That is my primary role. 24 Q You also on your curriculum vitae list being an 25 adjunct associate professor in the department of Page 21

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 epidemiology at the University of Massachusetts at 2 Amherst from 2005 to the present. 3 Is that accurate? 4 A Yes, sir. 5 Q Are you currently teaching any courses at 6 University of Massachusetts, Amherst? 7 A Not this semester. 8 Q When is the last time that you taught courses 9 there? 10 A Last academic year. 11 Q That would be the year 2008 to 2009? 12 A Correct. 13 Q Why are you not teaching a course this year? 14 A I will teach a course in the next semester. 15 This semester I am very busy and this is a voluntary 16 activity. 17 Q I see. 18 Has it been your practice to teach one course 19 per year at UMASS? 20 A No, sir. 21 Q How many courses per year in the last three 22 years have you taught? 23 A I have only taught two courses in the last 24 three years. 25 Q Okay. What were those classes? Page 22	1 concepts and methods mainly as applied to research in 2 musculoskeletal injury disorders. 3 Q Okay. 15 sessions that this course comprise, 4 how many of those sessions did you actually teach 5 yourself? 6 A Keep in mind this was a shared course. I think 7 I had full responsibility for one session and partial 8 responsibility for two others. 9 Q Okay. 10 A As well as participation in the seminar portion 11 of the class, which is more discussion oriented. 12 Q Other than the three organizers, were there 13 other people who actually taught the course? 14 A I believe there were one or two. I don't know 15 exactly how many, a few, and other invited speakers. 16 Q Okay. For the one session for which you have 17 full responsibility, what was the subject of that 18 session that you taught? 19 A It was either of the following two: The IARC 20 evaluation process or the emerging use of epidemiology 21 in European legislation known as REACH. 22 It is an acronym for Registration 23 Authorization -- 24 Q Okay. 25 A -- et cetera, as it compares to regulation and Page 24
1 A They were essentially the same class, different 2 years on the use of epidemiology in decision making. 3 Q Was that a graduate level course? 4 A Yes. 5 Q Was that an independent study or a regular 6 course listed? 7 A It was a classroom class, met once a week for 8 three hours. 9 Q For how many weeks? 10 A I believe total of 15. 11 Q Did you teach each of those sessions or were 12 you an invited speaker at one or a few of them? 13 A I was one of the organizers of the course. 14 Q How many organizers were there? 15 A There were two others. 16 Q Who were they? 17 A Dr. Sulski and Dr. Silverberg, also both 18 adjunct faculty members. 19 Q What are their specialties? 20 A Dr. Silverberg is a physician whose specialty 21 is outcomes research, a branch of epidemiology that 22 attempts to match what is known scientifically with what 23 is practiced clinically. 24 Dr. Sulski is a colleague of mine at Environ at 25 my office in Amherst. Her specialty is in epidemiology Page 23	1 use of epidemiologic evidence under EPA in the U.S. 2 Q Have you ever sat on an IARC committee other 3 than as an observer? 4 A No, I have not. 5 Q Have you sat on any of the implementing 6 committees for REACH? 7 A No. 8 Q In the courses which we have just been 9 discussing, did you in any way discuss benzene or 10 non-Hodgkin's lymphoma? 11 A No. 12 Q Okay. Other than the rubber worker 13 epidemiologic studies which you have done and which you 14 have identified on your curriculum vitae, do you have 15 any other publications which in any way relate to 16 benzene? 17 MR. GRANNIS: Overbroad. Vague. 18 THE WITNESS: Not exclusively or directly. 19 There probably are a number where indirectly benzene may 20 be relevant; for example, meta-analyses of occupational 21 exposure as a painter, to the extent that painters may 22 have been exposed to products containing some quantity 23 of benzene. 24 Q BY MR. METZGER: Where -- oh, the second -- 25 A That is the second one. I am citing this as an Page 25

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 example, if this is what you would like me to identify 2 for you. 3 Q Okay. So let me see. 4 You are referring to what is the second article 5 on your publications list on page 12; is that correct? 6 A That is correct. 7 Q As I look at the title of that it appears to be 8 concerning a meta-analyses of occupational exposure as a 9 painter for the specific outcomes of lung and bladder 10 cancer; is that correct? 11 A That is correct. 12 Q So in that study do you specifically address 13 non-Hodgkin's lymphoma or not? 14 A No. 15 Q Is this study one in which you have compiled 16 data and performed a meta-analysis of exposure data for 17 painters? 18 MR. GRANNIS: Vague. 19 THE WITNESS: No. Unfortunately there are very 20 poor exposure data for painters. 21 Q BY MR. METZGER: Okay. Have you read the 22 recently published article regarding painter's exposure 23 to benzene that was published in OEM, I think, within 24 the last few weeks? 25 A I can't recall that I have. Page 26	1 epidemiologic research studies as well as reviews and 2 syntheses of the epidemiologic engineering literature. 3 And the third is a bit more of a mix. It has 4 to do with advising, consulting, opinion giving to 5 clients and operating an epidemiology practice within 6 Environ, so some administrative responsibilities. 7 Q Okay. What percentage of the time that you 8 spend for your work for Environ is on litigation 9 support? 10 A It varies depending on the timing of the cases 11 that we are working on and the demands of those cases, 12 but it probably doesn't drop below 25 percent and it 13 probably doesn't go over 50 percent, somewhere in that 14 range. 15 Q And what percentage of your time at Environ is 16 spent advising clients? 17 A That is really the first priority so it depends 18 what the demand is at the time, but I would say it is 19 roughly a third on average. 20 Q And that is advising and consulting for 21 clients? 22 A For that piece that I identified, and that 23 includes some administrative. Do you want me to further 24 divide that? 25 Q Yes. I'd like a breakdown. Page 28
1 Q Okay. It is Chinese workers, does that ring -- 2 A Oh, yes, I have seen it. 3 Q Have you read that article? 4 A I haven't had time to, no. 5 Q Okay. Other than the second article on your 6 publications list that you have identified, are there 7 any other articles that you have which relate to 8 benzene? 9 A Indirectly. 10 Q Directly or indirectly, sure. 11 A I don't believe there are any that directly do 12 so. I will look to see if there are others that 13 indirectly address it. 14 MR. GRANNIS: While the doctor is doing that, 15 Raphael, where could I get a glass of water? 16 Thanks. 17 THE WITNESS: I believe that is it. 18 Q BY MR. METZGER: Okay. Is all of your 19 professional income currently derived from your work at 20 Environ? 21 A Yes, sir. 22 Q Would you describe for me the work that you do 23 for Environ. 24 A It divides roughly into three areas, one of 25 which is litigation support; another which is primary Page 27	1 How much time do you spend in administrative 2 work at Environ, what percentage of your time? 3 A That is probably 10 to 15 percent. 4 Q And how much time do you spend operating an 5 epidemiologic practice at Environ? 6 A I consider that part administrative activities. 7 Q Okay. And what percentage of your time do you 8 spend advising and consulting for clients outside of 9 litigation support? 10 A That is probably 20, 25 percent. 11 Q And what percentage of your time do you spend 12 reviewing and synthesizing the epidemiologic literature 13 at Environ? 14 A That is a fair amount of what I do because that 15 is a large part of what I do in the litigation area as 16 well as in the research area as well as in the client 17 advising area. 18 So I would say more than half of my time is 19 spent in that type of activity. 20 Q How much more than half? 21 A I don't know. These are all rough estimates. 22 I have never really split it out for that kind of 23 analysis. 24 Q Okay. What percentage of your time at Environ 25 is actually spent conducting primary epidemiologic Page 29

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 research studies? 2 A Well, that is what varies the most. During 3 phases of start-up and protocol development I could be 4 spending three, four days per week, and then there will 5 be long stretches where I don't do anything. So it is 6 very difficult to average. 7 Q Okay. In the year 2009 have you spent time at 8 Environ reviewing and synthesizing epidemiologic 9 literature apart from litigation? 10 A Yes, I have. 11 Q What have you done there this year in that 12 regard? 13 A These first two publications that are -- I 14 think you have the CV. The first two publications that 15 are in press are very large reviews that consumed a fair 16 amount of time this year. 17 Q Let's talk about those briefly then -- well, we 18 will get to them in just a minute. 19 A There are other areas, but yes, I spent a lot 20 of time reviewing and critiquing literature. 21 Q And in 2009 have you conducted any primary 22 epidemiologic research studies? 23 A Yes. 24 Q Which ones? 25 A The largest and most time consuming is based in Page 30	1 They are gradually bringing in things from your 2 CV that they have been printing out. 3 So we have here this document which we will 4 mark as Exhibit 2. 5 (Deposition Exhibit 2 was marked for 6 identification.) 7 Q BY MR. METZGER: I will ask you, is this the 8 list of testimony that you had faxed over? 9 A Yes. 10 MR. GRANNIS: And this is a document 11 entitled -- three-page document entitled, "Testimony and 12 Fees"; correct? 13 THE WITNESS: Yes. The fourth page is a fax 14 cover. 15 Q BY MR. METZGER: Why don't we just remove that 16 last page so it doesn't clutter up the exhibit, okay. 17 A Yes. It is three pages. 18 Q All right. And is this a list both of 19 deposition and trial testimony? 20 A Yes. 21 Q Okay. Now, the first case listed here is 22 O'Neill versus The Sherwin-Williams Company. 23 And you apparently gave a deposition in July of 24 this year; is that correct? 25 A Yes, sir. Page 32
1 Germany. It is a study of 18,000 men and women employed 2 in the porcelain manufacturing industry. 3 Q All right. Who is sponsoring that study? 4 A That is jointly sponsored by the European 5 silica trade group called Eurosil and the German 6 Government. 7 Q Okay. Regarding the first publication listed 8 on your CV, "Epidemiologic studies of formaldehyde 9 exposure and risk of leukemia and nasopharyngeal cancer: 10 A Meta-analysis," who sponsored that? 11 A That is sponsored by the formaldehyde council. 12 Q The second one, "Meta-analyses of occupational 13 exposure as a painter and lung and bladder cancer 14 morbidity and mortality," who sponsored that? 15 A That is sponsored by the National Paints and 16 Coatings Association. 17 Q Okay. And have you testified in cases for the 18 defense where the claimed exposure was formaldehyde? 19 A I have not. 20 Q Have you testified in cases where the claimed 21 exposure was paint? 22 A I did give a deposition in a case where the 23 exposure included use of a paint product. I don't quite 24 believe that is a good fit but paint was mentioned. 25 Q Okay. All right. Page 31	1 Q What was that case about? 2 A Mr. O'Neill was diagnosed with a bladder cancer 3 which he alleged to have been caused by his recent use 4 of a product manufactured by Sherwin-Williams. 5 Q A paint product? 6 A Which? 7 Q A paint product? 8 A A paint product, yes. I believe an epoxy 9 system, something I don't fully understand. 10 Q On whose behalf did you testify? 11 A I believe Sherwin-Williams. 12 Q What was the thrust of your testimony? 13 A Essentially that the alleged painting exposure 14 which consisted of I think half a dozen applications of 15 this material, within 10 years, maybe less of the 16 diagnosis of bladder cancer was incompatible with the 17 epidemiology of bladder cancers. 18 My understanding was also that there is no 19 chemical in that product that could cause bladder cancer 20 and it was on that basis the case was dismissed. 21 Q Who is the attorney who took your deposition? 22 A I don't know. I mean I don't remember. 23 Q When you say the case was dismissed, was there 24 a summary judgment brought that you are aware of? 25 A Yes, sir. Page 33

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 Q Did you provide a declaration in support of the 2 dismissal of that case by summary judgment? 3 A I don't recall. I believe that my testimony at 4 deposition was cited in that motion, but I just don't 5 recall so ... 6 Q And the next case, Willis versus R.J. Reynolds 7 Tobacco Company, what was that about? 8 A This is a case in which I was asked to comment 9 on what level of reduction or avoidance of risk occurs 10 among smokers who quit smoking, various stages of their 11 smoking histories. 12 Q What was the case about? 13 A This is one of complex series of cases that I 14 don't fully understand from a legal perspective, but 15 it's one of the so-called angle progeny cases, 16 individuals that had filed claims earlier, years and 17 years ago and that are coming back now. 18 Q These are claims where smokers were suing R.J. 19 Reynolds and perhaps other tobacco companies claiming 20 that tobacco had caused their lung cancers. 21 Is that it? 22 A Essentially. I don't want to represent that it 23 is as simple as that because I don't know, but that is 24 essentially my limited understanding of those cases. 25 Q And on whose behalf were you testifying in that Page 34	1 Q BY MR. METZGER: So without knowing what the 2 mechanism is and without knowing what the carcinogenic 3 constituent -- causative carcinogenic constituents are, 4 you can still determine that cigarette smoking causes 5 lung cancer; correct? 6 MR. GRANNIS: Argumentative. Irrelevant. 7 THE WITNESS: In this situation that can be 8 held because of the strength of the association between 9 those -- between the exposures and the occurrence of 10 lung cancers. 11 Q BY MR. METZGER: What is the strength of the 12 association? 13 A It depends how carefully you have measured the 14 exposure. 15 Q I am asking for cigarette smoking and lung 16 cancer, what is the strength of that association? 17 MR. GRANNIS: Irrelevant. Vague. 18 THE WITNESS: I would say that is not 19 answerable as simply as that because it is an 20 oversimplification. 21 Q BY MR. METZGER: Okay. 22 A Epidemiologically you have to specify a 23 quantity of exposure and you have to specify a specific 24 disease. If you asked me about adenocarcinomas -- 25 Q I am asking about lung cancers. Page 36
1 case? 2 A The tobacco companies. 3 Q Does smoking cause lung cancer? 4 A Absolutely. And of course in all of these 5 situations where chemicals are -- exposures cause 6 disease, it has to be an adequately high level to cause 7 that. 8 Q What is the carcinogenic constituent of 9 cigarette smoke that causes lung cancer? 10 MR. GRANNIS: Irrelevant. 11 THE WITNESS: I don't know that it is known. 12 There may be many of them. And I think that that's -- 13 there are many people working on that trying to 14 disentangle that. 15 Q BY MR. METZGER: How do you know if smoking 16 causes lung cancer if you don't know which constituent 17 does cause lung cancer? 18 MR. GRANNIS: Irrelevant. Argumentative. 19 THE WITNESS: Well, I know this from various 20 approaches, not the least of which is that this has been 21 demonstrated epidemiologically, so many times it can't 22 be counted, in that removing that exposure has been 23 demonstrated to have parallel reductions in risk. 24 So without knowing what the mechanism is, we 25 can test it experimentally at the population level. Page 35	1 A Lung cancers are -- 2 MR. GRANNIS: Excuse me, the witness has not 3 finished answering your previous question. He is 4 entitled to do so. I appreciate if you give him that 5 courtesy. 6 Go ahead, doctor. 7 THE WITNESS: Lung cancers are many, many 8 different diseases with slightly different etiologies, 9 meaning they have different constellation of causes. 10 If you ask me a more specific question about 11 adenocarcinoma of the lung, I'd give you a different 12 answer than if you asked me about small cell or squamous 13 cell. All of them are, in lay terms, considered lung 14 cancer. They're very different diseases. 15 On the exposure side I'd have to ask you 16 whether you are talking about a casual smoker of a 17 cigarette or two a day or a half a pack a day or a 18 serious smoker, 20 or 30 packs per day. 19 If you looked at squamous or small cell -- 20 Q BY MR. METZGER: 20 or 30 packs a day? 21 A I'm sorry. 20 or 30 cigarettes per day. Thank 22 you for correcting. 23 Q That is a real serious smoker. 24 A I think most I have seen is five but not 25 or 25 30. Page 37

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 But if you looked at a squamous cell carcinoma 2 risk among smokers of two to three packs a day, relative 3 risk might be 100 or 200. 4 Q I see. 5 A It is highly specific to both the specific 6 exposure and the specific disease. 7 Q How many types of lung cancer are there? 8 MR. GRANNIS: Irrelevant. Overbroad. 9 THE WITNESS: I'd have to look at the ICD 10 coding. It changes, you know. There are more added 11 over time as we understand that many of these cancers 12 actually are multiple diseases, but there are four main 13 groups. 14 Q BY MR. METZGER: And those are? 15 A Large cell, small cell, squamous cell and 16 adeno, and there are many subtypes. I know there are 17 certain subtypes of adeno that are not associated with 18 smoking. 19 So it is more complicated than what is the 20 relative risk of cigarette smoking. 21 Q Does cigarette smoking cause all of the four 22 major types of lung cancer that you just identified? 23 MR. GRANNIS: Argumentative. Irrelevant. 24 THE WITNESS: To some degree. It varies, as I 25 previously explained, by the amount of exposure and by Page 38	1 lung cancer which has been proven to be not caused by 2 cigarette smoking? 3 MR. GRANNIS: Vague. Overbroad. Irrelevant. 4 Argumentative. 5 Q BY MR. METZGER: I am not asking about 6 sufficiency of evidence. 7 A I understand. I also understand it is not an 8 epidemiologic question. I think that proving something 9 doesn't cause something is not compatible with the basic 10 approach we use to scientific method generally, but 11 specifically epidemiologically. 12 Q I understand you to be saying that epidemiology 13 doesn't do that. Epidemiology does not prove that 14 something does not cause something. 15 MR. GRANNIS: Vague. Overbroad. 16 Mischaracterizes testimony. 17 THE WITNESS: I didn't understand the question 18 as you phrased it, but I believe that you are asking 19 epidemiology doesn't or is not able, as is other 20 sciences, unable to prove this negative. And that is 21 the way that it is summarized in lay terms. 22 Q BY MR. METZGER: I see. 23 A The scientific method establishes a testable 24 hypothesis that there is an observable difference 25 between two groups. Page 40
1 the specific subtype of the disease. 2 Q BY MR. METZGER: Does cigarette smoking cause 3 the various subtypes, the four main types of lung 4 cancer? 5 MR. GRANNIS: Vague. Irrelevant. Overbroad. 6 Argumentative. 7 THE WITNESS: Again, it depends. There are 8 subtypes that either are shown to be weakly or 9 non-associated with smoking, or where there is 10 inadequate evidence available to conclude that a 11 specific subtype is reasonably represented by the larger 12 family. 13 Q BY MR. METZGER: Is there any subtype of lung 14 cancer that has been shown to not be caused by cigarette 15 smoking? 16 MR. GRANNIS: Vague. Irrelevant. Overbroad. 17 Argumentative. 18 THE WITNESS: Yes. There is a subtype called 19 B.A.C, bronchioalveolar carcinoma that I believe has 20 been looked at adequately to demonstrate 21 epidemiologically the evidence is mixed, so it is not 22 strong enough to conclude that it is causal 23 relationship. 24 Q BY MR. METZGER: But I wasn't quite asking you 25 that. What I was asking you is, is there any subtype of Page 39	1 Failing to see an observable difference doesn't 2 prove a negative; it disproves the hypothetical. We 3 build our understanding from this basic scientific 4 method and I believe it is not limited to epidemiologic. 5 Q So in layman's terms so that an average person 6 can understand this, are you saying that epidemiology 7 does not prove that a particular chemical does not cause 8 a particular disease? 9 MR. GRANNIS: Overbroad. Vague. 10 Mischaracterizes testimony. Argumentative. 11 THE WITNESS: The way we describe that in lay 12 terms is that there is inadequate evidence to reject the 13 hypothesis. 14 It may lend support for the null hypothesis, 15 that is that it doesn't cause the disease, but it 16 doesn't provide proof for that. 17 Q BY MR. METZGER: And you say that that is lay 18 terminology? 19 A It is. It doesn't get any better. 20 Q Okay. Well, then let me ask you the flip side 21 of this. Does epidemiology actually prove that a 22 chemical does cause a disease? 23 A I think that I have found -- 24 MR. GRANNIS: Vague and overbroad. 25 THE WITNESS: I found a more commonly used lay Page 41

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 explanation for your previous question. That is that 2 this is the white swan, black swan analogy. You can 3 repeatedly hypothesize that all swans are white and be 4 paraded in front of an endless stream of white swans but 5 still not be able to prove that there aren't black 6 swans. But as soon as you have identified a black swan, 7 you can disprove that hypothesis. 8 I think that is an analogy that's frequently 9 used in lay settings so you can understand the 10 difference between affirming epidemiologically or 11 observationally or scientifically versus disproving. 12 Q BY MR. METZGER: Is it true that epidemiologic 13 textbooks state that epidemiology does not prove causes 14 of disease? 15 MR. GRANNIS: Vague. Overbroad. 16 Argumentative. 17 THE WITNESS: Yes, epidemiology texts 18 appropriately identify that, but should also accurately 19 add that causality cannot be proven by any means except 20 some ridiculously obvious things like a gunshot wound 21 fatally injured someone. 22 As you move into chronic disease complex 23 epidemiology, then I think it is reasonable that proof 24 of causation cannot be determined. 25 Q BY MR. METZGER: Okay. All right. We were Page 42	1 that it is still pending. I just believe so. I don't 2 recall. 3 Q Sure. 4 A The Davis case, Mr. Davis had a biliary tract 5 tumor and alleged that that was caused by his exposures 6 while employed at BNSF. 7 Q He was a railroad worker? 8 A He was a tie plant worker. 9 Q What was the claimed exposure? 10 A It was a mix and it included most of the 11 chemicals or all of the chemicals that were used at that 12 facility. 13 I haven't finished. You were eager for my 14 words and I am getting there. The creosote was one. 15 Chromium, pentachlorophenol, in this category, mostly 16 wood preservatives. 17 Q What was the thrust of your testimony? 18 A I looked fairly comprehensively at each of 19 those exposures in the epidemiologic literature as well 20 as at that specific type of cancer and demonstrated that 21 there was no epidemiologic support for that hypothesis. 22 Q Who took your deposition? 23 A I am sorry. I don't recall. I will do a 24 better job and try to remember you in this deposition 25 for future reference, but I don't retain the names of Page 44
1 looking at this case list. The next case down Bishop 2 versus Shell Oil, what was that case about? 3 A This is an oil -- excuse me, oil production or 4 oil worker -- I don't recall the details. And I believe 5 it is a multiple myeloma case. 6 Q Was the claim that benzene from petroleum 7 products caused the worker's multiple lymphoma? 8 A That is what I think it is, yes. 9 Q And you gave a deposition in that case this 10 year? 11 A That is correct. 12 Q What was the thrust of your testimony? 13 A The epidemiologic literature on multiple 14 myeloma and benzene is very weak and not sufficient to 15 draw causal determination. 16 Q And you testified on behalf of Shell Oil 17 Company? 18 A And/or one of the other defendants. 19 Q Who took your deposition in that case? 20 A I don't recall. 21 Q Is that case still pending, to your knowledge? 22 A Yes, it is. 23 Q Okay. The next case, Davis versus BNSF Railway 24 Company, what was that about? 25 A I am sorry. I shouldn't say so definitively Page 43	1 the attorneys taking my depositions. 2 Q That case went to trial? 3 A It did. 4 Q Did you testify at trial? 5 A I did. 6 Q What was the result? 7 A Defense verdict. 8 Q The next case, Valdez versus A.W. Chesterton 9 Company, what was that about? 10 A I don't recall the specifics of that. 11 Q Do you recall generally that that was regarding 12 asbestos? 13 A That may be. I have given depositions in a 14 number of asbestos cases. 15 Q Have you testified for A.W. Chesterton? 16 A Not that I recall. The name is not familiar to 17 me. 18 Q In that case did you testify for the defense? 19 A Yes, sir. 20 Q You seem quite definitive. 21 In all of these cases have you testified for 22 the defense? 23 A No, sir. 24 Q All right. The next case, Kaplan versus R.J. 25 Reynolds, is that another one of the angle cases? Page 45

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 A Yes, it is. 2 Q You testified for the defense? 3 A I don't even remember. 4 Q For R.J. Reynolds; is that correct? 5 A I believe it was for all of the defendants. 6 Q All of the tobacco companies? 7 A Yes. 8 Q Is same true with the Grossman case? 9 A Yes. 10 Q The Gersten versus Asbestos Corporation, I 11 would assume that was some asbestos case; is that 12 correct? 13 A That is correct. 14 Q And whose behalf did you testify? 15 A I believe it was Plant Insulation. 16 Q That was one of the asbestos companies? 17 A Yes. 18 Q One of the defendants? 19 A Yes. 20 Q Who took your deposition in that case? 21 A I don't know. 22 Q The next case, Clayton -- sorry, Thompson 23 versus Asbestos Defendants, another similar case? 24 A Yes. 25 Q Collins versus A.W. Chesterton Company, another Page 46	1 and it was Burn & Brown, Oakland. 2 Q But was there one law firm who was representing 3 the plaintiffs? 4 A I don't know. 5 Q Do you recall the name of any law firm that was 6 associated with the plaintiffs? 7 A No. These were mainly phone depositions, some 8 of them 10 or 20 minutes and some never discussing the 9 science of the case, so I had fairly little interaction 10 with any parties in these. 11 Q Okay. Trombella versus Advocate Mines Limited, 12 what was that case about? 13 A It must have been similar because the 14 deposition was in the same day and there was a cluster 15 of cases in the same -- 16 Q You testified for the defendant asbestos 17 company? 18 A That would have been plants, yes. 19 Q Okay. Village of Bensenville, Illinois versus 20 City of Chicago, what was that about? 21 A Bensenville is the village adjacent to O'Hara. 22 Q Airport, right. 23 A And I was representing Bensenville as a 24 plaintiff concerned about the way the City of Chicago 25 was demolishing properties in their neighborhood while Page 48
1 asbestos case? 2 A Yes. 3 Q And you gave both deposition and trial 4 testimony in that case? 5 A Yes. 6 Q Barr versus Aladdin Heating Corporation, what 7 was that about? 8 A I think that was similar. These cases -- 9 Q Also asbestos -- 10 A -- cases in Alameda are all on behalf of a 11 plant which I provided testimony on state of the art. 12 Q I see. 13 And essentially that meant that the hazards of 14 asbestos were not knowable or known at a certain point 15 in time. 16 Is that what you mean? 17 A The question put to me is what would a 18 scientist at a particular point throughout history have 19 available and possibly understand as to what was 20 knowable. Did not come into what a company might know. 21 It really was a scientific question. 22 Q I understand. 23 Was it one law firm that was representing the 24 plaintiffs in these cases? 25 A I was retained by one law firm in these cases Page 47	1 people were still living next to the demolition site -- 2 Q The next case -- 3 A -- which included a hazardous waste site. 4 Q The next case, Marshall versus AC&S, another 5 asbestos case and you testified for the defense? 6 A That's correct. 7 Q City of St. Louis versus American Tobacco 8 Company, what was that about? 9 A This is a large and very complicated matter 10 that I don't understand entirely. To simplify it, I 11 will describe it probably in a simplistic way. 12 The hospitals in and around throughout Missouri 13 have jointly filed this case in an attempt to recoup 14 moneys that they expended on behalf of patients that 15 were either charity cases or non-paying, non-charity 16 cases -- 17 Q Lung cancer case -- 18 A -- alleging that their care caused damages, 19 financial damages to the hospitals in treating them. 20 Q Were these lung cancer patients suffering from 21 tobacco-related disease? 22 A That is where it is very complicated. 23 Q Is that what the claim was? 24 A No. It has to do with a long list of diseases 25 and -- Page 49

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 Q Was the claim that the tobacco companies had 2 caused these diseases thereby resulting in this 3 treatment for which the hospitals were not compensated 4 and the hospitals wanted the tobacco companies to 5 compensate the hospitals for treating these patients? 6 A Something like that. When I try to reiterate 7 this way, they say, "No, no, it's much more 8 complicated." 9 So I don't want to -- 10 Q What was the thrust of your testimony in this 11 case? 12 A That is ongoing and it is still unclear to me 13 all of the areas that I will be addressing. And I 14 understand this has been underway for 10 or eight more 15 years. 16 MR. GRANNIS: Have you testified in that case? 17 THE WITNESS: I gave a deposition. And at the 18 deposition I identified a large number of diseases that 19 I believe are caused by smoking. 20 Q BY MR. METZGER: So cigarette smoking doesn't 21 just cause lung cancer? 22 A That's right. 23 Q Oh, how do you know that? 24 A General causation, you know, is a judgment 25 largely based on available evidence and often -- and Page 50	1 angiosarcoma of the liver but can also cause another 2 host of -- a host of other diseases, including 3 acroosteolysis so... 4 Q BY MR. METZGER: Brain cancer? 5 A I don't agree at all with that, unless you have 6 found a new battery of epidemiologic studies. And I 7 have looked very closely at that. 8 Q If you want to agree with Rinkis, what about 9 hepatocellular carcinoma? 10 A I think that is a great question. 11 Q How about answering it? 12 A I would love to answer it. Would you like to 13 sponsor my research? I have access to very good data. 14 Q I can't afford you. No, thanks. 15 Let's move on. 16 A I thought we were almost close to coming to a 17 deal. 18 Q No. 19 A See, that is one of those good hypotheses for 20 which there are epidemiological -- or data that could be 21 used in epidemiological study to answer it. 22 Q Carter versus A.W. Chesterton Company, another 23 asbestos case you testified for the defense? 24 A Yes, just like the others above. 25 Q Okay. Johnese versus Ameron, what is that Page 52
1 with cigarette smoking there is substantial scientific 2 evidence that is specific to these diseases and from 3 which causation can be reasonably inferred. 4 Q So a chemical can actually cause more than one 5 disease? 6 MR. GRANNIS: Argumentative. Overbroad. 7 Vague. 8 THE WITNESS: And doesn't at all reflect what I 9 said in my previous answer. 10 Q BY MR. METZGER: I am just asking. 11 A Could you ask it as a new question. 12 Q I'm asking a new question. 13 A Maybe by tone you implied that's what I had 14 suggested. 15 MR. GRANNIS: Same objections, and 16 mischaracterizes previous testimony. 17 Q BY MR. METZGER: I will ask a new question. 18 A Thank you. 19 Q Can a chemical cause more than one disease? Is 20 that possible? 21 MR. GRANNIS: Vague. Overbroad. 22 Argumentative. 23 THE WITNESS: A specific chemical I believe 24 could cause more than one disease. I think that there 25 are chemicals such as vinyl chloride that causes Page 51	1 about? 2 I assume it is some paint-related case. 3 A I think so. I think it was a pancreatic cancer 4 case with non-specific exposure. 5 Q You testified for the paint company, Ameron? 6 A It is possible. I -- 7 Q For the defense, for some paint company in the 8 case? 9 A Correct, correct, or a defendant. I don't know 10 if they were necessarily a paint company. 11 Q All right. And you testified that the exposure 12 didn't cause the pancreatic cancer? 13 A I don't recall specifically my testimony, but 14 it would have been more likely something like that but 15 more along the lines that the epidemiologic evidence 16 doesn't support that claim. 17 Q Clark versus Kellogg Brown & Root, what was 18 that about? 19 You don't recall? 20 A This is a benzene case. 21 Q Okay. 22 A I don't recall the disease that Mr. Clark had. 23 Q Did you testify that benzene did not cause that 24 disease? 25 A I don't recall. Page 53

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 Q If I told you that the disease he had was acute 2 lymphocytic leukemia, would that have been your 3 testimony in the case? 4 MR. GRANNIS: Incomplete hypothetical. 5 THE WITNESS: I would say that the 6 epidemiologic data was insufficient to draw that 7 conclusion. 8 Q BY MR. METZGER: Okay. Cairns versus American 9 Optical, what was that about? 10 A This is an asbestos case. 11 Q You testified for the defense? 12 A Yes. 13 Q Hamman versus American Oil, what was that 14 about? 15 A I think this is a benzene case. I don't recall 16 the disease. 17 Q Did you testify for the defense? 18 A Yes. 19 Q Do you recall generally what your testimony 20 was? 21 A No. 22 Q Do you recall the plaintiff's attorney? 23 A No. 24 Q Weir versus ArvinMeritor, what was that about? 25 A I actually think that was the pancreatic cancer Page 54	1 was a Havner hearing in Texas. 2 Q Life testimony or declaration? 3 A It was life testimony before the judge. 4 Q Okay. You testified for the defense? 5 A Yes. 6 Q Mountney versus 84 Lumber Company, what was 7 that about? 8 A It is an asbestos case. 9 Q You testified for the defense? 10 A I testified on behalf of 84 Lumber. 11 Q What was the thrust of your testimony? 12 A The asbestos, if any, in joint compound, if it 13 had been sold by 84 Lumber was not capable of causing 14 Mr. Mountney's disease. 15 Q Why was that? 16 A I am sorry? 17 Q Why was that? 18 A Why was? 19 Q Why was it not capable of causing the disease? 20 MR. GRANNIS: Vague. Overbroad. 21 THE WITNESS: Two basic reasons. One is that I 22 believe this was a mesothelioma and chrysotile was not 23 clearly a cause of mesothelioma, especially -- if there 24 is any doubt at all, it is -- it disappears at levels 25 which might be exposed from joint compound. Page 56
1 case. 2 Q The one that you mentioned earlier? 3 A Yes. We are getting back too far for me to 4 remember these things. 5 Q In re: Tobacco Litigation, West Virginia, what 6 was that about? 7 A That is another long time ongoing case where I 8 believe my testimony was similar to that in the St. 9 Louis identifying the lists of diseases that I concluded 10 or caused by tobacco smoke. 11 Q You testified for the tobacco industry in this 12 case? 13 A Yes. 14 Q Okay. Cantu versus Refining & Marketing, is 15 that a benzene case? 16 A Yes. 17 Q What was the disease? 18 A Actually I think that was an NHL case. This -- 19 that's right. I did not give a deposition in this case. 20 That was a Daubert hearing that I participated in. 21 Q When you say a Daubert hearing, was this 22 actually a hearing that took place in court or just a 23 Daubert hearing where you submitted an affidavit or 24 declaration? 25 A I thought you were going to catch my error. It Page 55	1 Q BY MR. METZGER: What disappears? 2 A The risk. 3 Q Oh, okay. 4 A In other words, there is no evidence whatever 5 that low level exposures to chrysotile, if they occurred 6 at all in this case, could have contributed to a 7 mesothelioma. 8 Q Do you mean on an epidemiologic basis? 9 A Based on epidemiologic evidence, that 10 conclusion was derived. 11 Q Is epidemiology as a science capable of making 12 those assessments for extremely low dose exposures? 13 MR. GRANNIS: Argumentative. Vague. 14 Overbroad. 15 Q BY MR. METZGER: Do you understand the 16 question? 17 A I do understand the question. I think that it 18 is -- it is very broad and it is complicated to answer 19 what epidemiology is capable of and what you mean by low 20 exposures because, for example -- 21 Q Let me rephrase the question then. 22 A -- the insulators in Sulakoff's work were 23 considered low exposed. 24 Q Let me rephrase the question. 25 A All right. Page 57

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 Q In this case the exposure was to chrysotile in 2 what, joint compound? 3 A Alleged chrysotile. It was years and years 4 where the joint compound did not contain chrysotile. 5 So if you make it hypothetical, then we can get past the 6 specifics of this case. 7 Q Sure, sure. 8 A If this guy used joint compound yesterday, 9 nobody would say that anything in it contributed to his 10 disease. 11 Q So here is my question: Is epidemiology a 12 sufficiently precise and sensitive analytical device to 13 detect statistically significant increases in the rates 14 of occurrence of mesothelioma amongst workers who are 15 exposed to chrysotile asbestos from joint compound? 16 MR. GRANNIS: Vague. Overbroad. 17 Argumentative. Irrelevant. 18 THE WITNESS: It is still quite broad. You are 19 asking me about epidemiology. Epidemiology is a world 20 of practitioners and methods. 21 So you could say could -- could epidemiology 22 using state of the art techniques detect these things. 23 And I think that, well, if you look at quality of 24 studies and the numbers of individuals that have been 25 exposed to chrysotile fibers at low levels all their Page 58	1 deposition in an asbestos case, I don't recall. 2 Q Okay. Were you deposed by attorneys from the 3 Braden Purcell firm? 4 A I don't know. I am sorry. 5 Q You don't know, okay. 6 Next case, Lattin versus Borden, what was that 7 about? 8 A That is a vinyl chloride and brain cancer case. 9 Q I thought you said there was no such thing? 10 A There are cases. That is not what is lacking. 11 MR. GRANNIS: Mischaracterizes prior testimony. 12 Q BY MR. METZGER: Go ahead. 13 A That is not what we are short on. It is the 14 science. I can't say much about this, not because I 15 don't want to. I was a fact witness. 16 Q Really? 17 A I was in the court for five minutes. 18 Q What were you testifying about? 19 A I published the study on vinyl chloride workers 20 in the U.S. and counsel believed that I could comment on 21 my study without being identified as an expert. 22 Q I see. 23 Erroneously believed that? 24 A And the judge didn't agree with that so I was 25 excused after 10 minutes. Page 60
1 lives, then in fact we can set those individuals apart 2 epidemiologically from those that have been exposed to 3 much, much higher levels and to moderate to high level 4 of anthropoles. 5 Q BY MR. METZGER: So the answer to my question 6 is yes? 7 A Partly. It is not a "Yes" or "No" obviously. 8 Q All right. Coulter versus Parks, that was a 9 benzene lymphoma case; correct? 10 A Yes, I believe so. 11 Q And do you recall the name of the attorney who 12 took your deposition in that case? 13 A No. 14 Q I believe it was Phil Harley. 15 Does that ring a bell? 16 A I think it does, yes. Very nice guy. 17 Q He was a very nice guy. He recently died. 18 A Did he really? 19 Q Yeah. Melanoma, unfortunately. 20 A Oh, I'm very sorry to hear that. 21 Q Did he take your deposition in other of the 22 asbestos cases that we have discussed? 23 A This was not an asbestos case. 24 Q I know. 25 A Oh, do I recall whether he had taken my Page 59	1 Q Without testifying? 2 A A side bar. 3 MR. GRANNIS: So this case was one of failure 4 to designate you as an expert. 5 Is that it? 6 THE WITNESS: I can't say I know what happened 7 there. 8 MR. GRANNIS: Okay. 9 THE WITNESS: But I would say that I will be 10 very careful if ever asked again to testify as a fact 11 witness. 12 Q BY MR. METZGER: You were called by counsel to 13 testify by counsel for Borden, the defendant? 14 A By one of the defendants. 15 Q Ringstaff versus AMOCO, what is that about? 16 A That is a benzene case. 17 Q Disease? 18 A Maybe a CLL, CML maybe. I don't know. 19 Q Okay. What was the outcome of that case? I 20 see there was a trial. 21 A I don't recall. 22 Q Do you know who took your deposition? 23 A No. 24 Q Taylor versus AIRCO, what was that about? 25 A This is a vinyl chloride case. Page 61

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 Q On whose behalf did you testify? 2 A One of the defendants. 3 Q Okay. Can you recall the name of any 4 plaintiff's attorney who ever took your deposition? 5 MR. GRANNIS: Other than the deceased gentleman 6 that you referred to? 7 MR. METZGER: He didn't recall that one so I am 8 asking other than that, yes. 9 THE WITNESS: And other than yours. 10 Q BY MR. METZGER: I am not done yet. 11 Other than Phil Harley and me. 12 A I remember the first. 13 Q Who was that? 14 A It was a gentleman by the name of Withey. 15 Q Mike Withey? 16 A Do you know him? 17 Q Sure. 18 A Okay. 19 Q Have you been deposed by Dean Heartly? 20 A I am sorry. My -- 21 Q West Virginia, tall guy occasionally with a 22 beard. 23 A I don't -- I don't recall. 24 Q Hershall Hockson? 25 A Oh, I do remember Mr. Baggett. I believe that Page 62	1 Q BY MR. METZGER: So summing this all up, is it 2 correct that in the past five years, wherever there was 3 a claim of an occupational cancer or disease, in all of 4 the cases in which you testified, you testified on 5 behalf of the defense? 6 A That's right. If you are only talking about 7 testimony, that is correct. 8 Q Have you -- 9 A And the other caveat that it was an individual 10 rather than a town. 11 Q Right, right. 12 A Yes. 13 Q Have you ever testified on behalf of a worker 14 claiming to have suffered an occupational disease? 15 A Testified, no. 16 Q Okay. Let's take a break. 17 MR. GRANNIS: Okay. 18 (Brief recess.) 19 MR. METZGER: Back on the record. 20 (Deposition Exhibit 3 was marked for 21 identification.) 22 Q BY MR. METZGER: Dr. Mundt, is the document 23 that I'm providing you, which has been marked as Exhibit 24 3, a list of trial testimony which you provided on the 25 CD this morning? Page 64
1 was June Taylor. So I think that I had only given 2 depositions a few times before this list. This is five 3 years. And so I think those first had an impression on 4 me. No offense to any of your fine colleagues -- 5 Q Billy Baggett? 6 A -- since then. I don't recall their names, but 7 it was Mr. Baggett. 8 Q Jr. or Sr.? 9 A Jr. 10 Q Any others that you can recall? 11 A Not without prompting. I just don't remember. 12 MR. GRANNIS: Is this a good time to take a 13 break? 14 MR. METZGER: Just going to ask a few more 15 names. 16 Q What about Al Stewart? 17 A Doesn't ring a bell. 18 Q Steve Jansen? 19 A (No audible response.) 20 MR. GRANNIS: Is that a no? 21 THE WITNESS: Sorry, I am waiting for something 22 that rings a bell. I am sorry. I don't remember that. 23 MR. METZGER: Let me just wrap up on the cases 24 and we will take a break. 25 MR. GRANNIS: Sure. Page 63	1 A Yes, sir. 2 Q Okay. So this lists all of the trials that you 3 have testified in? 4 A I believe that there are trials and -- for 5 instance, I noticed there was hearing, so I think this 6 is testimony in court in front of a judge. 7 Q I understand. Okay. 8 Looks like we have addressed most of these 9 cases. The only one I don't think we did is the one at 10 the bottom, which is from 1996, the DiPetrillo versus 11 Narragansett Electric, what was that about? 12 A That was a multiple myeloma case and alleged 13 exposure was herbicide. 14 Q And you testified for the defendant? 15 A On behalf of Narragansett Electric, yes. 16 Q All right. We will mark as Exhibit 4 this 17 document from the CD. 18 (Deposition Exhibit 4 was marked for 19 identification.) 20 Q BY MR. METZGER: Is this a list of materials 21 that you have received from counsel for this case? 22 A Yes, sir, that -- I recognize it. 23 Q Did you read all of the materials on this list? 24 A No, I didn't. 25 Q Go through it and tell me which of the Page 65

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 materials you have actually read and which you haven't. 2 A May I mark it? 3 Q Sure. Let's do it that way. 4 How do you want to mark it just so we know 5 what -- 6 A Just put a checkmark next to the number. 7 Q That you have read? 8 A Yes. 9 Q Okay. 10 A All right. The third amended complaint, 11 Dr. Harrison's deposition and all of the exhibits, 12 depositions of Dr. Whysner, Garabrant, Sarna, more 13 deposition of Dr. Harrison, those are the ones that I 14 have read. 15 The rest of the materials I have scanned, 16 leafed through, but because there is so much in the 17 medical record, I can't tell you that I have looked at a 18 particular one. 19 Q Okay. 20 A And the same with the materials from the 21 defendants listed here, excerpts from depositions 36 22 through 53. I don't know what that last entry is. I 23 have not looked at it. 24 Q Okay. 25 A I don't -- I am actually going to put an "X" on Page 66	1 A They are. 2 Q And is this the collection of articles 3 regarding non-Hodgkin's lymphoma epidemiology that you 4 have reviewed and considered for this case? 5 A Yes, sir. 6 Q Are there any other articles regarding the 7 epidemiology of non-Hodgkin's lymphoma that you have 8 read, reviewed or considered for this case? 9 A So far this is what I have accumulated. I 10 believe that this accurately reflects the literature on 11 this NHL epidemiology. 12 Q So is the answer to my question no? 13 MR. GRANNIS: Hang on. I think he is still 14 answering. 15 THE WITNESS: I also recall that this was a 16 separate folder that also supports my opinions and that 17 I reviewed in this case. So maybe we just need to be 18 more specific on the -- 19 Q BY MR. METZGER: We will come back to this 20 question then. 21 Let me mark as Exhibit 6 then a document which 22 is a printout of a file listing entitled, "Miscellaneous 23 Articles" from your CV. 24 (Deposition Exhibit 6 was marked for 25 identification.) Page 68
1 those numbers. I don't think that I have looked at 2 these, and these are also scanned. 3 Q Okay. 4 A And I am familiar with and in order to identify 5 it to you, have this portion from the medical record 6 which I find to be important though my research in this 7 case. 8 MR. GRANNIS: You are referring to Exhibit 3 to 9 Dr. Sarna's deposition? 10 THE WITNESS: Correct. 11 Q BY MR. METZGER: Okay. All right. We will get 12 to that later. 13 My staff has printed out a file listing from 14 the CD that you provided and this appears to be 15 regarding non-Hodgkin's lymphoma epidemiology articles. 16 We will mark that as 5. 17 (Deposition Exhibit 5 was marked for 18 identification.) 19 Q BY MR. METZGER: Could you tell me if I have 20 correctly identified what that is? 21 A Yes, you have. The heading from the CD printed 22 accurately. 23 Q Okay. So this is a list of the articles 24 regarding non-Hodgkin's lymphoma epidemiology that are 25 actually on the CD that you have provided me? Page 67	1 Q BY MR. METZGER: Is that what you were 2 referring to? 3 A Yes, it is. Thank you. 4 And these don't fall neatly into a single 5 category. And since there aren't so many of them, they 6 are combined on this. 7 And between these two, these do represent the 8 published scientific literature which I relied in 9 formulating my opinions. 10 Q Between Exhibits 5 and 6? 11 A Yes. 12 Q Okay. Are there any epidemiology articles 13 regarding benzene, organic solvents or non-Hodgkin's 14 lymphoma that you are relying on for your opinions in 15 this case which are not listed on Exhibits 5 and/or 6? 16 A The only exception to this list would be 17 articles on which Dr. Harrison relies that I may not 18 have incorporated on my list and addressing his 19 testimony and what he might put forward might also 20 review and critique those articles if they are not on 21 this list. 22 Q How can I know which articles you are referring 23 to? 24 A When he identifies them, then I can identify 25 them. Page 69

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 Q Well, did you receive a CD-ROM which contained 2 all of the articles which Dr. Harrison produced? 3 A Yes. As I understand it is a very large 4 collection of articles that he provided. 5 Q Have you read all of those? 6 A I have not, no. 7 Q Have you read any of the articles that 8 Dr. Harrison provided which are not on your lists 9 Exhibit 5 and 6? 10 A I have not had a chance to compare. I have 11 done my evaluation based on articles that I have 12 identified and there is a good chance there is something 13 that he had identified that I was either unable to 14 identify or find a copy, but I have not made that 15 comparison. 16 Q Well, I am not really asking you to make a 17 comparison. What I want to know is, are there any 18 articles on the CD-ROM that Dr. Harrison produced that 19 you actually read other than those which are on your 20 lists Exhibits 5 and 6? 21 A I have not read all of the articles on his 22 list. It seems I think you are asking slightly 23 different question. 24 Given that I haven't read the articles on his 25 list, unless they are on my list -- Page 70	1 might be an older E-mail because we were first retained 2 in this case a year ago and there was a long inactive 3 period and then restarted in August I believe or 4 September. 5 Q BY MR. METZGER: So it might be missing -- 6 A There might have been an E-mail from an 7 attorney, I believe Mr. Yang at Poole & Shaffery, 8 contacting me initially on the case. 9 Q Okay. If you could just send that to me so we 10 could have that, I would appreciate it. 11 MR. GRANNIS: If it exists. 12 Q BY MR. METZGER: If you have it. If you don't 13 have it, you don't have it. 14 Okay. Is Exhibit 9 the billings in this case 15 which Environ submitted to the Poole & Shaffery firm 16 which retained you for this case? 17 A Yes, through September -- or through August, 18 sorry. 19 Q Are there any more recent billings that have 20 been prepared? 21 A There will be. It hasn't been prepared yet. 22 That will be for the month of September and we are into 23 October now. That will be forthcoming. 24 Q When does Environ send out bills? 25 A It is usually between the third and fourth week Page 72
1 Q You haven't read them? 2 A I haven't read them. 3 Q Fair enough. That is all I was asking. 4 A Okay. Good. I am glad you understood that 5 one. I am sorry. 6 Q You did. Tried to make it simple. Okay. All 7 right. 8 Let's see. I guess we have several copies of 9 this. We will mark this as Exhibit 7 the single page 10 entitled, "Summary of Opinions in Reese." 11 (Deposition Exhibit 7 was marked for 12 identification.) 13 Q BY MR. METZGER: Is this a list or summary of 14 the opinions that you have prepared for this case? 15 A Yes. 16 (Deposition Exhibit 8 was marked for 17 identification.) 18 Q BY MR. METZGER: Is Exhibit 8 a collection of 19 E-mails transmitting various materials to you that you 20 received for this case? 21 A Yes. 22 Q Okay. 23 (Deposition Exhibit 9 was marked for 24 identification.) 25 THE WITNESS: Excuse me, I just recall there Page 71	1 after a month ends. It runs through its process, so it 2 hadn't come out. The one for September hadn't come out 3 yet. Otherwise, I would have provided it. 4 Q Do you have an estimate as to how many hours 5 you have spent during the month of September and October 6 on this case? 7 A Not precisely, but a lot more than in any 8 previous months. 9 Q Give me your best estimate, if you could, 10 recognizing it's an estimate. 11 A I have probably spent a week to 10 days plus 12 staff time. I have no idea how much time. 13 Q How many hours per day? 14 A I was referring to day equivalents so ... 15 Q So -- 16 A 40 to 60 hours. 17 Q And eight to 10 weeks of those, is that what 18 you said? 19 A Days. 20 Q I am not understanding. 21 A That's right, we are not communicating. 22 I have probably spent a week. 23 Q Or 10 days? 24 A Or 10 days. So it is -- 25 Q Eight to 10 hours per day? Page 73

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 A Right. 2 Q I got it. Thank you. 3 And I would like the bill when it does come 4 out. If you could send me that too, please. 5 All right. And you have here some medical 6 records which were Exhibit 3 to Dr. Sarna's deposition. 7 And does this concern the thyroiditis? 8 A Yes, the thyroiditis as well as the site of the 9 lymphoma. 10 Q Okay. I am not going to need to attach that. 11 I believe now we did not -- I have not had my 12 staff yet print out the actual articles on the CD that 13 you provided us, but is it correct that all of the 14 articles that are on this CD are listed on Exhibits 5 15 and 6? 16 A I believe so, yes. 17 Q And -- 18 A You represented that was a screen listing of 19 those? 20 Q Yes. 21 A Right. 22 Q Recognizing that we have not printed out those 23 articles but that we have them on the CD, have you 24 actually now provided me either in paper form or 25 electronic form all of your files for this case? Page 74	1 THE WITNESS: I do address this more 2 specifically in my opinions here, but the 3 epidemiological literature on groups of individuals with 4 non-Hodgkin's lymphoma specifically in the thyroid have 5 also, concurrently or prior to the diagnosis, evidence 6 of thyroiditis. 7 Q BY MR. METZGER: Are you saying that all 8 lymphomas that occur in the thyroid either concurrently 9 or previously have lymphocytic thyroiditis? 10 A No. 11 MR. GRANNIS: Argumentative. Misstates prior 12 testimony. 13 THE WITNESS: No, I didn't say that. 14 Q BY MR. METZGER: Okay. Here is what I want to 15 know: Is the pathological description of inflammation 16 of the thyroid gland consistent with the diagnosis of a 17 non-Hodgkin's lymphoma occurring in the thyroid gland? 18 MR. GRANNIS: It's vague. Overbroad. 19 Misstates prior testimony. It is argumentative. 20 THE WITNESS: I find that to be a pathology 21 question. I am not an expert in that area. 22 Epidemiologically it is -- 23 Q BY MR. METZGER: I understand 24 epidemiologically, but -- 25 A Then I can't answer your pathology question. Page 76
1 A Yes, I have. 2 Q All right. 3 A Understanding that I have only provided you a 4 list of materials that were sent to me. They are not on 5 the CD. 6 Q Right. 7 A They are identifiable and voluminous but ... 8 Q Right. I understand. 9 So now let's take a look at your opinions, 10 which are Exhibit -- 11 A 7. 12 MR. GRANNIS: Yes. 13 Q BY MR. METZGER: There they are, correct. 14 Let's go over this if we could. 15 You first write, "I understand that Mr. Reese 16 was diagnosed with lymphocytic thyroiditis and diffuse 17 large B-cell thyroid lymphoma." 18 What is lymphocytic thyroiditis? 19 A It is inflammation of the thyroid in which 20 lymphocytes are present at some notable level. I am not 21 a pathologist. I am relying on the medical report 22 record for that information. 23 Q Is that type of pathological observation 24 consistent with non-Hodgkin's lymphoma? 25 MR. GRANNIS: Vague. Overbroad. Page 75	1 MR. GRANNIS: Dr. Mundt is here as an expert in 2 epidemiology. And if he wishes to answer your question 3 from an epidemiologic standpoint, I'd appreciate if you 4 would give him the opportunity to do so. 5 MR. METZGER: I thought he gave me his answer 6 to the prior question. 7 MR. GRANNIS: You cut him off, Raphael. 8 Q BY MR. METZGER: Well, I thought you had told 9 me that among patients -- 10 MR. GRANNIS: You still cut him off. I'd 11 appreciate if you would let him finish his answers. 12 Q BY MR. METZGER: Go ahead. 13 A Thank you. 14 The epidemiological perspective, the 15 thyroiditis is clearly a strong risk factor for certain 16 NHL's of the thyroid. 17 Q Okay. Incidentally, have you produced any 18 literature regarding that? 19 A Yes. I believe those articles that pertain to 20 this are in the miscellaneous. 21 Q Okay. All right. 22 MR. GRANNIS: That is Exhibit 6. 23 THE WITNESS: That is correct. 24 Q BY MR. METZGER: Let's just take a quick look 25 at that. Page 77

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 Tell me which of the articles on Exhibit 6 2 pertain to the epidemiology or the epidemiologic 3 association between chronic lymphocytic thyroiditis and 4 non-Hodgkin's lymphoma or B-cell lymphoma. 5 A I can't recall these just off the top of my 6 head, but there are -- there are probably four or five 7 among them. I believe Pedersen, Hyjek, Holm and others. 8 Q Okay. Now, you indicate in your opinions that 9 you have evaluated the epidemiologic literature 10 evaluating the association, if any, between exposure to 11 benzene and other organic solvents, as well as working 12 in printing and related occupations, and increased risk 13 of NHL's including subtypes such as DLBCL and DLBTL; 14 correct? 15 A More or less. I am not sure that you read the 16 word "benzene," but -- 17 Q Okay. In any event, you know where I am 18 referring to in your statement? 19 A Yes, in my preamble, yes. 20 Q In the preamble, okay. 21 Is it correct that there are a number of 22 epidemiologic studies which have shown statistically 23 significantly increased risks or rates of NHL among 24 benzene-exposed workers? 25 MR. GRANNIS: Vague. Overbroad. Incomplete Page 78	1 who committed suicide due to severe itching from his NHL 2 which was not counted in the pliofilm cohort because the 3 cause of death was suicide? 4 MR. GRANNIS: Argumentative. 5 THE WITNESS: I have seen this reported, but 6 you have to keep in mind if you want to count it you 7 would have to do the same thing in a reference 8 populations and make sure that it is a level of 9 inaccuracy that I think would be applied to across the 10 board. 11 Q BY MR. METZGER: So you are aware of that 12 situation? 13 A Yes. 14 Q I see. 15 And what is the incidence of mortality from 16 suicide due to severe itching from non-Hodgkin's 17 lymphoma in the general population? 18 MR. GRANNIS: Vague and ambiguous. Overbroad. 19 Argumentative. Incomplete hypothetical. 20 THE WITNESS: It is not a research question 21 that has ever been posed to me before so I haven't 22 looked at it. 23 Q BY MR. METZGER: You don't know what the 24 incidence is? 25 A I don't know that anyone knows what the Page 80
1 hypothetical. Argumentative. 2 THE WITNESS: There are epidemiological studies 3 that among their reports include statistically 4 significant measures of association in which the cohorts 5 were attempting to associate occupational exposures, 6 including benzene and NHL's as a class or as subsets, 7 subtypes of NHL's. 8 The only cohort I recall that is widely viewed 9 as limiting exposures to benzene is the pliofilm cohort 10 in which NHL's are in fact evaluated. 11 Q BY MR. METZGER: Okay. And there were NHL's 12 identified in the pliofilm cohort, were there not? 13 A There are NHL's identified in any cohort 14 because it is not an uncommon disease. They were not 15 identified in excess in the pliofilm cohort. 16 Q Isn't that because some of the NHL's were left 17 out; they were excluded? 18 MR. GRANNIS: Argumentative. 19 THE WITNESS: I have no reason to believe that 20 the reports as published and updated through at least 21 2002 have not had an opportunity to identify to show 22 NHL's in excess. As of the record that I have, there is 23 no excess. 24 Q BY MR. METZGER: So you are not aware that 25 there was in fact an NHL worker in the pliofilm cohort Page 79	1 incidence is. 2 Q Is that incidence rate ascertainable from 3 existing literature? 4 A I doubt it. 5 MR. GRANNIS: Vague and ambiguous. Overbroad. 6 Calls for speculation. Incomplete hypothetical. 7 Q BY MR. METZGER: So how would you control for 8 that since it can't be ascertained? 9 MR. GRANNIS: Vague and ambiguous. 10 Argumentative. Misstates prior testimony. 11 THE WITNESS: Epidemiologically you have to 12 evaluate whether or not that would lead to a bias. One 13 could add one more NHL to that in a very conservative 14 way and ignore those that might occur in a referent 15 population to determine what the sensitivity of the 16 result was to a single case. 17 Q BY MR. METZGER: Okay. Now, have you read the 18 most recent meta-analysis regarding benzene and 19 non-Hodgkin's lymphoma? 20 A There have been three. Let me clarify which 21 you are referring to. 22 Q Let me ask you please identify for me those 23 meta-analyses regarding benzene and non-Hodgkin's 24 lymphoma that you are aware of that you have read, 25 reviewed and considered for this case. Page 81

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 MR. GRANNIS: Well, that may be two different 2 questions; what's he aware of, what has he read, 3 reviewed and considered, you know. I'd prefer you ask 4 him one question and then another. 5 Q BY MR. METZGER: Let's start with those that 6 you are aware of. 7 A I am aware of Wong's, and I am blanking on the 8 next, and the third is Steinmaus. 9 Q Okay. 10 A If I could take a quick look at Exhibit 5, I 11 could provide it. 12 Q Okay. 13 A Thank you. 14 It is Lamm, the third author. 15 Q So you are familiar with the meta-analyses by 16 Wong, Lamm and Steinmaus; is that correct? 17 A Yes. 18 Q Any others? 19 A Not that I consider or self-identify as 20 meta-analysis. 21 Q I am just asking are you aware of any other 22 meta-analyses regarding benzene and non-Hodgkin's 23 lymphoma? 24 MR. GRANNIS: Overbroad. Vague. 25 THE WITNESS: I identify those as the Page 82	1 Q What reviews regarding benzene and 2 non-Hodgkin's lymphoma have you read, reviewed and 3 considered for this case that you rely on for your 4 opinions in this case? 5 A My reliance is on the primary studies, so I am 6 aware of and have read and reviewed not only the 7 meta-analyses but several reviews on non-Hodgkin's 8 lymphoma and on benzene and non-Hodgkin's lymphoma. 9 Q Which reviews regarding benzene and 10 non-Hodgkin's lymphoma have you read, reviewed or 11 considered for this case? 12 MR. GRANNIS: Vague. 13 THE WITNESS: The ones that I have are on the 14 disk. I can't tell you off the top of my head. 15 Q BY MR. METZGER: Take a look at the listing, 16 please. 17 A Unfortunately without the titles printed I 18 can't reliably identify these, but I know that that 19 Boffetta is a review, Alexander is a review, Morton. I 20 guess there is two Mortons. One in 2008 comes to mind 21 as a particularly relevant review of NHL. 22 I am afraid unless I look at the titles it is 23 difficult. 24 Q Okay. I want to go back to your CV. You 25 mentioned that you have been doing some studies with Page 84
1 meta-analyses distinct from other reviews where results 2 are -- 3 Q BY MR. METZGER: I am not talking about 4 reviews; I am talking about meta-analysis. 5 A Okay. Thank you. 6 I wanted to make sure we were talking about 7 meta-analyses as either the authors describe it or as I 8 would consider it. 9 Q So what I'm asking you is, setting aside 10 reviews and any other type of study, are you aware of 11 any meta-analysis regarding benzene and non-Hodgkin's 12 lymphoma other than those published by Wong, Lamm and 13 Steinmaus? 14 MR. GRANNIS: Vague and ambiguous. Overbroad. 15 THE WITNESS: I am aware of earlier ones which 16 I did not look at closely and factor in. 17 Q BY MR. METZGER: Can you identify it? 18 A Not offhand. 19 Q Can you tell me the results? 20 A No. I didn't examine older materials. I favor 21 newer materials. 22 Q Have you -- well, are you aware of any newer 23 meta-analyses regarding benzene and non-Hodgkin's 24 lymphoma than the three that you identified? 25 A No. Page 83	1 this group in Germany, and I think you identified an 2 article here by an author by the name of Straif or 3 Straif? 4 A Yes. Straif is an IARC employee. 5 Q Is that Kurt Straif? 6 A Kurt Straif, yes. We have worked together for 7 years. 8 Q Okay. Do you respect his work? 9 MR. GRANNIS: Vague. Overbroad. 10 THE WITNESS: I respect him as a colleague. 11 And I would have to look at a particular piece of work 12 because I think everyone is capable of producing 13 something that is not great. 14 I wouldn't label him -- I have no reason to say 15 that I disrespect him in any way. But with respect to 16 his work as a scientist and as an objective evaluator, I 17 would have to review, as I would a peer, submitted 18 publication to one of the journals I review for for the 19 quality of that work. 20 Q BY MR. METZGER: How many years have you worked 21 with Kurt Straif? 22 A I worked with Kurt directly for probably five 23 years surrounding the German rubber study, that 24 constellation of studies. 25 Q And during that time did you form an opinion Page 85

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 regarding the scientific integrity? 2 MR. GRANNIS: Vague and overbroad. 3 THE WITNESS: Well, generally I respect Kurt 4 and his scientific integrity. I would have to reserve 5 the right to comment on a particular piece of work just 6 not because he is a friend or colleague or any other 7 category of person, but as a fellow scientist, we tend 8 to review and critique each other's work. 9 Q BY MR. METZGER: Have you ever discussed with 10 him the relationship between benzene and non-Hodgkin's 11 lymphoma? 12 MR. GRANNIS: Vague and overbroad. 13 THE WITNESS: It is possible in the years we 14 worked together in the German rubber cohorts that may 15 have been discussed. I just don't have any specific 16 recall of it. 17 Q BY MR. METZGER: Okay. Have you prepared any 18 criticism of either the Steinmaus meta-analysis or -- 19 well, let me leave the question at that. 20 Have you done so? 21 A I have not. I have not been asked. Again, 22 this is -- 23 MR. GRANNIS: By your question, you mean like a 24 written critique? 25 MR. METZGER: Yes. Page 86	1 results from a wide array of studies and exposures. 2 Q Have you ever done a meta-analysis regarding 3 either benzene or organic solvents and NHL? 4 MR. GRANNIS: Vague. Overbroad. 5 THE WITNESS: No, I have not specifically done 6 that. 7 Q BY MR. METZGER: Okay. Let's go back to your 8 opinions. 9 In your first opinion you write that "Valid 10 interpretation of epidemiological evidence must consider 11 study strengths and weaknesses, most importantly the 12 avoidance of bias, or systematic error stemming from 13 study design and conduct, data availability, specificity 14 of exposure, specificity of disease, and random error, 15 among others." 16 Did I read that correctly? 17 A Yes. 18 Q Have you -- 19 MR. GRANNIS: Except for the last sentence. 20 MR. METZGER: I will get to that. 21 MR. GRANNIS: Okay. 22 Q BY MR. METZGER: Well, I will read the last 23 sentence for Mr. Grannis. "Failure to avoid or account 24 for such biases can result in invalid results and 25 interpretations." Page 88
1 THE WITNESS: I am certainly aware of what he 2 has done and I think it deserves some more in-depth 3 evaluation. But in the time that I have had available 4 to come up to speed on this case, it has not been a 5 priority. 6 Again, I rely on the primary studies, some of 7 which Steinmaus selects and cites, but that is not the 8 universe. And the end of the day I think that there are 9 serious questions raised by that paper that could be 10 addressed, but it's not a priority scientifically for me 11 to do that. 12 Q BY MR. METZGER: Have you done any statistical 13 compilation of the studies regarding organic solvents 14 and NHL? 15 A No. 16 Q Have you done any statistical compilation 17 regarding the studies of benzene and NHL? 18 MR. GRANNIS: Vague. Overbroad. 19 THE WITNESS: Statistical compilation may not 20 be a valid exercise so -- 21 Q BY MR. METZGER: I am just asking if you did 22 one or not. 23 A I just want to make sure that the reason I 24 wouldn't have done something like that is why would be 25 my question. Why would you statistically compile Page 87	1 That is the last sentence that you wrote in 2 that paragraph; is that correct? 3 A And you read it correctly. 4 Q So here is my question: Have you written out, 5 either for this case or to submit to any journal for 6 publication, an analysis of the strength and weaknesses 7 of the epidemiologic studies regarding benzene or 8 organic solvents and NHL? 9 MR. GRANNIS: Argumentative. Vague and 10 ambiguous. 11 THE WITNESS: I have not produced such a 12 document. 13 Q BY MR. METZGER: Okay. Have you produced such 14 a document regarding bias in those studies? 15 A No. 16 Q Or systematic error in those studies? 17 MR. GRANNIS: Same objections. 18 THE WITNESS: No, I have not produced written 19 documents of the qualities of or lack of qualities of 20 these various articles. 21 Q BY MR. METZGER: Or data availability? 22 MR. GRANNIS: Same objections. 23 THE WITNESS: Same answer. 24 Q BY MR. METZGER: Specificity of exposure? 25 MR. GRANNIS: Same objections. Page 89

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 THE WITNESS: That's right, I have not written 2 a report on this topic covering these dimensions of my 3 opinion. 4 Q BY MR. METZGER: Okay. Have you in any way 5 compiled a list of the studies that you think suffer 6 from such biases versus those that don't? 7 MR. GRANNIS: Same objections. 8 THE WITNESS: No. I think that it is an 9 oversimplification. If I were to critically assess the 10 individual studies, they would not fall into one or 11 another. 12 It really requires a critical assessment of how 13 those results might have come about and whether that is 14 a valid representation of the study. 15 Q BY MR. METZGER: In your second opinion you 16 write that "There is insufficient/inadequate evidence to 17 validly support a conclusion that these chemicals cause 18 NHL's, including diffuse large B-cell lymphoma." 19 What evidence are you looking to for you 20 conclude that the evidence would be sufficient or 21 adequate? 22 A Fair question. The method and process that I 23 use is pretty similar to what is used by the 24 epidemiology group at the IARC reviews where the better 25 studies are identified based on their methodology, Page 90	1 Q No. I want a complete listing; not an example. 2 A Well, I told you three minutes ago that I 3 didn't do that evaluation specifically for this case in 4 a way that I could represent that these are the 12 best 5 articles for this purpose. 6 But, for example, Rinsky, which I don't think 7 we see in Steinmaus, Sorahan, large study NHL's in some 8 of the most highly exposed workers in the U.K., not 9 included. 10 So my criticism is of what has been done and 11 that it fails to achieve a level adequate to draw the 12 conclusions that Dr. Harrison has drawn. 13 Q Well, I am not asking about Dr. Harrison's 14 conclusion; I am asking about your conclusion. 15 What I want to know is what quantum of evidence 16 do you need for you to conclude that the association 17 between benzene and NHL is causal, what is that level of 18 sufficient and adequate evidence for you? 19 MR. GRANNIS: Compound. Vague and ambiguous. 20 Overbroad. 21 Q BY MR. METZGER: Can you quantify it for me, 22 please? 23 A I don't think it can be quantified. I did 24 qualify it earlier by saying that you would need among 25 this group, however defined, of better studies, strong Page 92
1 typically case control, cohort studies. Not to say the 2 others are discarded, but they certainly carry less 3 weight. 4 And then of those that are on point, I would 5 identify studies looking at specific exposures and -- 6 for example, the diffuse B-cell lymphomas, there are a 7 few studies that look specifically at subtype NHL. 8 And among those that have reasonable quality, 9 that is large enough sample size, consideration of 10 confounding, consideration for potential for selection 11 bias, reporting bias; then look at among that subset how 12 strong and how consistently is that association 13 important. 14 Q Okay. Did you do that for this case? 15 MR. GRANNIS: Vague. Overbroad. 16 Argumentative. 17 THE WITNESS: In some ways I certainly have. 18 Q BY MR. METZGER: Okay. 19 A Not to the extent of -- well, let's say enough 20 of the review of these papers to note that they have not 21 been sufficiently critiqued by Dr. Harrison to justify 22 his conclusions. 23 Q Well, which are the pertinent studies that you 24 identified for this case? 25 A For example -- Page 91	1 and consistent associations that are not otherwise 2 explained by study bias or error. 3 Q How strong? 4 A I don't know that it needs to be specifically 5 quantified. If you have 20 studies and 15 of them show 6 positive associations ranging from, you know, 1. 7 something to 34 or higher, you would clearly in that 8 situation more readily embrace a conclusion, again, 9 assuming that the individual studies aren't flawed. 10 You might be more willing to conclude 11 epidemiologically that there is something going on than 12 in the literature that we have at hand where the results 13 range from appearing to be protective against NHL to 14 positive studies showing a statistically significant 15 association. 16 Q How consistent do the studies have to be? 17 A Again, I don't know that consistency is ever 18 quantified. It is I think part of the practice of 19 evaluating epidemiologic literature that one identifies 20 enough consistent evidence and a lack of opposing 21 evidence to lean toward a judgment of causation. 22 Q When you refer to studies showing a protective 23 evidence against NHL, are you referring to studies that 24 report statistically significant negative correlations 25 between benzene and NHL? Page 93

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 A It is interesting wording because it seems that 2 statistically significant negative associations are 3 usually described that way, but statistically 4 significant positive findings typically described as 5 causal. 6 I think epidemiologically we view them as 7 statistically significant positive or negative, and that 8 the big picture is some objective understanding of their 9 entirety. 10 Q I don't know that you answered my question, but 11 probably because I didn't understand your answer. 12 Let me ask you this: From all of the studies 13 that you have reviewed that are set forth on Exhibits 5 14 and 6, were there any studies that reported 15 statistically significantly negative correlations 16 between benzene exposure and NHL? 17 MR. GRANNIS: Vague and ambiguous. Overbroad. 18 Argumentative. 19 THE WITNESS: I would expect so. 20 Q BY MR. METZGER: I am not asking what you 21 expect. 22 Could you identify any studies? 23 A Not off the top of my head. 24 MR. GRANNIS: Same objection. 25 Q BY MR. METZGER: And during the course of your Page 94	1 in organic solvents. 2 A Yes, there certainly are. 3 Q What are they? 4 A They are in there. 5 Q Which are they? 6 A Well, we could go through it, but they are -- 7 Q I am asking you to identify any. 8 MR. GRANNIS: This is not a memory test. If 9 the witness would like to refer to a document or to his 10 CD-ROM, let him do so. 11 Q BY MR. METZGER: Can you identify any by 12 looking at the listing of the studies on Exhibits 5 or 13 6? 14 A Well, it is also not a meaningful exercise for 15 me because I am not putting forward that any of these 16 exposures are protective. 17 Q Okay. Fair enough. 18 A I am pointing out that the results are randomly 19 distributed about the null; some positive, some 20 negative, some significant, both in each direction. 21 Q What methodology did you employ in reaching 22 your conclusion regarding general causation? 23 MR. GRANNIS: Vague and ambiguous. Overbroad. 24 THE WITNESS: I would say the methodology is 25 described by the process that IARC uses, which is a Page 96
1 review of the study on Exhibits 5 and 6, which you 2 reviewed for this case, did you identify any 3 statistically significantly negative studies with a 4 correlation between organic solvent exposure and NHL? 5 MR. GRANNIS: Same objections. 6 THE WITNESS: I can't recall specifically. 7 Q BY MR. METZGER: Have you identified any 8 studies which demonstrate that exposure to solvents or 9 benzene produces a protective effect against the 10 development of non-Hodgkin's lymphoma? 11 MR. GRANNIS: Same objections. 12 THE WITNESS: And by protective you mean a 13 negative correlation. I am resistant to using the word 14 "protective" as much as I am resistant to using the word 15 "causal" for a positive study. 16 Q BY MR. METZGER: I only asked because you 17 referred to a protective study that showed a protective 18 effect against NHL. 19 Are there any? 20 MR. GRANNIS: Same objections. 21 THE WITNESS: Well, I don't know what your 22 question is. Are you asking whether there are studies 23 that find statistically significant deficits of NHL in 24 exposed populations? 25 Q BY MR. METZGER: Populations exposed to benzene Page 95	1 critical review and synthesis. 2 Q BY MR. METZGER: Is that based upon the 3 Bradford Hill factors? 4 A Certainly Bradford Hill in the '60s brought 5 occupational medicine or helped focus occupational 6 medicine on applying a little bit more reasoning in 7 drawing causal conclusions. 8 And I believe most epidemiologists are well 9 aware of Bradford Hill's guidelines and incorporate them 10 in their thinking. 11 Q Did you -- 12 A But I think that what Bradford Hill doesn't go 13 into adequately as would be, you know, embraced today is 14 a fuller critical assessment of the findings rather than 15 let's say a summation of the findings and applying 16 arbitrarily these guidelines. 17 I certainly do embrace those as seminal 18 developments as with the Surgeon General 64 parallel set 19 of scientific considerations that help focus scientific 20 evidence and epidemiologists on how to synthesize and 21 conclude based on that evidence. 22 Q In reaching your conclusion for general 23 causation in this case, did you evaluate the studies 24 using the Bradford Hill factors? 25 MR. GRANNIS: Argumentative. Page 97

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 THE WITNESS: I am not sure that is an 2 appropriate exercise. I think it is unusual for an 3 epidemiologist to sit down and use something, a 4 guideline like that. 5 On the other hand, the critical points that we 6 do use in evaluating individual studies are compatible 7 with those general principles. 8 But, for instance, to determine whether 9 exposure preceded the disease is not a particularly -- 10 although it is the most necessary, perhaps the only one 11 that's necessary in determining causation, not usually 12 the focus of any attention in a critical review or 13 assessment. 14 Q BY MR. METZGER: I appreciate your statement. 15 But I just want to know in reaching your conclusion in 16 this case did you or did you not attempt to faithfully 17 apply the Bradford Hill factors? 18 MR. GRANNIS: Excuse me. Vague. Ambiguous. 19 Overbroad. Argumentative. 20 THE WITNESS: And I don't want to be 21 argumentative because I know Bradford Hill and they are 22 mistakenly referred to as criteria often are well 23 respected, but that reduces what epidemiologists today 24 do to fairly intuitive concepts. 25 That doesn't mean that they necessarily apply Page 98	1 Q BY MR. METZGER: Okay. 2 A But not in a mechanical way. I don't want to 3 imply it is appropriate to take these nine guideposts, 4 guide points and that epidemiological critical review 5 can be reduced to ticking off nine boxes. 6 Q You did mention that the approach that you 7 followed was that in which you believe IARC employs; is 8 that correct? 9 A Yes, in the epidemiology section of IARC. 10 Q Okay. It is true, is it not, that IARC 11 classifies chemicals as to their carcinogenicity? 12 A That is I believe the purpose of the monograph 13 series and the associated meetings is to identify 14 carcinogens. 15 It has not been limited to chemicals per say. 16 It has included things like shift work and fire 17 fighting. 18 Q And occupations like painting? 19 A And painting, which are not chemicals or 20 exposures. 21 Q Right. Okay. 22 But it is also true, is it not, that IARC does 23 not classify chemicals as lymphomagens? 24 MR. GRANNIS: Overbroad. Vague. 25 THE WITNESS: That is not true. Technically I Page 100
1 directly to a study. They really were intended to apply 2 to the occupational medical community who in its day was 3 finding many, many associations and reporting them. 4 Bradford Hill was cautioning that you really 5 need to think through before you draw these conclusions. 6 So he says given an association, does it fit these 7 things. 8 Q BY MR. METZGER: I understand. 9 My question is, did you or did you not apply it 10 and consider the Bradford Hill factors in reaching your 11 causal opinion in this case? 12 MR. GRANNIS: Same objections. And asked and 13 answered. 14 THE WITNESS: I absolutely applied the 15 principles embraced by those. 16 Q BY MR. METZGER: Okay. 17 A But I do not go through a checklist of those 18 things, which is incompatible with their intended use. 19 Q When you say that you absolutely do that, did 20 you do that in this case? 21 A With what? 22 Q For in assessing the studies between -- 23 regarding benzene or organic solvent and NHL. 24 MR. GRANNIS: Vague. Overbroad. 25 THE WITNESS: Again, yes, absolutely. Page 99	1 understand what you are getting at. IARC traditionally 2 had identified chemicals as carcinogenic. 3 As of about 2006 they have required the 4 committees to identify the sites that are supportive of 5 that conclusion. 6 Of course that can't be exhaustively known. It 7 is a function of how much and how -- what the quality of 8 the epidemiology literature is on that particular 9 relationship. 10 Q BY MR. METZGER: But even since 2006 IARC does 11 not have a classification system for the classification 12 of lymphomagens. True? 13 A Well, if you narrow it to that, nor for any 14 other specific site. It is covered by their more recent 15 procedures for identifying the sites for which the -- 16 let's say Group I designation applies in their opinion. 17 Q Okay. In your second opinion, the last 18 sentence, the one that Mr. Grannis wanted -- I am sorry. 19 The last sentence of your second opinion says, 20 "Furthermore, there is substantially evidence detracting 21 from this hypothesis," namely that benzene or organic 22 solvents cause NHL. 23 What is that substantial evidence that you are 24 referring to? 25 A It comes in various forms. Let's simplify it Page 101

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 and say that is two forms. 2 One is the large number of studies that don't 3 find any association. I believe many of those resulted 4 in the findings in Lamm and Wong's meta-analyses. 5 The other is if you look at the range of 6 exposures; not just chemicals, but range of risk factors 7 say for NHL there is hundreds of them. 8 And though you can tease benzene or solvent out 9 of some of these studies, there is many, many other 10 exposures that have produced excess risk estimates, 11 including being a clergyman or involved in the 12 transportation industry or working with meat or working 13 on a farm. 14 So to isolate the benzene in chemicals from 15 this kind of cacophony of noise from these studies, I 16 think is not a balanced approach. 17 We really only have to look at say a state of 18 the art review like Morton 2008 to see that, despite all 19 of these findings across the studies, that these -- this 20 very qualified group doesn't identify any of them as 21 particularly compelling risk factors associated with 22 NHL. 23 Q Are there any primary studies that you consider 24 to provide substantial evidence detracting from the 25 hypothesis that benzene or organic solvents causes NHL? Page 102	1 not report a positive association, did any of them have 2 sufficient statistical power to detect a doubling of the 3 risk at low concentrations, around one part per million? 4 MR. GRANNIS: Argumentative. Vague and 5 ambiguous. Incomplete hypothetical. 6 THE WITNESS: I would think so. 7 Q BY MR. METZGER: Do you know so? 8 A I wasn't finished. I am sorry. If you want 9 to -- 10 MR. GRANNIS: Go ahead. 11 Q BY MR. METZGER: Are you speculating when you 12 say "I would think so"? 13 MR. GRANNIS: That is another question. Let 14 him finish the last question. 15 MR. METZGER: I thought that was an answer. 16 MR. GRANNIS: He just said he wasn't finished. 17 Q BY MR. METZGER: Give me your explanation and 18 then we will go on. 19 A Sorry, I have lost track of the question now. 20 Could we have a read back. 21 MR. GRANNIS: Thank you. 22 (Record read as follows: 23 "Q Did any of those studies -- what you 24 are referring to as the studies in the 25 Lamm review which did not report a Page 104
1 MR. GRANNIS: Vague. Overbroad. 2 Argumentative. 3 THE WITNESS: I think you are asking for 4 specific references. 5 Q BY MR. METZGER: Yes. 6 A I think that a look at the literature that I 7 have provided you there are numerous studies that fail 8 to show a positive association. And that those, though 9 they cannot prove a lack of association, certainly 10 detract from that hypothesis. 11 Q Can you identify those studies for me. 12 A I believe I did indirectly by citing the 13 studies identified in the meta-analyses of Wong and 14 Lamm. 15 Their arriving at a conclusion of no 16 association is driven by studies, some positive, some 17 negative, but on average showing no association. 18 Q Can you identify any other studies other than 19 those in Wong and Lamm? 20 A I am not representing Wong and Lamm as those 21 studies. I am representing that among their studies 22 reviewed will be ample studies that in sum provide no 23 evidence of increased risk in those populations. 24 Q Did any of those studies -- what you are 25 referring to as the studies in the Lamm review which did Page 103	1 positive association, did any of them 2 have sufficient statistical power to 3 detect a doubling of the risk at low 4 concentrations, around part per 5 million?") 6 THE WITNESS: And I began to answer that I 7 would think so, but not having done a power calculation 8 can't sit here and say yes. 9 But, for example, Sorahan. Sorahan is one of 10 the largest studies that both of those reviews I believe 11 consider that would have found an increase as large as a 12 doubling had there been one and there probably are 13 others but... 14 Q BY MR. METZGER: Are you referring to the 15 recent Sorahan study published around, what was it, 16 2005? 17 A Yes. 18 Q Well, that post dates both the Lamm and the 19 Wong reviews, doesn't it? 20 A Sorahan 2002, it might. You are right so ... 21 Q Okay. 22 A But I believe it answers your question, a paper 23 that has adequate power to detect a doubling. 24 Q Have you read any criticisms of the Sorahan 25 study? Page 105

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 A I recall an exchange or a criticism that was 2 appropriately addressed and dispensed with. I don't 3 recall what the criticism was. 4 Q Do you recall who authored the criticism? 5 A No. 6 Q Do you recall who authored the explanation or 7 the justification -- 8 A No. 9 Q -- addressing the criticism? 10 A No, I don't recall. 11 Q Okay. Now, I didn't -- in looking through the 12 lists of the literature on Exhibits 5 and 6, I didn't 13 see any animal studies. 14 Were there any? 15 A I am sorry. I am an epidemiologist. 16 Q So you didn't consider any animal studies for 17 your -- 18 A Epidemiology -- 19 MR. GRANNIS: Excuse me. Argumentative. Vague 20 and ambiguous. Overbroad. 21 THE WITNESS: -- has the pesky root of -demos 22 in it which pertains to people. 23 Q BY MR. METZGER: Well, my question though is 24 did you consider any animal studies regarding benzene 25 and lymphoma or organic solvent and lymphoma in reaching Page 106	1 animal studies; correct? 2 MR. GRANNIS: Same objections. 3 THE WITNESS: I did not review any animal tox 4 studies. 5 Q BY MR. METZGER: Did you review any 6 experimental studies regarding the ability of the 7 benzene or organic solvents to cause hematotoxicity, 8 lymphopoietic toxicity, alterations of immune function, 9 did you consider any of those studies? 10 MR. GRANNIS: Vague and ambiguous. Overbroad. 11 Argumentative. 12 THE WITNESS: In humans or in animals? 13 Q BY MR. METZGER: In either, in reaching your 14 opinions in this case. 15 A No. 16 MR. GRANNIS: Same objections. 17 Q BY MR. METZGER: Did you consider any studies 18 evaluating the clastogenic potential -- strike that. 19 Did you consider any studies evaluating 20 clastogenicity of benzene and/or organic solvents in 21 reaching your opinions in this case? 22 MR. GRANNIS: Vague and ambiguous. Overbroad. 23 Argumentative. 24 THE WITNESS: Yeah. I think I made it clear 25 that I reviewed the epidemiologic literature and I don't Page 108
1 your causal opinion in this case? 2 MR. GRANNIS: Compound. Vague and ambiguous. 3 Overbroad. Argumentative. 4 THE WITNESS: And outside of my area of 5 expertise. 6 Q BY MR. METZGER: So you did consider those; is 7 that correct? 8 MR. GRANNIS: Same objection. 9 THE WITNESS: I am an epidemiologist. 10 Q BY MR. METZGER: I just want to know if you 11 considered those, "Yes" or "No." I am not asking what 12 you are. 13 MR. GRANNIS: You are interrupting him again. 14 I believe he has given you his answer and explained the 15 reason for it. 16 MR. METZGER: I didn't get a clear answer. 17 Q Have you considered any animal studies 18 regarding benzene or solvent exposed animals and the 19 development of non-Hodgkin's lymphoma in reaching your 20 opinion as to whether solvents and benzene causes NHL? 21 MR. GRANNIS: Same objections. 22 THE WITNESS: My research and therefore my 23 opinions are based on my evaluation of the 24 epidemiological literature only. 25 Q BY MR. METZGER: So you did not consider any Page 107	1 think that the epidemiological studies address 2 toxicology or pathology directly. 3 I'm certainly dependent on them for 4 understanding what we are studying and how we might 5 design a study, but I did not review that literature. 6 It is outside of my area of expertise. 7 Q BY MR. METZGER: Okay. Do you believe that it 8 is appropriate to make a causal assessment without 9 considering animal studies and experimental studies? Do 10 you? 11 MR. GRANNIS: Argumentative. Vague and 12 ambiguous. Overbroad. Incomplete hypothetical. 13 THE WITNESS: It also depends on what is 14 available. Unfortunately, much research that we would 15 like to have on humans, the relevant species, in actual 16 doses that are encountered in whatever workplace 17 settings, but we don't. 18 So to some extent we have to factor in evidence 19 from other sciences to supplement what is seen 20 epidemiologically. 21 Q BY MR. METZGER: My question is, do you 22 consider it to be a valid scientific methodology not to 23 consider animal studies and other experimental studies 24 in reaching a determination on the issue of general 25 causation? Page 109

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 MR. GRANNIS: Vague and ambiguous. Overbroad. 2 Argumentative. Incomplete hypothetical. 3 THE WITNESS: I think that if one is conducting 4 this review epidemiologically, as the epidemiology 5 section would at IARC, they come to a conclusion despite 6 what others are discussing in the other rooms on animal 7 studies or on mechanism. 8 So they do come to a conclusion as to whether 9 the evidence epidemiologically is sufficient to support 10 a causal determination. 11 So the methodology -- 12 Q BY MR. METZGER: So you consider it a valid -- 13 A And I am not sure if you are referring to it in 14 any setting, but certainly an epidemiological evaluation 15 can be done exclusively of the evaluation of these 16 other. Ultimately I think they combine. 17 Q BY MR. METZGER: When you say they combine, do 18 you mean that in reaching a causal determination it is 19 both necessary and appropriate to consider all of the 20 available scientific evidence that bears on the 21 question, not just the epidemiology but also toxicology 22 and experimental studies? 23 MR. GRANNIS: Compound. Vague and ambiguous. 24 Argumentative. Overbroad. Incomplete hypothetical. 25 THE WITNESS: That is a different question. I Page 110	1 Q Which studies? 2 A I am not -- I can't say that he has identified 3 specifically a set of studies in which he relies. 4 Q Did you read the 200 odd page declaration that 5 he prepared regarding benzene/organic solvents and 6 non-Hodgkin's lymphoma? 7 A I did. 8 Q Okay. And there were a lot of studies 9 identified in that, were there not? 10 A There is a huge number of studies identified -- 11 Q Which of those studies do you have -- 12 A -- some of which I expect he will specifically 13 identify as key in relying upon. I believe there was 14 one, Hayes. I expect that if he advances his opinions 15 based on Hayes, that I would critique Hayes because I 16 don't think he has. 17 Q All right. What are your critiques of the 18 Hayes study? 19 MR. GRANNIS: Which Hayes study? 20 MR. METZGER: The one that he is referring to. 21 MR. GRANNIS: Well, okay. Vague and ambiguous. 22 Overbroad. Incomplete hypothetical. Argumentative. He 23 did not say "the Hayes study." 24 The witness did not say "the Hayes study." The 25 witness said, "Hayes." Page 112
1 do believe that to make a causal judgment we want to 2 factor in all available evidence from these other 3 fields. 4 I think you had worded it quite differently 5 before so I had a hard time answering it. 6 Q BY MR. METZGER: And in fact when IARC makes 7 its determinations, IARC reviews and assesses the 8 strength of the animal evidence and also the other 9 experimental studies, including DNA studies and other 10 types of studies. True? 11 MR. GRANNIS: Vague and ambiguous. Overbroad. 12 THE WITNESS: Generally true, and as available. 13 For instance, for painting there were no animal studies 14 and I presume there are no animals that are painting. 15 Q BY MR. METZGER: Okay. Are all of the opinions 16 that you have formed for this case set forth in Exhibit 17 7? 18 A Certainly these are my central opinions. There 19 are probably variations on these that supplement these 20 opinions. 21 For example, to the extent that evidence put 22 forward by let's say Dr. Harrison relies on 23 epidemiological studies, I would expect to critique, as 24 we discussed earlier, on these criteria, those studies 25 that he relies upon. Page 111	1 Q BY MR. METZGER: I assume that you are 2 referring to the 1997 study by Hayes published in JNCI; 3 is that correct, doctor? 4 MR. GRANNIS: That's not what Dr. Harrison 5 limited himself to. 6 THE WITNESS: Well, in fact that is one of 7 several from the group that includes Yin. I think the 8 same results were published many times. 9 Q BY MR. METZGER: Actually the results regarding 10 lymphoma were published in the Hayes 1997; correct, not 11 in the other -- 12 A I don't think that is accurate, but we could 13 check. 14 Q What are your criticisms of the Hayes 1997 15 study? 16 A Well, for one, with respect to NHL there is 17 certain question regarding the actual diagnosis of 18 NHL. 19 Q Really? 20 A In the article -- 21 MR. GRANNIS: Excuse me, counsel. 22 Q BY MR. METZGER: Are you serious? 23 MR. GRANNIS: Excuse me, counsel. The witness 24 has not finished his answer. He is entitled to answer 25 your question. Page 113


A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 Q BY MR. METZGER: I am sorry. I do apologize 2 for interrupting. I was just flabbergasted by the first 3 statement. 4 MR. GRANNIS: Okay. Flabbergasted -- 5 Q BY MR. METZGER: Finish your answer and we will 6 go ahead and talk about that. 7 MR. GRANNIS: One thing at a time, exactly. 8 Go ahead. 9 THE WITNESS: For example, you will read in 10 many of the NCI publications that there were panels of 11 reviewers verifying diagnosis and that they looked at 12 pathological specimens for these cases. 13 Do you know how many they had for NHL? Four. 14 So three of which were confirmed, two of which were 15 follicular, one of which was diffuse B. The rest we 16 don't know. 17 I raise the question. I am not saying that I 18 know that those are undiagnosed, but I think there is 19 that sense that the quality of the diagnosis is better 20 than it actually is if you read deeply into the Hayes 21 family of publications. 22 Q BY MR. METZGER: And where do you -- in which 23 Hayes study do you find what you just stated, that there 24 were four that were pathologically reviewed? 25 A I believe it is Travis. May I refer to Exhibit Page 114	1 MR. GRANNIS: Argumentative. Vague and 2 ambiguous. Overbroad. 3 THE WITNESS: I think the intent was good. The 4 reality of any of these studies is not the intent, 5 however. It is what is in the data. 6 Q BY MR. METZGER: Let's talk about -- 7 A Noteworthy, since you point out that the Mayo 8 Clinic diagnosed these cases, that the one that -- of 9 the four that is questionably NHL has always been 10 included in the analyses as if it were confirmed, as 11 were the other, what were there, 12 or maybe 20 total. 12 I don't recall the number. 13 But the rest that were not confirmed are all 14 included. And that harkens to your comment on the 15 Rinsky, that there are always cases that might have been 16 in and out. 17 You will find that in the Hayes study that you 18 don't have to remove one or two or more or add one or 19 two more to the referent group that whole statistically 20 significant finding comes apart. 21 Q Can you identify for me any other epidemiology 22 study in which the investigators went to the trouble of 23 attempting to confirm pathological diagnosis on the 24 reports by sending the specimens themselves to the Mayo 25 Clinic for pathological analysis? Page 116
1 5? 2 MR. GRANNIS: 5. 3 THE WITNESS: 5 or 6. 4 Q BY MR. METZGER: I know the Travis study. That 5 is fine. 6 MR. GRANNIS: But if he wants to refer to it -- 7 Q BY MR. METZGER: You could refer to whatever 8 you want. Look at whatever you want. I know what you 9 are referring to. 10 MR. GRANNIS: This is 5 here or there? 11 MR. METZGER: I think this is my set. 12 MR. GRANNIS: Well, I see. 13 All right. Go ahead. 14 THE WITNESS: Travis is there, Travis '94. 15 Q BY MR. METZGER: All right. In fact, regarding 16 the pathology review, the pathology specimens that were 17 the subject of the Hayes study were reviewed by 18 pathologists at the Mayo Clinic, were they not? 19 MR. GRANNIS: Vague. Overbroad. Ambiguous. 20 THE WITNESS: I understand that all four of 21 them. 22 Q BY MR. METZGER: And do you consider -- isn't 23 that a very positive feature of the study, that the 24 specimens were in fact reviewed by pathologists from the 25 Mayo Clinic? Page 115	1 MR. GRANNIS: Argumentative. Vague and 2 ambiguous. Overbroad. 3 THE WITNESS: I think that the pathological 4 confirmation is much more prevalent in the U.S. and that 5 registry based studies and just the degree of accurate 6 diagnosis is going to be greater in the U.S. 7 I think there were fundamental concerns about 8 the quality of the diagnoses and the data in China and 9 therefore this was implemented to try to address that. 10 I think -- I am not questioning their intent. 11 Again, the reality was that they could not obtain path 12 verification on the vast majority of the cases. 13 Q BY MR. METZGER: And the epidemiologic studies 14 that you have conducted, have you ever sent or arranged 15 for the pathology specimens to be sent to the Mayo 16 Clinic for pathological confirmation of the diagnosis? 17 MR. GRANNIS: Argumentative. Vague and 18 ambiguous. Overbroad. 19 THE WITNESS: I say analogously in my German 20 silica worker study, we sent every single x-ray to the 21 German B-readers to be re-read so that we would have a 22 high quality of diagnosis before we tried to published 23 any paper on the risks -- quantitative risks of 24 silicosis and myelo Class I,I x-ray interpretation. 25 Q BY MR. METZGER: In any of the epidemiologic Page 117

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 studies that you have done, did you ever send pathology 2 specimens of patients diagnosed with cancer to the Mayo 3 Clinic to have the Mayo Clinic's expert pathologists 4 confirm the diagnosis? 5 MR. GRANNIS: Argumentative. Vague and 6 ambiguous. Overbroad. 7 THE WITNESS: No, I have not. I have not had 8 the opportunity to do comparable research in a place 9 where I had seriously questions about a diagnostic 10 capability locally. 11 Q BY MR. METZGER: You mentioned that there were 12 some variation on a theme for these opinions. 13 What other opinions do you have for this case 14 that are not set forth on Exhibit 7? 15 MR. GRANNIS: Mischaracterizes his prior 16 testimony. 17 THE WITNESS: These in fact are the main themes 18 and anything that I would testify to as far as I know 19 right now at this moment, given other, you know, usual 20 caveats that things may change or another paper may be 21 published that somehow changes things, my opinions will 22 largely be based on these. 23 They could be -- this is only a few paragraphs. 24 I didn't write a 300-page report, so obviously these 25 could be expanded in detail, but they would be Page 118	1 that the matters on which Dr. Harrison is relying for 2 his assessment of the general causation issue are those 3 papers identified in his 200 odd page declaration, plus 4 the additional papers which supplement that that were 5 published after he prepared that declaration. 6 So with that understanding, are there any 7 opinions that you have for this case that are not set 8 forth in Exhibit 7? 9 A No. 10 Q Okay. And have you -- is there any particular 11 work that you have been asked to perform for this case 12 that you have not yet done? 13 A No. I have not been asked to do anything more 14 than what I have described here. 15 Q Were there any materials or publications that 16 you wanted to read for this case but which were not 17 available to you so you could not consider them in 18 reaching your opinions? 19 A That is a very good question. I appreciate 20 that. I believe that I to date have been able to find 21 and consider any of those materials that arose in the 22 course of my review. 23 Q Okay. Is your opinion in this case limited to 24 opinions on the subject of general causation or are you 25 also opining regarding specific causation? Page 120
1 encompassed under these. 2 Q BY MR. METZGER: Are there any opinions that 3 you have formed in this case that are not encompassed in 4 the opinions set forth in Exhibit 7? 5 A No, sir. I did my best to write these as 6 carefully as I could to cover those bases. 7 Q Have you completed your work in this case? 8 A I don't think so. 9 Q What else do you need to do that you haven't 10 done? 11 A I think when it becomes clearer what 12 specifically Dr. Harrison might rely upon -- I have 13 described this before -- I will take a closer, more 14 critical look at it to see whether his conclusions can 15 be substantiated when the quality of the study and the, 16 you know, evaluation of these -- these are things that 17 he did not consider that I could tell for any one of the 18 hundreds of papers that he identified. 19 I would -- 20 MR. GRANNIS: "These" being the issues 21 addressed in your summary of opinions? 22 THE WITNESS: Paragraph 1 of my opinions, I 23 would expect to apply that to each and every paper that 24 he puts forward. 25 Q BY MR. METZGER: I'd like to represent to you Page 119	1 A Well, that construct is -- translates into 2 epidemiologically causation determination because 3 epidemiology we tend to focus on determining general 4 causation. 5 Q Right. 6 A Where general causation is substantiated and a 7 conclusion can reasonably be determined, there are 8 epidemiological approaches to addressing specific 9 causation. 10 Q Have you done that in this case or have you not 11 because you do not believe that general causation is 12 satisfied? 13 A Well, I am confident that general causation is 14 not met with respect to the B -- diffuse-B, whether it 15 is in the thyroid or not, that has not been determined. 16 There is additionally evidence that risk 17 factors that Mr. Reese has evidence of do cause that 18 disease or are strongly associated with it in 19 epidemiologic terms. 20 Q Well, I guess my question is, are you going to 21 be testifying at trial that Mr. Reese's exposure to 22 benzene was insufficient to cause hematologic disease? 23 A I am not aware that that is the question in 24 this case. I think that Mr. Reese has a specific 25 disease and I think that the epidemiological evidence is Page 121

A3074BC
KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

1 REPORTER'S CERTIFICATION 2 3 I, SHERI A. PLY, CSR No. 6507, a Certified 4 Shorthand Reporter in and for the State of California do 5 hereby certify: 6 That the foregoing proceedings were taken before 7 me at the time and place therein set forth, at which 8 time the witness was placed under oath by me; 9 That the testimony of the witness and all 10 objections made at the time of the examination were 11 recorded stenographically by me and were thereafter 12 transcribed; 13 That the foregoing transcript is a true and 14 correct record of the testimony so taken. 15 I further certify that I am not a relative or 16 employee of any attorney or of any of the parties, nor 17 financially interested in the action. 18 I declare under the penalty of perjury under the 19 laws of the State of California that the foregoing is 20 true and correct. 21 22 Dated this 21st day of October, 2009. 23  24 _____ 25 SHERI A. PLY, CSR No. 6507	
Page 126	

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

A				
ability 108:6	Aladdin 47:6	approaches 35:20 121:8	103:17 104:1 105:1	44:1 46:5,15 50:19
able 14:19 40:19 42:5	Alameda 47:10	appropriate 7:16,17 98:2	associations 93:1,6 94:2	51:23 55:8 56:22 59:10
120:20	Alexander 84:19	100:3 109:8 110:19	99:3	59:14 62:25 65:4 68:10
absolutely 11:22 35:4	alleged 33:3,13 44:5 58:3	appropriately 42:18	assume 46:11 53:2 113:1	72:3,7 74:11,16 77:19
99:14,19,25	65:12 122:10	106:2	assuming 93:9	78:7 79:19 97:8 100:7
abstracts 10:22 11:3,6	alleging 49:18	arbitrarily 97:16	Atkinson-Baker 1:21	100:12 102:3 103:12
academic 22:10	altercations 108:8	area 29:15,16,17 76:21	attach 74:10	105:10,22 107:14
access 52:13	ambiguous 80:18 81:5,9	107:4 109:6	attempt 49:13 98:16	109:7 111:1 112:13
accomplish 123:25	83:14 89:10 92:19	areas 19:7 27:24 30:19	attempting 79:5 116:23	114:25 120:20 121:11
account 88:23	94:17 96:23 98:18	50:13	attempts 23:22	122:18
accumulated 68:9	104:5 106:20 107:2	argumentative 14:8,24	attention 98:12	believed 60:20,23
accurate 10:17 22:3	108:10,22 109:12	15:5,19 35:18 36:6	attorney 33:21 54:22	bell 59:15 63:17,22
113:12 117:5	110:1,23 111:11	38:23 39:6,17 40:4	59:11 62:4 72:7 126:16	benefit 19:11
accurately 18:8 42:18	112:21 115:19 116:2	41:10 42:16 51:6,22	attorneys 45:1 60:2	Bensenville 48:19,21,23
67:22 68:10	117:2,18 118:6 122:21	57:13 58:17 76:11,19	audible 63:19	BENTLEY 4:21
achieve 92:11	amended 66:10	79:1,18 80:4,19 81:10	August 72:3,17	benzene 12:18 13:23 14:3
acronym 24:22	American 49:7 54:8,13	89:9 91:16 94:18 97:25	author 13:13,15 82:14	14:5 15:2 25:9,16,19
acroosteolysis 52:3	Ameron 52:25 53:5	98:19,21 103:2 104:4	85:2	25:23 26:23 27:8 43:6
action 126:17	Amherst 17:3 22:2,6	106:19 107:3 108:11	authored 13:3 106:4,6	43:14 53:20,23 54:15
activities 19:12 21:20	23:25 123:24	108:23 109:11 110:2	Authorization 24:23	55:15 59:9 61:16 69:13
29:6	AMOCO 61:15	110:24 112:22 116:1	authors 15:4 83:7	78:11,16 79:6,9 81:18
activity 22:16 29:19	amount 29:14 30:16	117:1,17 118:5 122:20	availability 88:13 89:21	81:23 82:22 83:11,23
actual 9:19 13:20 74:12	38:25	arose 120:21	available 39:10 47:19	84:1,8,9 86:10 87:17
109:15 113:17	ample 103:22	arrange 20:1	50:25 87:3 109:14	88:3 89:7 92:17 93:25
acute 54:1	analogously 117:19	arranged 117:14	110:20 111:2,12	94:16 95:9,25 99:23
AC&S 49:4	analogy 42:2,8	array 88:1	120:17 123:5	101:21 102:8,14,25
add 16:10 42:19 81:13	analyses 116:10	arriving 103:15	average 28:19 30:6 41:5	106:24 107:18,20
116:18	analysis 29:23 89:6	art 47:11 58:22 102:18	103:17	108:7,20 121:22
added 38:10	116:25	article 13:4 26:4,22 27:3	avoid 88:23	benzene-exposed 12:12
additional 120:4	analytical 58:12	27:5 85:2 113:20	avoidance 34:9 88:12	14:22 15:10 78:24
additionally 121:16	and/or 43:18 69:15	articles 5:20,21 9:17,19	aware 33:24 79:24 80:11	benzene/organic 112:5
additions 125:6	108:20	10:21 11:3 27:7 67:15	81:24 82:2,6,7,21	BERMAN 4:5
address 12:24 26:12	Angeles 1:2 2:2 3:11,17	67:23 68:2,6,23 69:12	83:10,15,22 84:6 87:1	best 73:9 92:4 119:5
27:13 76:1 109:1 117:9	4:7,12,18,23 125:2	69:17,20,22 70:2,4,7	97:9 121:23	better 41:19 44:24 90:24
122:3	angiosarcoma 52:1	70:11,18,21,24 74:12	a.m 2:16 7:2	92:25 114:19
addressed 65:8 87:10	angle 34:15 45:25	74:14,23 77:19 78:1	A.W 45:8,15 46:25 52:22	bias 81:12 88:12 89:14
106:2 119:21	animal 106:13,16,24	89:20 92:5	A3074BC 1:25	91:11,11 93:2
addressing 50:13 69:18	107:17 108:1,3 109:9	ARTS 4:15		biases 88:24 90:6
106:9 121:8	109:23 110:6 111:8,13	ArvinMeritor 54:24		bibliography 9:20
adeno 38:16,17	animals 107:18 108:12	asbestos 45:12,14 46:10		big 94:8
adenocarcinoma 37:11	111:14	46:11,16,23 47:1,9,14		biliary 44:4
adenocarcinomas 36:24	answer 5:9 10:24 37:12	48:16 49:5 52:23 54:10		bill 74:3
adequate 90:21 92:11,18	51:9 52:12,21 57:18	56:8,12 58:15 59:22,23		billings 9:23 72:14,19
105:23	59:5 68:12 76:25 77:2	60:1		bills 72:24
adequately 35:6 39:20	77:5 89:23 94:11	ascertainable 81:2		Billy 63:5
97:13	104:15 105:6 107:14	ascertained 81:8		BISGAARD 3:15
adjacent 48:21	107:16 113:24,24	aside 83:9		Bishop 43:1
adjunct 16:23 17:5 18:3	114:5	asked 8:13 11:2 20:24		bit 28:3 97:6
18:6,14,23 19:2 21:25	answerable 36:19	34:8 36:24 37:12 61:10		black 42:2,5,6
23:18	answered 94:10 99:13	86:21 95:16 99:12		bladder 26:9 31:13 33:2
administrative 28:6,23	answering 37:3 52:11	120:11,13		33:16,17,19
29:1,6	68:14 111:5	asking 11:23 14:2,12 21:6		blanking 82:7
advance 123:18	answers 77:11 105:22	21:7 36:15,25 39:24,25		BNSF 43:23 44:6
advanced 19:7	anthropoles 59:4	40:5,18 51:10,12 58:19		board 80:10
advances 112:14	apart 30:9 59:1 116:20	62:8 70:16,22 71:3		Boffetta 84:19
advising 19:6,14 28:4,16	apologize 114:1	82:21 83:9 87:21 92:13		BONNEVILLE 3:10
28:20 29:8,17	apparently 32:23	92:14 94:20 95:22 96:7		Borden 60:6 61:13
Advocate 48:11	appearing 93:13	103:3 107:11		bottom 65:10
affidavit 55:23	appears 26:7 67:14	assess 90:9		Boulevard 2:15 3:5 4:6
affirming 42:10	applications 33:14	assesses 111:7		boxes 100:5
afford 52:14	applied 24:1 80:9 99:14	assessing 99:22		Braden 4:15 60:3
afraid 84:22	applies 101:16	assessment 90:12 97:14		Bradford 97:3,4,9,12,24
ago 17:10,10,23 19:19	apply 98:17,25 99:1,9	98:13 109:8 120:2		98:17,21 99:4,10
20:25 34:17 72:2 92:2	119:23 122:6	122:15,16		brain 52:4 60:8
agree 52:5,8 60:24	applying 97:6,15	assessments 57:12		branch 23:21
ahead 37:6 60:12 77:12	appointed 18:14,23	associate 21:25 79:5		break 63:13,24 64:16
104:10 114:6,8 115:13	appointment 16:23 18:9	associated 38:17 48:6		breakdown 28:25
AIRCO 61:24	19:3	100:13 102:21 121:18		Brief 10:6 64:18
Airport 48:22	appreciate 37:4 72:10	association 17:21 31:16		briefly 30:17
AI 63:16	77:3,11 98:14 120:19	36:8,12,16 78:3,10		bringing 32:1
	approach 40:10 100:6	79:4 91:12 92:16 93:15		BRISBOIS 3:15
	102:16	99:6 102:3 103:8,9,16		broad 57:18 58:18

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

bronchioalveolar 39:19 brought 33:24 97:4 Brown 48:1 53:17 build 41:3 Burn 48:1 busy 22:15 B-cell 75:17 78:4 90:18 91:6 122:12 B-readers 117:21 B.A.C 39:19 C C 3:1 4:1 cacophony 102:15 Cairns 54:8 calculation 105:7 California 1:1,7,14 2:1,7 2:16 3:6,11,17 4:7,12 4:18,23 7:1 125:1 126:4,19 call 7:17 8:8 9:12 called 7:15 8:13 31:5 39:18 61:12 Calls 81:6 cancer 11:13 26:10 31:9 31:13 33:2,16,19 35:3 35:9,16,17 36:5,16 37:14 38:7,22 39:4,14 40:1 44:20 49:17,20 50:21 52:4 53:3,12 54:25 60:8 64:3 118:2 cancers 11:19 13:5 33:17 34:20 36:10,25 37:1,7 38:11 candidates 19:7,15 21:14 Cantu 55:14 capability 118:10 capable 56:13,19 57:11 57:19 85:12 captured 122:8 carcinogenic 35:8 36:2,3 101:2 carcinogenicity 100:11 carcinogens 100:14 carcinoma 38:1 39:19 52:9 care 49:18 careful 61:10 carefully 36:13 119:6 Carolina 16:24 17:5 CARR 3:19 carry 91:2 Carter 52:22 case 9:15 11:25 13:22 14:5 31:22 32:21 33:1 33:20,23 34:2,6,8,12 35:1 43:1,1,2,5,9,19,21 43:23 44:4 45:2,8,18 45:24 46:8,11,20,22,23 47:1,4 48:9,12 49:2,4,5 49:13,17 50:11,16 52:23 53:2,4,8,20 54:3 54:10,15 55:1,7,12,15 55:18,19 56:8 57:6 58:1,6 59:9,12,23 60:1 60:6,8 61:3,16,19,25 65:12,21 67:7 68:4,8 68:17 69:15 71:14,20 72:2,8,14,16 73:6 74:25 81:16,25 84:3,4 84:11 87:4 89:5 91:1	91:14,24 92:3 95:2 97:23 98:16 99:11,20 107:1 108:14,21 111:16 118:13 119:3,7 120:7,11,16,23 121:10 121:24 122:7 cases 8:25 28:10,11 31:17 31:20 34:13,15,24 45:14,21,25 47:8,10,24 47:25 48:15 49:15,16 59:22 60:10 63:23 64:4 65:9 114:12 116:8,15 117:12 casual 37:16 catch 55:25 categories 11:19 category 44:15 69:5 86:7 causal 14:5 39:22 43:15 92:17 94:5 95:15 97:7 99:11 107:1 109:8 110:10,18 111:1 122:13,15 causality 42:19 causation 42:24 50:24 51:3 93:21 96:22 97:23 98:11 109:25 120:2,24 120:25 121:2,4,6,9,11 121:13 122:3,5,6,9,18 122:19,24 causative 36:3 cause 13:23 33:19 35:3,5 35:6,17 38:21 39:2 40:9,14 41:7,15,22 50:21 51:4,19,24 52:1 53:12,23 56:23 80:3 90:17 101:22 108:7 121:17,22 caused 33:3 34:20 39:14 40:1 43:7 44:5 49:18 50:2,19 55:10 122:1,11 causes 12:6 15:10 35:9,16 36:4 37:9 42:13 51:25 102:25 107:20 causing 56:13,19 cautioning 99:4 caveat 64:9 caveats 118:20 CD 8:10 9:1,13,22 64:25 65:17 67:14,21,25 74:12,14,23 75:5 CD-ROM 70:1,18 96:10 cell 37:12,13,19 38:1,15 38:15,15 122:12 central 111:18 certain 38:17 47:14 77:15 113:17 certainly 21:12 87:1 91:2 91:17 96:2 97:4,17 103:9 109:3 110:14 111:18 certificates 14:13 CERTIFICATION 126:1 certified 123:19 126:3 certify 126:5,15 cetera 24:25 chance 70:10,12 change 118:20 changes 38:10 118:21 123:9,15 Chapel 16:25 charity 49:15	check 15:24 113:13 123:2 checklist 99:17 checkmark 66:6 chemical 15:18 33:19 41:7,22 51:4,19,23 chemicals 12:19 20:7 35:5 44:11,11 51:25 90:17 100:11,15,19,23 101:2 102:6,14 Chesterton 45:8,15 46:25 52:22 Chicago 48:20,24 China 117:8 Chinese 27:1 chloride 51:25 60:8,19 61:25 Chromium 44:15 chronic 42:22 78:3 chrysolite 56:22 57:5 58:1,3,4,15,25 cigarette 35:9 36:4,15 37:17 38:20,21 39:2,14 40:2 50:20 51:1 cigarettes 37:21 cited 34:4 cites 87:7 citing 25:25 103:12 City 48:20,24 49:7 125:10 claim 43:6 49:23 50:1 53:16 64:3 122:10 claimed 31:18,20 44:9 claiming 34:19 64:14 claims 34:16,18 clarify 13:25 81:20 Clark 53:17,22 class 23:1,7 24:11 79:6 117:24 classes 22:25 classification 101:11,11 classifies 100:11 classify 100:23 classroom 23:7 clastogenic 108:18 clastogenicity 108:20 Clayton 46:22 clear 107:16 108:24 clearer 119:11 clearly 56:23 77:15 93:7 clergyman 102:11 client 29:16 clients 15:17,21 19:11 28:5,16,21 29:8 Clinic 115:18,25 116:8 116:25 117:16 118:3 clinically 23:23 Clinic's 118:3 CLL 61:18 close 52:16 closely 52:7 83:16 closer 119:13 cluster 48:14 clutter 32:16 CML 61:18 CNA 4:9 Coatings 31:16 coding 38:10 cohort 12:17 79:8,9,12,13 79:15,25 80:2 91:1 cohorts 79:4 86:14 colleague 23:24 85:10 86:6	colleagues 17:12 19:11 63:4 collection 68:2 70:4 71:18 Collins 46:25 combine 110:16,17 combined 69:6 come 8:3 47:20 68:19 73:2,2 74:3 87:4 90:13 110:5,8 comes 84:20 101:25 116:20 coming 34:17 52:16 commencing 2:16 comment 34:8 60:20 86:5 116:14 committed 80:1 committee 25:2 committees 25:6 101:4 commonly 41:25 communicating 73:21 community 99:2 companies 15:17,18,21 34:19 35:2 46:6,16 50:1,4 company 4:14,15 32:22 34:7 43:17,24 45:9 46:25 47:20 48:17 49:8 52:22 53:5,7,10 56:6 comparable 118:8 compare 70:10 compares 24:25 comparison 70:15,17 compatible 40:9 98:6 compelling 102:21 compensate 50:5 compensated 50:3 compilation 87:13,16,19 compile 87:25 compiled 26:15 90:5 complaint 66:10 complete 10:15 11:5 92:1 completed 119:7 complex 12:16 34:13 42:22 complicated 13:24 38:19 49:9,22 50:8 57:18 compound 56:12,25 58:2 58:4,8,15 92:19 107:2 110:23 comprehensively 44:18 comprise 24:3 concentrations 104:3 105:4 concepts 24:1 98:24 concern 74:7 concerned 48:24 concerning 26:8 concerns 117:7 conclude 39:10,22 90:20 92:16 93:10 97:21 122:1 concluded 55:9 conclusion 54:7 57:10 90:17 92:14,14 93:8 96:22 97:22 98:15 101:5 103:15 110:5,8 121:7 122:10,13 conclusions 91:22 92:12 97:7 99:5 119:14 concurrently 76:5,8 conduct 88:13	conducted 11:8,10,17,25 12:3,10 30:21 117:14 conducting 29:25 110:3 confident 121:13 confirm 116:23 118:4 confirmation 117:4,16 confirmed 114:14 116:10 116:13 confounding 91:10 conservative 81:13 consider 29:6 82:19 83:8 88:10 99:10 102:23 105:11 106:16,24 107:6,25 108:9,17,19 109:22,23 110:12,19 115:22 119:17 120:17 120:21 consideration 91:9,10 considerations 97:19 considered 37:13 57:23 68:4,8 81:25 82:3 84:3 84:11 107:11,17 considering 109:9 consistently 33:14 consistency 93:17 consistent 75:24 76:16 93:1,16,20 constantly 91:12 constellation 37:9 85:24 constituent 35:8,16 36:3 constituents 36:3 construct 121:1 consultation 19:20 20:15 consulting 15:15 19:6 28:4,20 29:8 consumed 30:15 consuming 30:25 contacting 72:8 contacts 19:10 21:21 contain 13:18 58:4 contained 70:1 125:8 containing 9:16 25:22 contribute 19:8 contributed 57:6 58:9 122:11 control 11:25 81:7 91:1 copies 9:19,23 71:8 copy 70:14 123:19 Corp 15:25 corporation 1:7 2:7 4:15 46:10 47:6 correct 7:13,14 12:9 13:16 15:13,16,18,21 16:1,25 20:14 21:22 22:12 26:5,6,10,11 32:12,24 36:5 43:11 46:4,12,13 49:6 53:9,9 59:9 64:2,7 67:10 74:13 75:13 77:23 78:14,21 82:16 89:2 100:8 107:7 108:1 113:3,10 125:8 126:14 126:20 correcting 37:22 correction 123:10 corrections 123:8 125:6 correctly 67:20 88:16 89:3 correlation 95:4,13 correlations 93:24 94:15 correspondence 6:4 9:23 Coulter 59:8
--	---	---	--	---

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

council 31:11 counsel 9:16 15:23 60:20 61:12,13 65:21 113:21 113:23 123:15 124:4 count 80:6 counted 35:22 80:2 COUNTY 1:2 2:2 125:2 Couple 17:10 course 18:2,3 22:13,14,18 23:3,6,13 24:3,6,13 35:4 94:25 101:6 120:22 122:23 courses 18:12,17,24 22:5 22:8,21,23 25:8 court 1:1,21 2:1 55:22 60:17 65:6 123:3,17 courtesy 37:5 cover 32:14 119:6 covered 101:14 covering 90:2 covers 13:4 creosote 44:14 criteria 98:22 111:24 critical 90:12 97:1,14 98:5,12 100:4 119:14 critically 90:9 criticism 86:18 92:10 106:1,3,4,9 criticisms 105:24 113:14 critique 69:20 86:8,24 111:23 112:15 critiqued 91:21 critiques 112:17 critiquing 30:20 CSR 1:24 2:17 126:3,25 current 10:13,25 currently 15:12 19:14 20:20 22:5 27:19 curriculum 5:13 7:24 8:16,20 10:11 16:22 21:24 25:14 cut 77:7,10 cutting 123:22 CV 8:5,23 18:8 30:14 31:8 32:2 68:23 84:24 D D 5:1 Dallas 3:21 damages 49:18,19 data 13:20,25 14:2,10,15 26:16,16,20 52:13,20 54:6 88:13 89:21 116:5 117:8 date 10:23 11:5 120:20 Dated 126:22 dates 105:18 Daubert 55:20,21,23 Davis 43:23 44:4,4 day 37:17,17,18,20,21 38:2 48:14 73:13,14,25 87:8 99:2 125:9 126:22 days 30:4 73:11,19,23,24 123:13 deal 52:17 Dean 62:19 death 12:7 14:12 15:11 80:3 deaths 12:1 deceased 62:5 decision 23:2	declaration 34:1 55:24 56:2 112:4 120:3,5 declare 125:4 126:18 deeply 114:20 defendant 3:8,14 4:3,9 4:20 48:16 53:9 61:13 65:14 defendants 1:9 2:9 4:14 43:18 46:5,18,23 61:14 62:2 66:21 defense 31:18 45:7,18,22 46:2 49:5 52:23 53:7 54:11,17 56:4,9 64:5 124:4 deficits 95:23 defined 92:25 definitive 45:20 definitively 43:25 degree 38:24 117:5 deletions 125:6 demand 28:18 demands 28:11 demolishing 48:25 demolition 49:1 demonstrate 39:20 95:8 demonstrated 35:21,23 44:20 demos 106:21 department 16:23 17:12 19:13 21:25 dependent 109:3 depending 28:10 depends 28:17 36:13 39:7 109:13 deposed 60:2 62:19 deposing 7:22 deposition 1:12 2:14 5:12 6:2 8:9 9:3,4 10:5,8 14:17 15:22 31:22 32:5 32:19,23 33:21 34:4 43:9,19 44:22,24 46:20 47:3 48:14 50:17,18 55:19 59:12,21 60:1 61:22 62:4 64:20 65:18 66:11,13 67:9,17 68:24 71:11,16,23 74:6 depositions 45:1,13 48:7 63:2 66:12,21 derived 27:19 57:10 describe 27:22 41:11 49:11 83:7 described 94:3,4 96:25 119:13 120:14 description 5:13 6:3 76:15 deserves 87:2 design 88:13 109:5 designate 61:4 designation 101:16 designed 12:4 desirous 125:7 despite 102:18 110:5 detail 118:25 details 20:9 43:4 detect 58:13,22 104:2 105:3,23 determination 43:15 109:24 110:10,18 121:2 determinations 111:7 determine 36:4 81:15 98:8	determined 42:24 121:7 121:15 determining 98:11 121:3 detract 103:10 detracting 101:20 102:24 development 20:4 30:3 95:10 107:19 developments 97:18 device 58:12 diagnosed 33:2 75:16 116:8 118:2 diagnoses 117:8 diagnosis 33:16 76:5,16 113:17 114:11,19 116:23 117:6,16,22 118:4 diagnostic 118:9 died 59:17 difference 11:20 40:24 41:1 42:10 different 23:1 37:8,8,9,11 37:14 70:23 82:1 110:25 differently 111:4 difficult 30:6 84:23 diffuse 75:16 90:18 91:6 114:15 122:12 diffuse-B 121:14 dimensions 90:2 DiPetrillo 65:10 direction 96:20 directly 25:18 27:10,11 85:22 99:1 109:2 123:23 disappears 56:24 57:1 discarded 91:2 discuss 25:9 discussed 59:22 86:9,15 111:24 discussing 25:9 48:8 110:6 discussion 24:11 disease 12:7,11 15:11 35:6 36:24 38:6 39:1 41:8,15,22 42:14,22 49:21 51:5,19,24 53:22 53:24 54:1,16 55:17 56:14,19 58:10 61:17 64:3,14 79:14 88:14 98:9 121:18,22,25 122:2 diseases 11:12 37:8,14 38:12 49:24 50:2,18 51:2 52:2 55:9 disentangle 35:14 disk 8:15,17 84:14 dismissal 34:2 dismissed 33:20,23 disorders 24:2 dispensed 106:2 dispersion 20:6 disprove 42:7 disproves 41:2 disproving 42:11 disrespect 85:15 distinct 83:1 distributed 96:19 divide 28:24 divides 27:24 DLBCL 78:13 DLBTL 78:13 DNA 111:9	doctor 7:15 27:14 37:6 113:3 doctoral 19:7,14 21:5,14 document 8:22 32:3,10 32:11 64:22 65:17 68:21 89:12,14 96:9 documents 89:19 doing 27:14 84:25 dose 57:12 122:16 doses 109:16 doubling 104:2 105:3,12 105:23 doubt 56:24 81:4 dozen 33:14 Dr 7:18,19 8:13,16 10:10 23:17,17,20,24 64:22 66:11,12,13 67:9 69:17 70:2,8,18 74:6 77:1 91:21 92:12,13 111:22 113:4 119:12 120:1 123:24 draw 43:15 54:6 92:11 99:5 drawing 97:7 drawn 92:12 driven 103:16 drop 28:12 due 80:1,16 duly 7:5 DVD 7:25 E E 3:1,1,20 4:1,1,11 5:1,11 6:1 eager 44:13 earlier 34:16 55:2 83:15 92:24 111:24 early 20:1 East 2:15 3:5 effect 95:9,18 123:19 eight 50:14 73:17,25 either 24:19 39:8 49:15 70:13 74:24 76:8 83:7 86:18 88:3 89:5 108:13 Electric 65:11,15 electronic 74:25 embrace 93:8 97:17 embraced 97:13 99:15 emerging 24:20 employ 96:21 employed 16:14 31:1 44:6 employee 85:4 126:16 employs 100:7 encompassed 119:1,3 encountered 109:16 endless 42:4 ends 73:1 engineering 28:2 entire 8:1 entirely 49:10 entirety 94:9 entitled 32:11,11 37:4 68:22 71:10 113:24 entry 13:3,7 66:22 envelope 123:25 Environ 15:13,17,25 16:14,17,20 19:24 20:12 23:24 27:20,23 28:6,8,15 29:2,5,13,24 30:8 72:15,24	environmental 15:15 EPA 25:1 epidemiologic 11:8,20,23 12:3,10 15:2 25:1,13 28:1,2 29:5,12,25 30:8 30:22 31:8 40:8 41:4 42:12 43:13 44:19,21 52:6 53:15 54:6 57:8,9 77:3 78:2,9,22 89:7 93:19 108:25 117:13 117:25 121:19 epidemiological 11:10 52:20,21 76:3 77:14 79:2 88:10 100:4 107:24 109:1 110:14 111:23 121:8,25 epidemiologically 35:21 36:22 39:21 40:11 42:10 59:2 76:22,24 81:11 93:11 94:6 109:20 110:4,9 121:2 epidemiologist 7:11 98:3 106:15 107:9 epidemiologists 97:8,20 98:23 epidemiology 5:20 16:24 17:12 21:2,4,9 22:1 23:2,21,25 24:20 28:5 33:17 40:12,13,19 41:6 41:21 42:13,17,23 57:11,19 58:11,19,19 58:21 67:15,24 68:3,7 68:11 69:12 77:2 78:2 90:24 100:9 101:8 106:18 110:4,21 116:21 121:3 epoxy 33:8 equivalents 73:14 Erroneously 60:23 error 55:25 88:12,14 89:16 93:2 especially 56:23 ESQ 3:5,10,19 4:5,11,17 4:22 essentially 23:1 33:13 34:22,24 47:13 establishes 40:23 estimate 73:4,9,10 estimates 29:21 102:10 et 24:25 etiologies 37:8 European 24:21 31:4 Eurosil 31:5 evaluate 81:12 97:23 evaluated 78:9 79:10 evaluating 78:10 93:19 98:6 108:18,19 evaluation 24:20 70:11 87:3 92:3 107:23 110:14,15 119:16 evaluator 85:16 event 78:17 evidence 25:1 39:10,21 40:6 41:12 50:25 51:2 53:15 57:4,9 76:5 88:10 90:16,19,20 92:15,18 93:20,21,23 97:20,21 101:20,23 102:24 103:23 109:18 110:9,20 111:2,8,21 121:16,17,25 exactly 24:15 114:7
---	--	--	---	---

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

exam 21:1,12 examination 5:5 7:8 126:10 examine 13:25 83:20 examined 7:5 15:11 example 25:20 26:1 57:20 91:6,25 92:1,6 105:9 111:21 114:9 exams 19:7 20:21 21:1,3 21:5,8 exception 69:16 excerpts 66:21 excess 79:15,22,23 102:10 exchange 106:1 excluded 79:17 excluding 12:6 exclusively 15:20 25:18 110:15 excuse 37:2 43:3 71:25 98:18 106:19 113:21 113:23 excused 60:25 EXECUTED 125:9 exercise 87:20 96:14 98:2 exhaustively 101:6 exhibit 10:8,10 32:4,5,16 64:20,23 65:16,18 67:8 67:17 68:21,24 70:9 71:9,11,16,18,23 72:14 74:6 75:10 77:22 78:1 82:10 111:16 114:25 118:14 119:4 120:8 exhibits 66:11 69:10,15 70:20 74:14 94:13 95:1 96:12 106:12 existing 81:3 exists 72:11 expanded 118:25 expect 94:19,21 111:23 112:12,14 119:23 expected 18:16,20 expended 49:14 experimental 108:6 109:9,23 110:22 111:9 experimentally 35:25 expert 19:8 60:21 61:4 76:21 77:1 118:3 expertise 107:5 109:6 explained 38:25 93:2 107:14 explanation 42:1 104:17 106:6 exposed 12:18 25:22 56:25 57:23 58:15,25 59:2 92:8 95:24,25 107:18 exposure 20:5,6 25:21 26:8,16,20,22 31:9,13 31:18,21,23 33:13 35:22 36:14,23 37:15 38:6,25 44:9 53:4,11 58:1 65:13 78:10 88:14 89:24 94:16 95:4,8 98:9 121:21 exposures 35:5 36:9 44:5 44:19 57:5,12,20 79:5 79:9 88:1 91:5 96:16 100:20 102:6,10 122:1 122:10 extent 25:21 91:19 109:18 111:21	extremely 57:12 E-mail 6:3 16:7 72:1,6 E-mailed 8:5 E-mails 71:19 F facility 44:12 fact 18:6 59:1 60:15 61:10 79:10,25 111:6 113:6 115:15,24 118:17 factor 77:15 83:16 109:18 111:2 factors 97:3,24 98:17 99:10 102:6,21 121:17 facts 122:7 faculty 19:2 23:18 fail 103:7 Failing 41:1 fails 92:11 failure 61:3 88:23 fair 29:14 30:15 71:3 90:22 96:17 fairly 44:18 48:9 98:24 faithfully 98:16 fall 69:4 90:10 familiar 15:1,6,9 45:16 67:4 82:15 family 39:12 114:21 far 55:3 68:9 118:18 farm 102:13 fatally 42:21 favor 83:20 fax 32:13 faxed 8:6,14 32:8 feature 115:23 Fees 5:15 32:12 fellow 86:7 fibers 58:25 fields 111:3 Fifth 3:10 fighting 100:17 Figueroa 3:16 4:17 file 1:25 8:1 9:10 67:13 68:22 filed 34:16 49:13 files 9:16 74:25 financial 49:19 financially 126:17 find 67:6 70:14 76:20 95:23 102:3 114:23 116:17 120:20 finding 99:3 116:20 findings 94:4 97:14,15 102:4,19 fine 63:4 115:5 124:2 finish 77:11 104:14 114:5 finished 37:3 44:13 104:8 104:16 113:24 fire 100:16 firm 15:15 47:23,25 48:2 48:5 60:3 72:15 first 7:5 13:13,15 28:17 30:13,14 31:7 32:21 62:12 63:3 72:1 75:15 88:9 114:2 fit 31:24 99:6 five 21:18 37:24 60:17 63:2 64:2 78:6 85:22 flabbergasted 114:2,4 flawed 93:9	flip 41:20 Floor 4:6,12 Flower 4:22 focus 97:5,19 98:12 121:3 folder 68:16 follicular 114:15 followed 100:7 following 24:19 follows 7:6 104:22 force 123:19 foregoing 125:5,7 126:6 126:13,19 FORGEY 3:19 form 9:17 74:24,25 85:25 formaldehyde 31:8,11,18 formed 111:16 119:3 forms 101:25 102:1 formulating 69:9 forth 94:13 111:16 118:14 119:4 120:8 126:7 forthcoming 72:23 forward 69:19 96:15 111:22 119:24 123:4 123:12,14,16 found 41:23,25 52:6 105:11 foundation 14:9 15:5 four 9:7 13:17 30:4 38:12 38:21 39:3 78:6 114:13 114:24 115:20 116:9 fourth 32:13 72:25 frame 19:18 frequently 17:4 42:8 friend 86:6 front 42:4 65:6 full 16:14 24:7,17 123:19 fuller 97:14 fully 33:9 34:14 function 101:7 108:8 fundamental 117:7 funded 17:14 funding 17:18 further 20:4 28:23 126:15 Furthermore 101:20 future 18:12 44:25 G GANS 1:7 2:7 Garabrant 66:12 gasp 122:22 gather 14:11 general 50:24 80:17 96:22 97:18,22 98:7 109:24 120:2,24 121:3 121:6,11,13 122:5,6,9 122:19 generally 40:10 45:11 54:19 86:3 111:12 generated 20:6 gentleman 62:5,14 German 13:13 31:5 85:23 86:14 117:19,21 Germany 12:16 31:1 85:1 Gersten 46:10 getting 44:14 55:3 101:1 give 31:22 37:4,11 55:19 73:9 77:4 104:17 given 8:10 11:3 45:13	63:1 70:24 99:6 107:14 118:19 giving 28:4 glad 8:14 71:4 gland 76:16,17 glass 27:15 go 10:4 17:4 28:13 37:6 60:12 65:25 75:14 77:12 84:24 88:7 96:6 97:12 99:17 104:10,18 114:6,8 115:13 goes 122:17 going 8:2,8,9 9:11 10:4 55:25 63:14 66:25 74:10 93:11 117:6 121:20 good 31:24 52:13,19 63:12 70:12 71:4 116:3 120:19 Government 31:6 gradually 32:1 graduate 23:3 Grannis 4:17 8:5,12 14:8 14:24 15:5,19 16:2,10 20:17 25:17 26:18 27:14 32:10 35:10,18 36:6,17 37:2 38:8,23 39:5,16 40:3,15 41:9 41:24 42:15 50:16 51:6 51:15,21 54:4 56:20 57:13 58:16 60:11 61:3 61:8 62:5 63:12,20,25 64:17 67:8 68:13 72:11 75:12,25 76:11,18 77:1 77:7,10,22 78:25 79:18 80:4,18 81:5,9 82:1,24 83:14 84:12 85:9 86:2 86:12,23 87:18 88:4,19 88:21,23 89:9,17,22,25 90:7 91:15 92:19 94:17 94:24 95:5,11,20 96:8 96:23 97:25 98:18 99:12,24 100:24 101:18 103:1 104:4,10 104:13,16,21 106:19 107:2,8,13,21 108:2,10 108:16,22 109:11 110:1,23 111:11 112:19,21 113:4,21,23 114:4,7 115:2,6,10,12 115:19 116:1 117:1,17 118:5,15 119:20 122:20 123:4,15,21 GRAPHIC 4:15 great 52:10 85:13 greater 117:6 Grossman 46:8 group 3:4 31:5 85:1 90:24 92:25 101:16 102:20 113:7 116:19 groups 38:13 40:25 76:3 guess 71:8 84:20 121:20 guide 100:4 guideline 98:4 guidelines 97:9,16 guideposts 100:3 gunshot 42:20 guy 58:8 59:16,17 62:21 H H 5:11 6:1	half 29:18,20 33:14 37:17 Hamman 54:13 HAMMER 4:22 hand 93:12 98:5 handwriting 16:4 Hang 68:13 happened 61:6 hard 111:5 harkens 116:14 Harley 59:14 62:11 Harrison 66:13 69:17 70:2,8,18 91:21 92:12 111:22 113:4 119:12 120:1 Harrison's 66:11 92:13 Havner 56:1 Hayes 112:14,15,15,18 112:19,23,24,25 113:2 113:10,14 114:20,23 115:17 116:17 hazardous 49:3 hazards 47:13 head 78:6 84:14 94:23 heading 67:21 health 17:16 19:25 hear 59:20 hearing 55:20,21,22,23 56:1 65:5 Heartly 62:19 HEATHER 3:19 Heating 47:6 held 36:8 help 97:19 helped 20:1 97:5 hematologic 121:22 hematotoxicity 108:7 HENNING 4:5 hepatocoele 52:9 herbicide 65:13 Hershall 62:24 high 35:6 59:3 117:22 higher 59:3 93:7 highly 38:5 92:8 Hill 16:25 97:3,4,12,24 98:17,21 99:4,10 Hill's 97:9 histories 34:11 history 47:18 Hockson 62:24 HOLDINGS 4:9 HOLLAND 4:3 Holm 78:7 hooking 20:12 hospitals 49:12,19 50:3,4 50:5 host 52:2,2 hours 16:16 23:8 73:4,13 73:16,25 huge 112:10 humans 108:12 109:15 hundreds 15:7 102:7 119:18 Hyjek 78:7 hypotheses 52:19 hypothesis 40:24 41:13 41:14 42:7 44:21 101:21 102:25 103:10 hypothesize 42:3 hypothetical 41:2 54:4 58:5 79:1 80:19 81:6 104:5 109:12 110:2,24 112:22
--	--	--	--	--

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

I IARC 24:19 25:2 85:4 90:24 96:25 100:7,9,10 100:22 101:1,10 110:5 111:6,7 ICD 38:9 idea 73:12 identifiable 75:7 identification 10:9 16:1 32:6 64:21 65:19 67:18 68:25 71:12,17,24 identified 11:7 14:20 25:14 27:6 28:22 38:22 42:6 50:18 60:21 67:20 70:12,13 79:12,13,15 83:24 85:1 90:25 91:24 95:7 101:2 103:13 112:2,9,10 119:18 120:3 identifies 69:24 93:19 identify 26:1 42:18 67:4 69:24 70:14 79:21 81:22 82:25 83:17 84:18 91:5 94:22 95:2 96:7,11 100:13 101:4 102:20 103:11,18 112:13 116:21 identifying 55:9 101:15 ignore 81:14 Illinois 48:19 illogical 122:23 immune 108:8 implemented 117:9 implementing 25:5 implied 51:13 imply 100:3 important 67:6 91:13 importantly 88:11 impression 63:3 inaccuracy 80:9 inactive 72:2 inadequate 39:10 41:12 incidence 80:15,24 81:1,2 Incidentally 77:17 include 19:3,4,5 79:3 included 31:23 44:10 49:3 92:9 100:16 116:10,14 includes 19:6 28:23 113:7 including 15:20 52:2 78:13 79:6 90:18 102:11 111:9 inclusive 1:8 2:8 income 27:19 incompatible 33:16 99:18 Incomplete 54:4 78:25 80:19 81:6 104:5 109:12 110:2,24 112:22 incorporate 97:9 incorporated 8:23 69:18 increase 105:11 increased 14:21 78:12,23 103:23 increases 58:13 independent 23:5 index 9:20 indicate 14:20 78:8 indicates 16:22 indication 15:23 indirectly 25:19 27:9,10	27:13 103:12 individual 64:9 90:10 93:9 98:6 individuals 34:16 58:24 59:1 76:3 industry 13:14 17:17 31:2 55:11 102:12 inferred 51:3 inflammation 75:19 76:15 information 5:7 16:2 75:22 initially 72:8 injured 42:21 injury 24:2 INK 1:7 2:7 4:3,14,15 instance 65:5 98:8 111:13 INSTRUCTED 5:9 insufficient 54:6 121:22 122:1 insufficient/inadequate 90:16 Insulation 46:15 insulators 57:22 integrity 86:1,4 intended 99:1,18 intent 116:3,4 117:10 interaction 48:9 interest 11:12 interested 126:17 interesting 94:1 interests 17:21 International 15:25 interpretation 88:10 117:24 interpretations 88:25 interpreted 14:15 interrupting 107:13 114:2 Interruption 16:12 introduce 7:10 20:1 intuitive 98:24 invalid 88:24 investigate 12:4 investigated 12:11 investigators 116:22 invited 23:12 24:15 Invoices 6:5 involved 102:11 in-depth 87:2 Irrelevant 35:10,18 36:6 36:17 38:8,23 39:5,16 40:3 58:17 isolate 102:14 issue 109:24 120:2 issues 119:20 itching 80:1,16 I,I 117:24 J Jansen 63:18 JENNIFER 3:10 JNCI 113:2 job 44:24 John 4:17 8:2 Johnese 52:25 JOHNSON 3:9 joint 19:24 56:12,25 58:2 58:4,8,15 jointly 31:4 49:13 JONES 3:19	JOSHUA 4:5 journal 89:5 journals 85:18 Jr 63:8,9 judge 56:3 60:24 65:6 judgment 33:24 34:2 50:24 93:21 111:1 July 32:23 June 63:1 justification 106:7 justify 91:21 K Kaplan 45:24 keep 24:6 80:6 Kellogg 53:17 Kenneth 1:13 2:14 5:3 7:4,11 125:19 key 112:13 kind 29:22 102:15 know 14:12 20:9 24:14 29:21 33:22 34:23 35:11,15,16,19 38:10 38:16 46:21 47:20 48:4 50:23,24 53:9 59:24 60:4,5 61:6,18,22 62:16 66:4,22 69:22 70:17 76:15 78:17 80:23,25 82:3 84:18 92:15 93:4,6,17 94:10 95:21 97:13 98:15,21 104:7 107:10 114:13 114:16,18 115:4,8 118:18,19 119:16 123:11 knowable 47:14,20 knowing 35:24 36:1,2 knowledge 43:21 knowledgeable 19:9 known 23:22 24:21 35:11 47:14 101:6 knows 80:25 KOHL 4:20 KOHN 4:21 Kurt 85:5,6,21,22 86:3 L label 85:14 lack 89:19 93:20 103:9 lacking 60:10 Lacks 14:8 15:5 Lamm 82:14,16 83:12 102:4 103:14,19,20,25 104:25 105:18 Lane 3:20 large 12:16 17:13,16 21:17 29:15 30:15 38:15 49:9 50:18 70:3 75:17 90:18 91:9 92:7 102:2 105:11 122:12 largely 50:25 118:22 larger 39:11 largest 30:25 105:10 latency 122:17 Lattin 60:6 law 3:4 47:23,25 48:2,5 laws 126:19 lay 37:13 40:21 41:11,17 41:25 42:9 layman's 41:5 lead 81:12	leafed 66:16 lean 93:21 leave 86:19 LEE 4:22 left 79:16 legal 34:14 legislation 24:21 lend 41:14 let's 11:24 30:17 52:15 64:16 66:3 71:8 75:9 75:14 77:24 82:5 88:7 91:19 97:15 101:16,25 111:22 116:6 leukemia 31:9 54:2 level 23:3 34:9 35:6,25 57:5 59:3 75:20 80:8 92:11,17 122:4 levels 56:24 58:25 59:3 LEWIS 3:15 life 56:2,3 limited 21:3 34:24 41:4 48:11 100:15 113:5 120:23 limiting 79:9 lines 53:15 list 5:18 8:19,25 9:2,6,18 12:20 13:12 21:24 26:5 27:6 32:8,18 43:1 49:24 63:2 64:24 65:20 65:23 67:23 69:16,18 69:21 70:22,25,25 71:13 75:4 90:5 123:10 listed 10:22 11:4 23:6 31:7 32:21 66:21 69:15 74:14 listing 9:15 67:13 68:22 74:18 84:15 92:1 96:12 lists 55:9 65:2 70:8,20 106:12 literature 11:17 28:2 29:12 30:9,20 43:13 44:19 68:10 69:8 76:3 77:18 78:9 81:3 93:12 93:19 101:8 103:6 106:12 107:24 108:25 109:5 litigation 27:25 28:8 29:9 29:15 30:9 55:5 little 48:9 97:6 live 17:2 liver 52:1 lives 59:1 living 49:1 LLP 3:15,19 4:5,10,16 locally 118:10 location 18:21 lodge 123:17 long 1:14 2:16 3:6 7:1 30:5 49:24 55:7 72:2 look 26:7 27:12 38:9 58:23 75:9 77:24 82:10 83:16 84:15,22 85:11 91:7,11 102:5,17 103:6 115:8 119:14 looked 11:18 14:2,12 37:19 38:1 39:20 44:18 52:7 66:17,23 67:1 80:22 114:11 looking 43:1 90:19 91:5 96:12 106:11 Looks 65:8 Los 1:2 2:2 3:11,17 4:7	4:12,18,23 125:2 lost 104:19 123:18 lot 30:19 73:7 112:8 Louis 49:7 55:9 love 52:12 low 57:5,12,19,23 58:25 104:3 105:3 Lumber 56:6,10,13 lung 26:9 31:13 34:20 35:3,9,16,17 36:5,10 36:15,25 37:1,7,11,13 38:7,22 39:3,13 40:1 49:17,20 50:21 lymphocytes 75:20 lymphocytic 54:2 75:16 75:18 76:9 78:3 lymphoma 11:9,11 12:1 12:5,24 13:21,23 14:1 14:4,6,22 15:3 25:10 26:13 43:7 59:9 67:15 67:24 68:3,7 69:14 74:9 75:17,24 76:4,17 78:4,4 80:17 81:19,24 82:23 83:12,24 84:2,8 84:8,10 86:11 90:18 95:10 106:25,25 107:19 112:6 113:10 122:12 lymphomagens 100:23 lymphomagens 101:12 lymphomas 76:8 91:6 lymphopoietic 108:8 M MADDEN 4:20 main 38:12 39:3 118:17 MAJESKI 4:21 major 15:17 38:22 majority 117:12 making 23:2 57:11 125:7 manufactured 33:4 manufacturing 31:2 mark 32:4 65:16 66:2,4 67:16 68:21 71:9 marked 10:8 32:5 64:20 64:23 65:18 67:17 68:24 71:11,16,23 Marketing 55:14 Marshall 49:4 Massachusetts 17:3 22:1 22:6 match 23:22 matchmaker 20:10 material 33:15 materials 5:18 9:15 14:11 65:20,23 66:1,15,20 71:19 75:4 83:20,21 120:15,21 matter 9:24 49:9 123:1 matters 120:1 Mayo 115:18,25 116:7,24 117:15 118:2,3 McGOLDRICK 3:19 mean 8:4,7 13:25 20:12 33:22 47:16 57:8,19 86:23 95:12 98:25 110:18 meaning 37:9 meaningful 96:14 means 42:19 meant 47:13
--	--	---	---	--

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

measured 36:13 measures 79:4 meat 102:12 mechanical 100:2 mechanism 35:24 36:2 110:7 medical 66:17 67:5 74:5 75:21 99:2 medicine 97:5,6 meetings 100:13 Melanoma 59:19 members 23:18 memory 14:25 96:8 men 31:1 mention 100:6 mentioned 31:24 55:2 84:25 118:11 mesothelioma 56:22,23 57:7 58:14 met 7:19 23:7 121:14 meta-analyses 25:20 26:8 31:12 81:23 82:15,22 83:1,7,23 84:7 102:4 103:13 meta-analysis 26:16 31:10 81:18 82:20 83:4 83:11 86:18 88:2 method 40:10,23 41:4 90:22 methodology 90:25 96:21 96:24 109:22 110:11 methods 24:1 58:20 METZGER 3:4,5 5:6 7:9 8:2,7,16 10:7,10 14:19 15:1,8,22 16:11,13 20:20 25:24 26:21 27:18 32:7,15 35:15 36:1,11,21 37:20 38:14 39:2,13,24 40:5,22 41:17 42:12,25 50:20 51:10,17 52:4 54:8 57:1,15 59:5 60:12 61:12 62:7,10 63:14,23 64:1,19,22 65:20 67:11 67:19 68:19 69:1 71:13 71:18 72:5,12 75:13 76:7,14,23 77:5,8,12 77:24 79:11,24 80:11 80:23 81:7,17 82:5 83:3,17 84:15 85:20 86:9,17,25 87:12,21 88:7,20,22 89:13,21,24 90:4,15 91:18 92:21 94:20,25 95:7,16,25 96:11 97:2 98:14 99:8 99:16 100:1 101:10 103:5 104:7,11,15,17 105:14 106:23 107:6 107:10,16,25 108:5,13 108:17 109:7,21 110:12,17 111:6,15 112:20 113:1,9,22 114:1,5,22 115:4,7,11 115:15,22 116:6 117:13,25 118:11 119:2,25 122:25 124:2 middle 13:12 middleman 123:22 Mike 62:15 million 104:3 105:5 mind 24:6 80:6 84:20 mine 23:24	Mines 48:11 minute 30:18 minutes 48:8 60:17,25 92:2 Misc 5:21 miscellaneous 68:22 77:20 mischaracterizes 40:16 41:10 51:16 60:11 118:15 missing 72:5 Missouri 49:12 Misstates 76:11,19 81:10 mistakenly 98:22 mix 28:3 44:10 mixed 39:21 Mockingbird 3:20 models 20:5 moderate 59:3 moment 11:24 118:19 moneys 49:14 monograph 100:12 month 10:20 72:22 73:1 73:5 months 73:8 morbidity 31:14 morning 16:3 64:25 MORRIS 4:10 mortality 11:13 13:5 31:14 80:15 Morton 84:19 102:18 Mortons 84:20 motion 34:4 Mountney 56:6 Mountney's 56:14 move 42:22 52:15 Multipage 5:13 6:3,5 multiple 38:12 43:5,7,13 65:12 Mundt 1:13 2:14 5:3 7:4 7:11,18,19 8:13,16 10:10 64:22 77:1 123:24 125:19 musculoskeletal 24:2 mutual 19:11 myelo 117:24 myeloma 43:5,14 65:12	networking 19:10 21:21 never 7:22 29:22 48:8 new 51:11,12,17 52:6 newer 83:21,22 NHL 5:19 13:19 14:13 55:18 68:11 78:23 79:25 80:1 81:13 84:21 87:14,17 88:3 89:8 91:7 92:17 93:13,23,25 94:16 95:4,18,23 99:23 101:22 102:7,22,25 107:20 113:16,18 114:13 116:9 NHL's 77:16 78:13 79:6 79:7,10,11,13,16,22 90:18 92:7 nice 59:16,17 nine 100:3,5 noise 102:15 non-associated 39:9 non-charity 49:15 non-Hodgkin's 11:9,11 12:1,5,24 13:21,23 14:1,4,6,22 15:3 25:10 26:13 67:15,24 68:3,7 69:13 75:24 76:4,17 78:4 80:16 81:19,23 82:22 83:11,23 84:2,7 84:8,10 86:10 95:10 107:19 112:6 non-paying 49:15 non-respiratory 13:5 non-specific 53:4 North 3:16 16:24 17:5 notable 75:20 notarized 123:7 note 91:20 Noteworthy 116:7 noticed 65:5 notify 123:15 null 41:14 96:19 number 5:13 6:3 16:1 21:17 25:19 45:14 50:18 66:6 78:21 102:2 112:10 116:12 numbers 58:24 67:1 numerous 103:7	occur 76:8 81:14 occurred 20:1 57:5 occurrence 36:9 58:14 occurring 76:17 occurs 34:9 123:10 Ocean 2:15 3:5 October 1:15 2:17 7:1 72:23 73:5 126:22 odd 112:4 120:3 OEM 26:23 offense 63:4 offhand 83:18 office 8:13 9:9 23:25 123:25 oh 25:24 27:2 50:23 57:3 59:20,25 62:25 oil 15:17,20 43:2,3,4,16 54:13 okay 7:17,22,23 9:22 10:4 11:8,16 12:10 13:17 15:1,8,12 16:6 18:6 20:15,20 22:25 24:3,9,16,24 25:12 26:3,21 27:1,5,18 28:7 29:7,24 30:7 31:7,17 31:25 32:16,21 36:21 41:20 42:25 43:23 48:11,19 52:25 53:21 54:8 55:14 56:4 57:3 60:2,5 61:8,19 62:3,18 64:16,17 65:2,7 66:9 66:19,24 67:3,11,23 69:12 71:4,6,22 72:9 72:14 74:10 76:14 77:17,21 78:8,17,20 79:11 81:17 82:9,12 83:5 84:24 85:8 86:17 88:7,21 89:13 90:4 91:14,18 96:17 99:16 100:1,10,21 101:17 105:21 106:11 109:7 111:15 112:8,21 114:4 120:10,23 older 72:1 83:20 once 17:8 23:7 ones 30:24 66:13 83:15 84:13 One-page 5:16,21,22 ongoing 50:12 55:7 operating 28:5 29:4 opining 120:25 opinion 28:4 85:25 88:9 90:3,15 99:11 101:16 101:17,19 107:1,20 120:23 opinions 5:23 9:17 10:1 13:22 14:4 68:16 69:9 69:14 71:10,14 75:9 76:2 78:8 84:4 88:8 107:23 108:14,21 111:15,18,20 112:14 118:12,13,21 119:2,4 119:21,22 120:7,18,24 opportunity 77:4 79:21 118:8 opposing 93:20 Optical 54:9 order 67:4 organic 69:13 78:11 87:13 88:3 89:8 95:4 96:1 99:23 101:21 102:25 106:25 108:7	108:20 organizers 23:13,14 24:12 oriented 24:11 original 123:4,12,14,16 123:18,23 other's 15:9 86:8 outcome 61:19 outcomes 12:11 23:21 26:9 outside 16:19 29:8 107:4 109:6 overbroad 25:17 38:8 39:5,16 40:3,15 41:9 41:24 42:15 51:6,21 56:20 57:14 58:16 75:25 76:18 78:25 80:18 81:5 82:24 83:14 85:9 86:2,12 87:18 88:4 91:15 92:20 94:17 96:23 98:19 99:24 100:24 103:1 106:20 107:3 108:10,22 109:12 110:1,24 111:11 112:22 115:19 116:2 117:2,18 118:6 122:21 oversimplification 36:20 90:9 O'Hara 48:21 O'Neill 32:22 33:2
P				
P 3:1,1 4:1,1 pack 37:17 packs 37:18,20 38:2 page 5:5,13 6:3 13:3,7,12 26:5 32:13,16 71:9 112:4 120:3 pages 32:17 123:9 paint 31:21,23,24 33:5,7 33:8 53:5,7,10 painter 25:21 26:9 31:13 painters 25:21 26:17,20 painter's 26:22 painting 33:13 100:18,19 111:13,14 Paints 31:15 paint-related 53:2 pancreatic 53:3,12 54:25 panels 114:10 paper 74:24 87:9 105:22 117:23 118:20 119:23 papers 91:20 119:18 120:3,4 paraded 42:4 paragraph 89:2 119:22 paragraphs 118:23 parallel 35:23 97:18 Parks 59:8 part 8:24 13:4 20:1 29:6 29:15 93:18 104:3 105:4 partial 24:7 participated 55:20 participating 20:10 participation 24:10 particular 20:7 41:7,8 47:18 66:18 85:11 86:5 101:8 120:10 particularly 84:21 98:9				

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

102:21 parties 48:10 126:16 Partly 59:7 path 117:11 pathological 75:23 76:15 114:12 116:23,25 117:3,16 pathologically 114:24 pathologist 75:21 pathologists 115:18,24 118:3 pathology 76:20,25 109:2 115:16,16 117:15 118:1 patients 12:1 49:14,20 50:5 77:9 118:2 payable 15:25 Pedersen 78:7 peer 85:17 penalty 123:6 125:4 126:18 pending 43:21 44:1 pentachlorophenol 44:15 penultimate 13:3 people 24:13 35:13 49:1 106:22 percent 28:12,13 29:3,10 percentage 28:7,15 29:2 29:7,11,24 perchloroethylene 11:18 11:18 perform 120:11 performed 26:16 period 18:15 72:3 perjury 123:6 125:5 126:18 person 41:5 86:7 perspective 34:14 77:14 pertain 20:5 77:19 78:2 106:22 pertinent 91:23 pesky 106:21 petroleum 43:6 phases 30:3 Phil 59:14 62:11 phone 48:7 phrased 40:18 physician 23:20 Ph.D 1:13 2:14 5:3 7:4,13 125:19 picture 94:8 piece 28:22 85:11 86:5 place 11:7 55:22 118:8 126:7 placed 126:8 plaintiff 1:5 2:5,15 3:3 48:24 plaintiffs 47:24 48:3,6 plaintiff's 54:22 62:4 plant 44:8 46:15 47:11 plants 48:18 please 7:10 11:24 74:4 81:22 84:16 92:22 pleasure 7:22 pliofilm 79:9,12,15,25 80:2 plus 73:11 120:3 Ply 1:24 2:17 126:3,25 point 8:7 47:14,18 91:4 116:7 pointing 96:18 points 98:5 100:4	POLICH 4:10 Poole 4:16 72:7,15 poor 26:20 Poorly 16:10 population 35:25 80:17 81:15 populations 15:10 80:8 95:24,25 103:23 porcelain 31:2 portion 24:10 67:5 portions 12:17 posed 80:21 positive 93:6,14 94:4,7 95:15 96:19 103:8,16 104:1 105:1 115:23 possible 51:20 53:6 86:13 possibly 47:19 post 105:18 potential 91:10 108:18 power 104:2 105:2,7,23 practice 7:12 22:18 28:5 29:5 93:18 practiced 23:23 practitioner 19:9 20:11 practitioners 58:20 preamble 78:19,20 preceded 98:9 precise 58:12 precisely 73:7 prefer 7:15 82:3 preference 7:16 preparation 14:4,17 prepare 21:1,3,6,7,8 prepared 10:19 11:4 17:13 21:12 71:14 72:20,21 86:17 112:5 120:5 preparing 19:6 20:21 present 3:15 4:10 22:2 75:20 presentations 10:21 11:3 11:6 presently 18:11 19:20 preservatives 44:16 preserve 123:17 press 30:15 presume 111:14 presumed 12:17 pretty 90:23 prevalent 117:4 previous 37:3 42:1 51:9 51:16 73:8 previously 38:25 76:9 pre-addressed 123:24 pre-stamped 123:24 primary 21:23 27:25 29:25 30:21 84:5 87:6 102:23 principal 15:12 principles 98:7 99:15 print 10:5 74:12 printed 8:3 67:13,21 74:22 84:17 printing 4:14 32:2 78:12 printout 68:22 prior 5:16 60:11 76:5,11 76:19 77:6 81:10 118:15 priority 28:17 87:5,10 probably 19:18 25:19 28:12,13 29:3,10 49:11 73:11,22 78:6 85:22	94:11 105:12 111:19 procedures 101:15 proceedings 16:12 126:6 process 24:20 73:1 90:22 96:25 produced 8:10 70:2,18 77:17 89:11,13,18 102:10 produces 95:9 producing 85:12 product 31:23 33:4,5,7,8 33:19 production 43:3 products 4:3 25:22 43:7 professional 16:19 19:12 27:19 professor 16:23 17:5 18:4 18:7,14,23 21:25 progeny 34:15 project 19:24 20:3,8,11 20:13 promotional 21:22 prompting 63:11 proof 41:16 42:23 properties 48:25 proposal 17:13,15 propose 123:3 proposed 124:1 protective 93:13,22 95:9 95:12,14,17,17 96:16 protocol 30:3 prove 40:13,20 41:2,7,21 42:5,13 103:9 proven 40:1 42:19 provide 13:10 19:2,10 34:1 41:16 82:11 102:24 103:22 provided 7:25 9:13,16 15:23,23 16:2 20:16 47:11 64:24 67:14,25 70:4,8 73:3 74:13,24 75:3 103:7 providing 19:20 64:23 proving 40:8 public 19:25 publication 31:7 85:18 89:6 publications 8:19 11:2 12:15,20,21,24 13:21 14:3,17 25:15 26:5 27:6 30:13,14 114:10 114:21 120:15 published 14:16 15:3 26:22,23 60:19 69:8 79:20 83:12 105:15 113:2,8,10 117:22 118:21 120:5 Purcell 60:3 PURDY 4:10 purpose 21:13 92:5 100:12 pursuing 19:25 put 47:17 66:6,25 69:19 111:21 puts 119:24 putting 96:15 P.M 124:5	qualities 89:19,19 quality 58:23 85:19 91:8 101:7 114:19 117:8,22 119:15 quantified 92:23 93:5,18 quantify 92:21 quantitative 117:23 quantity 25:22 36:23 quantum 92:15 question 10:24 11:1 13:24 37:3,10 40:8,17 42:1 47:17,21 51:11,12 51:17 52:10 57:16,17 57:21,24 58:11 59:5 68:12,20 70:23 76:21 76:25 77:2,6 80:20 82:4 86:19,23 87:25 89:4 90:22 94:10 95:22 99:9 104:13,14,19 105:22 106:23 109:21 110:21,25 113:17,25 114:17 120:19 121:20 121:23 questionably 116:9 questioning 117:10 questions 5:9 21:4,12 82:2 87:9 118:9 quick 77:24 82:10 QUINONES 4:5 quit 34:10 quite 31:23 39:24 45:20 58:18 111:4	reasonable 42:23 91:8 reasonably 39:11 51:3 121:7 reasoning 97:6 reasons 56:21 recall 10:25 12:23 13:1 15:7 17:20 21:17 26:25 34:3,5 43:4,20 44:2,23 45:10,11,16 48:5 53:13 53:19,22,25 54:15,19 54:22 59:11,25 60:1 61:21 62:3,7,23 63:6 63:10 68:15 71:25 78:5 79:8 86:16 95:6 106:1 106:3,4,6,10 116:12 receive 70:1 received 5:18 16:7 65:21 71:20 recess 8:3,11 10:6 64:18 RECKITT-BENCKIS... 4:15 recognize 65:22 recognizing 73:10 74:22 record 3:15 4:10 10:4,7 16:11,13 64:19 66:17 67:5 75:22 79:22 104:22 126:14 recorded 126:11 records 74:6 recoup 49:13 reduced 100:5 reduces 98:23 reduction 34:9 reductions 35:23 Reese 1:4 2:4 5:23 71:10 75:15 121:17,24 Reese's 121:21 refer 93:22 96:9 114:25 115:6,7 reference 44:25 80:7 references 103:4 referent 81:14 116:19 referred 62:6 95:17 98:22 referring 26:4 67:8 69:2 69:22 73:14 78:18 81:21 93:23 101:24 103:25 104:24 105:14 110:13 112:20 113:2 115:9 Refining 55:14 reflect 51:8 reflects 68:10 regard 30:12 regarding 11:9 13:20 14:3,21 15:2 21:8 26:22 31:7 45:11 67:15 67:24 68:3,6 69:13 77:18 81:18,23 82:22 83:11,23 84:1,9 86:1 87:13,17 88:2 89:7,14 96:22 99:23 106:24 107:18 108:6 112:5 113:9,17 115:15 120:25 Registration 24:22 registry 117:5 regular 23:5 regulation 24:25 reiterate 50:6 reject 41:12 relate 25:15 27:7
R				
R 3:1 4:1 railroad 44:7 Railway 43:23 raise 114:17 raised 87:9 random 88:14 randomly 96:18 range 15:10 19:2 28:14 93:13 102:5,6 ranging 93:6 Raphael 3:5 27:15 77:7 rarely 17:6,7 rate 81:2 rates 58:13 78:23 raw 14:11 REACH 24:21 25:6 reaching 96:21 97:22 98:15 99:10 106:25 107:19 108:13,21 109:24 110:18 120:18 read 16:7 26:21 27:3 65:23 66:1,7,14 68:8 70:5,7,19,21,24 71:1,2 78:15 81:17,24 82:2 84:2,6,10 88:16,22 89:3 104:20,22 105:24 112:4 114:9,20 120:16 123:5 125:5 readily 93:8 real 37:23 reality 116:4 117:11 really 28:17 29:22 47:21 59:18 60:16 70:16 90:12 99:1,4 102:17 113:19 reason 79:19 85:14 87:23 107:15				
Q				
qualified 102:20 qualify 92:24				

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

related 78:12 relationship 14:5 39:23 86:10 101:9 relative 38:2,20 126:15 relevant 25:20 84:21 109:15 reliably 84:18 reliance 84:5 relied 69:8 relies 69:17 111:22,25 112:3 rely 9:17 84:3 87:6 119:12 relying 69:14 75:21 112:13 120:1 remember 33:22 44:24 46:3 55:4 62:12,25 63:11,22 remove 32:15 116:18 removing 35:22 repeatedly 42:3 rephrase 57:21,24 report 75:21 90:2 93:24 104:1,25 118:24 reported 1:24 14:13 80:5 94:14 reporter 123:3,23 126:4 Reporters 1:21 REPORTER'S 126:1 reporting 91:11 99:3 reports 79:3,20 116:24 represent 34:22 69:7 92:4 119:25 representation 90:14 represented 39:11 74:18 representing 47:23 48:2 48:23 103:20,21 represents 18:8 REQUESTED 5:7 require 8:8 required 101:3 requires 90:12 research 17:13 23:21 24:1 28:1 29:16 30:1 30:22 52:13 67:6 80:20 107:22 109:14 118:8 reserve 86:4 resistent 95:13,14 resources 19:10 21:21 respect 13:22 85:8,10,15 86:3 113:16 121:14 respected 98:23 response 63:19 responsibilities 19:4 28:6 responsibility 24:7,8,17 rest 21:20 66:15 114:15 116:13 restarted 72:3 result 45:6 81:16 88:24 resulted 102:3 resulting 50:2 results 13:18 14:16 15:7 83:1,19 88:1,24 90:13 93:12 96:18 113:8,9 retain 44:25 retained 47:25 72:1,16 return 123:25 review 11:17,21 13:20 14:16 69:20 84:19,19 84:21 85:17,18 86:8 91:20 95:1 97:1 98:12 100:4 102:18 103:25	104:25 108:3,5 109:5 110:4 115:16 120:22 reviewed 68:4,8,17 81:25 82:3 84:2,6,10 94:13 95:2 103:22 108:25 114:24 115:17,24 reviewers 114:11 reviewing 29:12 30:8,20 reviews 28:1 30:15 83:1,4 83:10 84:1,7,9 90:24 105:10,19 111:7 Reynolds 4:15 34:6,19 45:25 46:4 re-read 117:21 RICHARD 4:11 ridiculously 42:20 right 13:6 20:18 31:3,25 32:18 42:25 45:24 48:22 50:22 53:11 55:19 57:25 59:8 64:6 64:11,11 65:16 66:10 67:11 71:7 73:21 74:1 74:5,21 75:2,6,8 77:21 86:5 90:1 100:21 105:20 112:17 115:13 115:15 118:19 121:5 122:19,25 ring 27:1 59:15 63:17 rings 63:22 Ringstaff 61:15 Rinkis 52:8 Rinsky 92:6 116:15 risk 14:21 31:9 34:9 35:23 38:2,3,20 57:2 77:15 78:12 102:6,10 102:21 103:23 104:3 105:3 121:16 risks 12:4 78:23 117:23 117:23 river 12:16 role 21:23 rooms 110:6 root 53:17 106:21 ROPERS 4:21 rough 29:21 roughly 27:24 28:19 RPR 1:24 2:18 rubber 13:13 14:22 25:12 85:23 86:14 runs 73:1 R.J 34:6,18 45:24 46:4	110:20 scientifically 23:22 42:11 87:10 scientist 47:18 85:16 86:7 screen 74:18 second 25:24,25 26:4 27:5 31:12 90:15 101:17,19 section 100:9 110:5 see 18:10 22:17 26:3 27:12 38:4 40:22 41:1 47:12 52:19 60:22 61:20 71:8 80:14 92:7 102:18 106:13 115:12 119:14 seeking 17:18 seen 27:2 37:24 80:5 109:19 selection 91:10 selects 87:7 self-identify 82:19 semester 22:7,14,15 semiconductor 17:17,21 seminal 97:17 seminar 24:10 send 72:9,24 74:4 118:1 sending 116:24 sense 114:19 122:15 sensitive 58:12 sensitivity 81:15 sent 75:4 117:14,15,20 sentence 88:19,23 89:1 101:18,19 separate 8:22 68:16 September 72:4,17,22 73:2,5 series 12:15 34:13 100:13 serious 37:18,23 87:9 113:22 seriously 118:9 serve 17:5 service 19:2 session 24:7,16,18 sessions 23:11 24:3,4 set 59:1 94:13 97:18 111:16 112:3 115:11 118:14 119:4 120:7 126:7 setting 83:9 110:14 settings 42:9 109:17 Seventh 4:11 severe 80:1,16 Shaffery 4:16 72:7,15 shared 24:6 sheet 123:10 Shell 43:2,16 Sheri 1:24 2:17 126:3,25 Sherwin-Williams 32:22 33:4,11 shift 100:16 short 60:13 Shorthand 126:4 show 12:20 79:21 93:5 103:8 showed 95:17 showing 93:14,22 103:17 shown 39:8,14 78:22 side 37:15 41:20 61:2 sign 123:5 signed 123:18 significant 58:13 79:4 93:14,24 94:2,4,7	95:23 96:20 116:20 significantly 78:23 94:15 95:3 silica 31:5 117:20 silicosis 117:24 Silverberg 23:17,20 similar 46:23 47:8 48:13 55:8 90:23 simple 34:23 71:6 simplify 49:10 101:25 simplistic 49:11 simply 36:19 123:21 single 69:4 71:9 81:16 117:20 sir 8:18 10:12 15:14 16:15,21 17:1 18:8,13 18:18,25 22:4,20 27:21 32:25 33:25 45:19,23 65:1,22 68:5 119:5 sit 98:3 105:8 site 49:1,3 74:8 101:14 sites 101:4,15 situation 36:7 80:12 93:8 situations 35:5 sixth 13:8 size 91:9 slightly 37:8 70:22 small 37:12,19 38:15 SMITH 3:15 4:5 smoke 35:9 55:10 smoker 37:16,18,23 smokers 34:10,18 38:2 smoking 34:10,11 35:3 35:15 36:4,15 38:18,20 38:21 39:2,9,15 40:2 50:19,20 51:1 sold 56:13 solvent 95:4 99:23 102:8 106:25 107:18 solvents 12:18 69:13 78:11 87:13 88:3 89:8 95:8 96:1 101:22 102:25 107:20 108:7 108:20 112:5 SON 4:3 soon 42:6 sophisticated 20:5 Sorahan 92:7 105:9,9,15 105:20,24 sorry 11:5 13:11 14:10 37:21 43:25 44:23 46:22 56:16 59:20 60:4 62:20 63:21,22 71:5 72:18 101:18 104:8,19 106:15 114:1 sort 122:17 sources 20:6 South 4:17,22 so-called 34:15 speaker 23:12 speakers 24:15 specialties 23:19 specialty 21:2 23:20,25 species 109:15 specific 15:7 26:9 36:23 37:10 38:5,5,6 39:1,11 44:20 51:2,23 68:18 86:15 91:5 101:14 103:4 120:25 121:8,24 122:7,13,15,16,16,18 122:23 specifically 12:4,5,6,23	12:25 17:20 26:12 40:11 53:13 76:2,4 88:5 91:7 92:3 93:4 95:6 112:3,12 119:12 122:3 specificity 88:13,14 89:24 specifics 45:10 58:6 specify 36:22,23 specimens 114:12 115:16 115:24 116:24 117:15 118:2 speculating 104:11 speculation 81:6 speed 87:4 spend 28:8 29:1,4,8,11 spending 30:4 spent 28:16 29:19,25 30:7,19 73:5,11,22 split 29:22 sponsor 52:13 sponsored 31:4,10,11,14 31:15 sponsoring 31:3 squamous 37:12,19 38:1 38:15 Sr 63:8 ss 125:1 St 49:7 55:8 staff 67:13 73:12 74:12 stages 34:10 standpoint 77:3 start 82:5 start-up 30:3 state 1:1 2:1 42:13 47:11 58:22 102:17 125:1,10 126:4,19 stated 114:23 statement 10:1 78:18 98:14 114:3 statistical 87:12,16,19 104:2 105:2 statistically 58:13 78:22 79:3 87:25 93:14,24 94:2,3,7,15 95:3,23 116:19 Steinmaus 82:8,16 83:13 86:18 87:7 92:7 stemming 88:12 stenographically 126:11 STEPTOE 3:9 Steve 63:18 Stewart 63:16 stick 11:24 stip 124:1 stipulated 123:20 124:3,4 Straif 13:4 85:2,3,4,5,6 85:21 stream 42:4 Street 3:10,16 4:11,17,22 strength 36:8,11,16 89:6 111:8 strengths 88:11 stretches 30:5 strike 18:2 108:18 strong 39:22 77:15 91:12 92:25 93:3 strongly 121:18 studies 11:9,11,13,23 12:11,14 13:17 14:20 14:23 15:2,9 25:13 28:1 30:1,22 31:8 52:6 58:24 78:22 79:2 84:5
---	--	--	--	---

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

84:25 85:24 87:6,13,17 88:1 89:7,14,16 90:5 90:10,25 91:1,5,7,23 92:25 93:5,9,14,16,22 93:23 94:12,14,22 95:3 95:8,22 96:12 97:23 98:6 99:22 102:2,9,15 102:19,23 103:7,11,13 103:16,18,21,21,22,24 103:25 104:23,24 105:10 106:13,16,24 107:17 108:1,4,6,9,17 108:19 109:1,9,9,23,23 110:7,22 111:9,9,10,13 111:23,24 112:1,3,8,10 112:11 116:4 117:5,13 118:1	SUPERIOR 1:1 2:1 4:14 supplement 109:19 111:19 120:4 SUPPLY 1:7 2:7 support 27:25 28:9 29:9 34:1 41:14 44:21 53:16 90:17 110:9 122:9 supported 122:13 supportive 101:4 supports 68:16 sure 21:11 27:10 44:3 58:7,7 62:17 63:25 66:3 78:15 80:8 83:6 87:23 98:1 110:13 Surgeon 97:18 surrounding 85:23 SUTPHIN 4:15 swan 42:2,2,6 swans 42:3,4,6 sworn 7:5 syntheses 28:2 synthesis 97:1 synthesize 97:20 synthesizing 29:12 30:8 system 33:9 101:11 systematic 88:12 89:16	testimony 5:15,17 9:2,3,4 9:6,10 15:24 32:8,11 32:19 33:12 34:3 40:16 41:10 43:12 44:17 47:4 47:11 50:10 51:16 53:13 54:3,19 55:8 56:2,3,11 60:11 64:7 64:24 65:6 69:19 76:12 76:19 81:10 118:16 123:9 125:8 126:9,14 Texas 3:21 56:1 textbooks 42:13 texts 42:17 Thank 37:21 51:18 69:3 74:2 77:13 82:13 83:5 104:21 thanks 27:16 52:14 theme 118:12 themes 118:17 thing 11:14 60:9 80:7 114:7 things 32:1 42:20 55:4 58:22 99:7,18 100:16 118:20 21 119:16 124:1 think 13:10 14:14 18:8 20:5,18 24:6 26:23 30:14 33:14 35:12 37:24 40:8 41:23 42:8 42:23 43:8 47:8 51:24 52:10 53:3,3 54:15,25 55:18 57:17 58:23 59:16 63:1,3 65:5,9 67:1 68:13 70:22 80:9 85:1,12 87:2,8 90:5,8 92:6,23 93:18 94:6 97:12 98:2 99:5 102:16 103:3,6 104:6,12 105:7 108:24 109:1 110:3,16 111:4 112:16 113:7,12 114:18 115:11 116:3 117:3,7,10 119:8,11 121:24,25 122:7 thinking 97:10 third 13:7 28:3,19 66:10 72:25 82:8,14 THOMAS 1:4 2:4 Thompson 46:22 thought 52:16 55:25 60:9 77:5,8 104:15 three 13:10 21:19 22:21 22:24 23:8 24:12 27:24 30:4 32:17 38:2 81:20 83:24 92:2 114:14 three-page 5:15,19 32:11 thrust 33:12 43:12 44:17 50:10 56:11 thyroid 75:17,19 76:4,8 76:16,17 77:16 121:15 122:12 thyroiditis 74:7,8 75:16 75:18 76:6,9 77:15 78:3 ticking 100:5 tie 44:8 time 8:12 16:14 17:9 18:1 19:17,18 20:23 22:8 27:4 28:7,15,18 29:1,2 29:4,7,11,18,24 30:7 30:16,20,25 38:11 47:15 55:7 63:12 73:12 73:12 85:25 87:3 111:5	114:7 124:5 126:7,8,10 times 35:21 63:2 113:8 timing 28:10 title 26:7 titles 84:17,22 tobacco 34:7,19,20 35:2 46:6 49:7 50:1,4 55:5 55:10,11 tobacco-related 49:21 today 97:13 98:23 today's 15:24 told 54:1 77:8 92:2 tone 51:13 top 78:5 84:14 94:23 topic 90:2 total 23:10 116:11 town 64:10 tox 108:3 toxicity 108:8 toxicology 109:2 110:21 track 104:19 tract 44:4 trade 17:21 31:5 traditionally 101:1 training 7:12 transcribed 126:12 transcript 123:4,13,14,16 125:5,8 126:13 translates 121:1 transmit 123:23 transmittals 123:22 transmitting 71:19 transportation 102:12 Travis 114:25 115:4,14 115:14 treating 49:19 50:5 treatment 50:3 trial 9:2,9 32:19 45:2,4 47:3 61:20 64:24 121:21 123:18 trials 65:2,4 tried 71:6 117:22 Trombella 48:11 trouble 116:22 true 42:12 46:8 100:10 100:22,25 101:12 111:10,12 125:7 126:13,20 try 44:24 50:6 117:9 trying 35:13 Tuesday 2:17 7:1 tumor 44:5 turn 122:22 two 17:23 19:19 20:25 21:9,11,19 22:23 23:15 24:8,14,19 30:13,14 37:17 38:2 40:25 56:21 69:7 82:1 84:20 102:1 114:14 116:18,19 Two-page 5:18 two-part 13:4 type 11:14 29:19 44:20 75:23 83:10 types 38:7,22 39:3 111:10 typically 91:1 94:4	19:3,25 21:9 unclear 50:12 uncommon 79:14 undersigned 125:4 understand 33:9 34:14 38:11 40:7,7,12,17 41:6 42:9 47:19,22 49:10 50:14 57:15,17 65:7 70:3 75:8,15 76:23 94:11 99:8 101:1 115:20 122:14 understanding 18:16,19 18:22 33:18 34:24 41:3 73:20 75:3 94:8 109:4 120:6 understood 71:4 underway 50:14 undiagnosed 114:18 unfortunately 26:19 59:19 84:17 109:14 universe 87:8 university 16:24 17:4 19:12,21 20:13,16,21 21:21 122:1,6 unusual 98:2 updated 10:19 79:20 use 14:15 23:2 24:20 25:1 31:23 33:3 40:10 90:23 98:3,6 99:18 uses 96:25 usual 118:19 usually 8:9 72:25 94:3 98:11 122:17 U.K. 92:8 U.S. 25:1 60:20 117:4,6
study 11:21,25 12:3,16 13:8,13 14:11 15:6 17:16,19 23:5 26:12,15 31:1,3 52:21 60:19,21 83:10 85:23 88:11,13 90:14 92:7 93:2 95:1 95:15,17 99:1 105:15 105:25 109:5 112:18 112:19,23,24 113:2,15 114:23 115:4,17,23 116:17,22 117:20 119:15 studying 109:4 stuff 8:3 10:5 STULTZ 4:11 subject 20:8 24:17 115:17 120:24 submit 89:5 submitted 55:23 72:15 85:17 subset 91:11 subsets 79:6 substantial 51:1 101:23 102:24 substantially 101:20 122:11 substantiated 119:15 121:6 subtype 39:1,11,13,18,25 91:7 subtypes 38:16,17 39:3,8 78:13 79:7 suffer 90:5 suffered 64:14 suffering 49:20 sufficiency 40:6 sufficient 43:14 90:20 92:18 104:2 105:2 110:9 sufficiently 58:12 91:21 suggest 123:21 suggested 51:14 124:1 suicide 80:1,3,16 suing 34:18 Suite 2:15 3:6,11,16,20 4:18,23 Sulakoff's 57:22 Sulski 23:17,24 sum 103:22 summarized 40:21 summary 5:22 10:1 33:24 34:2 71:10,13 119:21 summation 97:15 summing 64:1	T T 5:11 6:1 take 59:21 63:12,24 64:16 75:9 77:24 82:10 84:15 100:3 119:13 taken 2:14 11:7 59:25 126:6,14 talk 30:17 114:6 116:6 talking 8:12 37:16 64:6 83:3,4,6 122:23 tall 62:21 taught 18:1,3 22:8,22,23 24:13,18 tax 15:25 Taylor 61:24 63:1 teach 18:11,16 22:14,18 23:11 24:4 teaching 17:23 18:24 19:3,4 22:5,13 tease 102:8 Technically 100:25 techniques 58:22 TELEPHONE 3:18 4:4 4:21 tell 14:19 65:25 66:17 67:19 78:1 83:19 84:14 119:17 tend 86:7 121:3 terminology 41:18 terms 37:13 40:21 41:5 41:12 121:19 test 35:25 96:8 testable 40:23 testified 7:6 9:1 31:17,20 43:16 45:15,21 46:2 48:16 49:5 50:16 52:23 53:5,11 54:11 55:11 56:4,9,10 64:4,4,13,15 65:3,14 testify 33:10 45:4,18 46:14 53:23 54:17 61:10,13 62:1 118:18 testifying 34:25 60:18 61:1 121:21	T 19:17,18 20:23 22:8 27:4 28:7,15,18 29:1,2 29:4,7,11,18,24 30:7 30:16,20,25 38:11 47:15 55:7 63:12 73:12 73:12 85:25 87:3 111:5	U ultimately 17:14 110:16 UMASS 22:19 unable 40:20 70:13 UNC 18:4,7,12,17,23	V vague 20:17 25:17 26:18 36:17 39:5,16 40:3,15 41:9,24 42:15 51:7,21 56:20 57:13 58:16 75:25 76:18 78:25 80:18 81:5,9 82:24 83:14 84:12 85:9 86:2 86:12 87:18 88:4 89:9 91:15 92:19 94:17 96:23 98:18 99:24 100:24 103:1 104:4 106:19 107:2 108:10 108:22 109:11 110:1 110:23 111:11 112:21 115:19 116:1 117:1,17 118:5 122:20 Valdez 45:8 valid 87:20 88:9 90:14 109:22 110:12 validly 90:17 VAN 4:3 variation 118:12 variations 111:19 varies 28:10 30:2 38:24 various 11:19 20:6 34:10 35:19 39:3 71:19 89:20 101:25 vast 117:12 verdict 45:7 verification 117:12 verifying 114:11 versus 32:22 34:6 42:11 43:2,23 45:8,24 46:10 46:23,25 47:6 48:11,19

A3074BC

KENNETH A. MUNDT, Ph.D. OCTOBER 13, 2009

49:4,7 52:22,25 53:17 54:8,13,24 55:14 56:6 59:8 60:6 61:15,24 65:10 90:6 view 14:10 94:6 viewed 79:8 village 48:19,21 vinyl 51:25 60:8,19 61:25 Virginia 55:5 62:21 vitae 5:14 7:24 8:17,20 10:11 16:22 21:24 25:14 voluminous 75:7 voluntary 22:15 vs 1:6 2:6 W waiting 63:21 want 8:8 28:23 34:22 50:9 52:8 60:15 66:4 70:17 76:14 80:6 84:24 87:23 92:1,15 98:15,20 100:2 104:8 107:10 111:1 115:8,8 wanted 50:4 83:6 101:18 120:16 wants 115:6 wasn't 39:24 104:8,16 waste 49:3 water 27:15 way 14:10 25:9,15 40:21 41:11 48:24 49:11 50:7 66:3 81:14 85:15 90:4 92:4 94:3 100:2 WAYNE 1:4 2:4 ways 91:17 weak 43:14 weakly 39:8 weaknesses 88:11 89:6 week 16:16 23:7 30:4 72:25 73:11,22 weeks 23:9 26:24 73:17 weight 91:3 Weiland 13:7,9 WEIMAN 4:3 Weir 54:24 went 17:9,22 45:2 116:22 West 3:10 4:11 55:5 62:21 white 42:2,3,4 Whysner 66:12 wide 19:2 88:1 widely 79:8 willing 93:10 Willis 34:6 Wilshire 4:6 wishes 77:2 Withey 62:14,15 witness 5:3,9 14:10,25 15:6,20 20:18 25:18 26:19 27:17 32:13 35:11,19 36:7,18 37:2 37:7 38:9,24 39:7,18 40:17 41:11,25 42:17 50:17 51:8,23 54:5 56:21 58:18 60:15 61:6 61:9,11 62:9 63:21 67:10 68:15 71:25 76:1 76:13,20 77:23 79:2,19 80:5,20 81:11 82:25 83:15 84:13 85:10 86:3	86:13 87:1,19 88:5 89:11,18,23 90:1,8 91:17 94:19 95:6,12,21 96:9,24 98:1,20 99:14 99:25 100:25 103:3 104:6 105:6 106:21 107:4,9,22 108:3,12,24 109:13 110:3,25 111:12 112:24,25 113:6,23 114:9 115:3 115:14,20 116:3 117:3 117:19 118:7,17 119:22 122:22 126:8,9 women 13:13 31:1 Wong 82:16 83:12 103:13,19,20 105:19 Wong's 82:7 102:4 wood 4:5 44:16 word 14:15 78:16 95:13 95:14 worded 111:4 wording 10:25 94:1 words 44:14 57:4 work 8:2 16:16,17,19 21:22 27:19,22 28:8 29:2 57:22 85:8,11,16 85:19 86:5,8 100:16 119:7 120:11 worked 85:6,20,22 86:14 worker 25:12 43:4 44:7,8 64:13 79:25 117:20 workers 12:12,16,17 14:23 17:16 27:1 58:14 60:19 78:24 92:8 worker's 43:7 working 28:11 35:13 78:11 102:12,12 workplace 109:16 world 58:19 wouldn't 85:14 87:24 wound 42:20 wrap 63:23 write 75:15 88:9 90:16 118:24 119:5 written 21:4 86:24 89:4 89:18 90:1 wrote 16:8,9 89:1 www.depo.com 1:22 X X 5:1,11 6:1 66:25 x-ray 117:20,24 Y Yang 72:7 Yeah 59:19 108:24 year 17:8,10,23 19:18 20:2,25 22:10,11,13,19 22:21 30:7,11,16 32:24 43:10 72:2 years 9:7 17:10 21:10,12 22:22,24 23:2 33:15 34:16,17 50:15 58:3,3 63:3 64:2 85:7,20,23 86:13 yesterday 58:8 Yin 113:7 1 1 1:7 2:7 5:13 10:8,10 93:6 119:22	10 5:14 29:3 33:15 48:8 50:14 60:25 73:11,17 73:23,24,25 100 38:3 1055 4:11 10960 4:6 1100 4:23 12 26:5 92:4 116:11 12:10 124:5 1200 3:16 13 1:15 2:17 7:1 14 13:3,12 15 13:7 23:10 24:3 29:3 93:5 18th 4:6 18,000 31:1 1996 65:10 1997 113:2,10,14 2 2 5:15 13:4 32:4,5 20 29:10 37:18,20,21 48:8 93:5 116:11 125:10 200 1:7 2:7 38:3 112:4 120:3 2002 79:21 105:20 2005 22:2 105:16 2006 101:3,10 2007 18:9,15 2008 22:11 84:20 102:18 2009 1:15 2:17 7:1 22:11 30:7,21 126:22 2012 18:9,15 21st 126:22 213 4:19 213)250-1800 3:17 213)312-2000 4:24 213)417-5189 4:13 213)43909421 3:12 214)828-9200 3:21 221 3:16 24th 4:12 25 28:12 29:10 37:24 2520 4:18 288-3376 1:22 3 3 5:16 64:20,24 67:8 74:6 3M 3:8 30 37:18,20,21,25 123:13 300-page 118:24 310)481-7600 4:7 32 5:15 34 93:7 36 66:21 4 4 5:18 65:16,18 40 73:16 401 2:15 3:5 439-5390 4:19 445 4:17 5 5 5:19 67:16,17 69:10,15 70:9,20 74:14 82:10 94:13 95:1 96:12 106:12 115:1,2,3,10 50 16:18 28:13 515 4:22 53 66:22	5307 3:20 562)437-4499 3:7 6 6 5:21 68:21,24 69:10,15 70:9,20 74:15 77:22 78:1 94:14 95:1 96:13 106:12 115:3 60 16:18 73:16 60s 97:4 600 3:20 633 3:10 64 5:17 97:18 65 5:18 6507 1:24 2:18 126:3,25 67 5:20 68 5:21 7 7 5:6,22 71:9,11 75:11 111:17 118:14 119:4 120:8 700 3:11 71 5:23 6:4,5 75206 3:21 8 8 6:3 71:16,18 800 1:22 2:16 3:6 84 56:6,10,13 9 9 6:5 71:23 72:14 9:05 2:16 7:2 90012 3:17 90017-2503 4:12 90024-3804 4:7 90071 4:18,23 90071-3500 3:11 90802 3:6 94 115:14
--	--	---	---